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Abstract
There is a significant worldwide demand for a small calibre vascular graft for use as a
bypass or replacement conduit. Our lab has developed a novel nanocomposite poly-
mer based on polyhedral oligomeric silsesquioxane and poly(carbonate-urea)urethane
(POSS-PCU) which has displayed promising properties in vitro. In this thesis, POSS-
PCU has been utilised to fabricate prosthetic small calibre conduits for use as arterial
replacements. An important feature in determining the success of a graft is the wall
structure which includes porosity, pore size and pore interconnectivity, which play a
crucial role not only in determining the extent of graft healing but also on mechanical
behaviour. A novel extrusion/phase inversion method was investigated and optimised
to produce grafts with a range of pore sizes (0-30 µm) and porosities (up to 90%).
With mismatches in mechanical properties implicated in the aetiology of intimal hy-
perplasia, the dynamic mechanical behaviour of grafts was investigated. Grafts could
be engineered with compliance values ranging from 5 to 12 per mmHg × 10−2 com-
pared to an average value of 5.9 per mmHg × 10−2 for the native artery. Biocompati-
bility is largely dependent on surface properties which were extensively characterised
for each of the porous grafts. Grafts were found to readily endothelialise in vitro and
were resistant to platelet activation. An external graft reinforcement method was de-
veloped in order to minimise graft kinking. Finally, the grafts were evaluated in vivo
in an ovine model following GLP protocols for a period of 9 months. A patency rate
of 70% was achieved (n=10). The positive in vitro results and successful conclusion
to the large animal trial suggest that POSS-PCU small calibre grafts are a promising
candidate for cardiovascular reconstructions.
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1
Cardiovascular Disease and Treatments
Cardiovascular diseases (CVD), such as myocardial infarction (MI) and peripheral ar-
terial disease (PAD), are the principle cause of death globally. In 2006, nearly 200,000
deaths were attributed to CVD in the UK alone [1]. In addition to the morbidity
and mortality associated with CVD, there is also a significant economic burden, esti-
mated to be over $30.7bn annually. CVDs are often associated with occlusion of the
blood vessels resulting in ischaemia and damage to the surrounding tissue. Current
therapies aim to relieve ischaemia, by restoring vascular perfusion, through surgical
interventions, which include balloon angioplasty, with or without stenting, and bypass
surgery. Unfortunately, 40% of surgical interventions fail within the first year due,
principally, to thrombosis, restenosis and graft stenosis resulting in graft occlusion.
This problem is particularly acute in the treatment of low flow, small calibre – less
than 6mm in diameter – vessels such as the coronary, carotid and peripheral arteries.
With minimal alternative treatment options available, there is a considerable clinical
demand for improvements in invasive therapies and surgical techniques for revascu-
larisation. Therapies include the development of improved implants such as stents
and prosthetic grafts.
1.1 Blood Vessel Anatomy
The circulatory system is the largest organ in the human body and is comprised of
arteries, arterioles, capillaries, venules and veins. Arteries and arterioles are designed
to withstand high blood pressures and consist of 3 layers (fig 1.1): the tunica intima,
tunica media and tunica adventitia. The tunica intima is the innermost layer, in direct
contact with blood, consisting of longitudinally arranged squamous endothelial cells
(EC). The endothelium acts as a protective barrier regulating vascular permeability,
inflammation, coagulation and fibrinolysis [2–4]. The middle layer, tunica media,
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is composed primarily of concentrically arranged smooth muscle cells (SMC). The
medial layer is responsible for vascular tone through the contraction and dilation of
the muscular and elastic components in response to mechanical stimuli or nervous
innervations [5]. The outermost layer, tunica adventitia, is a collagen rich connective
tissue layer consisting of fibroblasts, nerves, lymph vessels and capillaries known as
the vaso vasorum. The vaso vasorum is responsible for supplying the advenititia and
the outer part of the media with oxygen and nutrients [6]. It also provides the blood
vessel with the mechanical strength to cope with high blood pressures [7].
Figure 1.1: Blood vessel anatomy. The structure consists of 3 distinct layers: the out-
ermost tunica adventitia, primarily composed of fibroblasts and collagen, which provides
mechanical strength to the vessel. The tunica media which consists of smooth muscle cells
inbetween the elastic lamina. The tunica media is responsible for controlling vasomotor
tone. The innermost tunica intima regulating coagulation, inflammation and fibrinolysis
and is composed of a thin layer of endothelial cells.
1.2 Atherosclerosis
Principle amongst the causes of ischaemia and CVD is atherosclerosis – a condition
in which the artery wall thickens due to the build up of fatty materials such as choles-
terol. Atherosclerosis can lead to the narrowing and blockage of the arteries to the
brain, heart, legs, arms, stomach or kidneys and can lead to stroke, myocardial infarc-
tion (MI), amputation and even death. Atherosclerosis is characterised as a chronic
inflammatory response in the arteries due to the accumulation of macrophages pro-
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moted by low density lipoproteins (LDL), without the adequate removal of fats and
cholesterol from the macrophages by functional high density lipoproteins (HDL) [8].
Lesions tend to develop at arterial bifurcations or major curvatures, areas which
show an increased permeability to macromolecules like LDL [9]. An endothelial dys-
function, possibly due to chemical or mechanical injury, shear stress or the presence
of elevated levels of modified LDL, leads to an increase in permeability allowing
LDL into the intima [10]. Leukocytes and monocytes then migrate into the intima
and transform into macrophages, which take up the LDL creating lipid rich foam
cells; characterising a general state of inflammation. Activated platelets, EC and
macrophages all release platelet derived growth factor (PDGF) which induces the
migration of SMC into the intima. The proliferating SMC form a fibrous cap sur-
rounding a lipid core, consisting of the foam cells, forming a focal intimal thickening
known as a plaque. In advanced stages of the disease, a narrowing of the arterial lu-
men develops with a high risk for the formation of superimposed thrombosis leading
to acute ischemia of the end organ. Detection is difficult as atherosclerosis tends to
be quite advanced, having progressed for decades, before it manifests itself clinically.
Known risk factors include lifestyle choices such as smoking and drinking as well as
diabetes, hypertension and hyperlipidemia.
1.3 Treatment Options
Treatment options for atherosclerosis can be roughly divided into three main cate-
gories: lifestyle changes, medicines or surgical intervention. A change in lifestyle is
usually the first step in treating atherosclerosis with regular exercise, change in diet,
reduction in alcohol intake and a cessation of smoking encouraged. However, if that
has a limited impact the next stage is for medication. Statins, a class of drugs used
to lower cholesterol levels, have been shown to be effective in reducing incidences of
intermittent claudication and angina pectoris [11]. Described as the most important
contribution to clinical medicine and pharmacology of the 20th century, beta block-
ers have been shown to lower blood pressure which reduces the hearts workload and
incidences of MI [12, 13]. Anti-platelet therapy can be administered to reduce the
proclivity for blood clots. Aspirin, clopidogrel and abciximab have all been shown to
be efficacious in reducing thrombotic complications in CVD [14,15].
When medical intervention fails and blockage of an artery has progressed to the point
where there is a severe reduction in blood flow, surgery needs to be considered. In oc-
clusions smaller than 70%, a minimally invasive procedure known as a percutaneous
transluminal angioplasty (PTA), or balloon angioplasty, can be carried out. PTA is
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a procedure in which a small balloon at the tip of a catheter is inserted through the
blocked or narrowed area of the artery. The balloon is inflated to a pre-determined
diameter to dilate the artery and push the plaque back to open the diseased blood ves-
sel. When the balloon is inflated, the fatty plaque or blockage is compressed against
the artery walls and the diameter of the blood vessel is widened to increase blood
flow. In some cases, balloon angioplasty is performed in combination with a stenting
procedure. A stent is a small metal mesh tube that acts as a scaffold to provide
support inside the artery. A catheter, placed over a guide wire, is used to insert the
stent into the narrowed artery. Once in place, the stent is deployed and expands to
the size of the artery and holds it open. A balloon may be used to insert the stent or
the stent may have an outward force itself that allows it to expand independently. If a
balloon is used to deliver and deploy or expand the stent, it is deflated and removed,
and the stent stays in place permanently. Since the inception of stents, the number
of people opting for the minimally invasive procedure has grown steadily. However,
question marks have been raised more recently over the efficacy of stenting patients
with stable coronary artery disease [16].
In more serious occlusions, 70% or more, or in cases where stenosis is multi-focal or
when multiple vessels are involved; invasive bypass surgery is recommended. Bypass
surgery involves circumventing blocked arteries with an alternative conduit restoring
blood flow distal to the blockage. To bypass the blockage, the surgeon makes a small
opening in the diseased artery and places a graft above and below the blockage to
allow blood flow around the blockage. Whilst bypass surgery is considerably more
costly and involves extended hospital stays; survival rates in the coronary and carotid
position are significantly greater compared to PTA, suggesting bypass surgery still
has a considerable role to play despite the growing popularity of minimally invasive
procedures [17,18].
The conduit of choice for bypass surgery is still autologous vessels. Arterial grafts –
such as the left or right internal thoracic artery, radial artery and more rarely the
right gastroepiploic artery or inferior epigastric arteries – are the favoured options
for coronary grafting demonstrating patency rates in excess of 90% at 15 years [19].
Despite their remarkable patency rates, only 30% of surgeons use arterial grafts in
over 90% of their operations with the majority of surgeons often avoiding using ar-
terial grafts [20]. Reasons for not using arterial grafts include the time taken for
mobilisation, especially during emergency revascularisation, and restricted dimen-
sions especially in the elderly population [21]. However, the major disadvantage to
the use of arterial grafts is insufficient material for multiple grafting. For these rea-
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sons the great saphenous vein (GSV) remains the most popular conduit for bypass
surgery. Patency rates for the GSV are not as impressive as arterial grafts – 50% after
10 years – with thrombosis, intimal hyperplasia (IH), and the onset of progressive
atheroscelrosis principle factors in vein graft failure [22]. The harvesting of the GSV
still requires a second, invasive procedure, with potential concomitant morbidities,
and the problem of insufficient material still exists. This is particularly problematic
as the number patients requiring repeat operations is steadily increasing [23]. This
has led to 30% of patients requiring surgery not having suitable or sufficient blood
vessels to be used for transplantation [24]. As a result, synthetic grafts have been
developed to try and meet the pressing clinical need.
1.4 Prosthetic Grafts
Synthetic grafts, made from polyethylene terephthalate (PET) and expanded poly-
tetrafluoroethylene (ePTFE), have offered viable alternative prostheses for vascular
reconstructions. PET is a polyester fibre that can be woven or knitted into a fabric
resulting in prosthesis with two distinct structures. Woven grafts tend to be mini-
mally permeable to liquids with high bursting strengths and a limited tendency to
deform under stress. Knitted grafts, on the other hand, tend to contain large voids,
allowing tissue ingrowth, but also requiring preclotting or coating with a thin layer
of blood proteins to prevent blood leakage through the walls. ePTFE, better known
as teflon, is a synthetic, semi-crystalline, thermosetting fluoropolymer patented by
Gore for use as a vascular prosthesis. ePTFE is strong, chemically inert, durable and
biocompatible making it an ideal vascular graft material. Clinical trials suggest there
is little difference in patency between the two grafts – both function adequately in
the replacement of large arteries yet disappoint in the replacement of small diameter
or under low flow conditions. Patency rates were a rather impressive 90% at 5 years
and 80% at 8 years at the aortoilliac position [25, 26]. However, when it came to
the above knee femoropopliteal bypass, patency rates dropped to 63% at 3 years and
decreasing further to 36% after 5 years [27, 28]. Graft failure is primarily due to the
acute thrombogenicity of the graft material in the short term and anastomotic IH in
the long term [29].
In addition to PET and ePTFE, polyurethanes (PU) have been heavily investigated
for use as vascular grafts. PU are a chain of organic units linked together by a ure-
thane bond. They are composed of hard and soft segments which offers a degree of
versatility in the characteristics of the final material through fine tuning the properties
of the individual components. PU were initially greeted with enthusiasm as they had
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two significant advantages over PET and ePTFE: elasticity, meaning they were more
compliant, and ease of handling. The hard segment provided the tensile strength
and rigidity whilst the soft segment provided the flexibility. This initial enthusiasm
was dampened due to the lack of long term durability, with polyester based soft seg-
ments suffering from hydrolysis, whilst polyether based PUs susceptible to oxidative
attack [30]. The next generation of PU were carbonate-based which were resistant
to degradation [31]. Poly(carbonate-urea)urethane grafts were implanted into the
aorto-iliac artery of eight dogs and were found to be patent at 36 months. Currently
a PU graft is available for use for haemodialysis access having been approved by the
Food and Drug Administration (FDA).
(a) ePTFE (b) PU (c) PET
Figure 1.2: Commercially available synthetic grafts and the chemical structure of synthetic
graft materials
1.5 Failure Mechanisms of Prosthetic Grafts
Graft failure can often be attributed to two primary causes: thrombosis and IH. Early
failure is often due to poor surgical technique, thrombosis or infection. Infection can
be as a result of contamination during surgery or inefficient sterilisation process.
Midterm failure – 3 months to 2 years – is often associated with cellular infiltration
or IH whereas late failure is often due to the development of atherosclerotic lesions
in the graft.
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Thrombosis
In the native vessel, blood is in contact with the endothelium, a thin layer of cells
forming an interface with circulating blood in the lumen and the rest of the vessel. En-
dothelial cells form a barrier against the blood through the entirety of the circulatory
system from the smallest capillary to the heart. The endothelium provides a non-
thrombogenic surface as it contains a variety of anti-thrombogenic and fibrinolytic
factors including heparan sulphate, which acts as a cofactor for activating antithrom-
bin III, a protease that cleaves several factors in the coagulation cascade [32].
On the implantation of a synthetic graft, an exogenous material with a distinct lack
of an endothelium is introduced into the circulation resulting in the adsorption of
various plasma proteins and activation of the coagulation cascade, providing bind-
ing sites for integrin receptor mediated adhesion and activation of platelets amongst
other cells [33]. The composition and confirmation of proteins adsorbed is determined
by the interfacial interactions between polymer surface and proteins and can dictate
subsequent reactions including platelet activation, thrombus formation, and comple-
ment activation [34]. Platelets are highly sensitive, anuclear, disc shaped fragments
of cells circulating throughout the blood stream. Platelets bind to the plasma pro-
teins fibronectin, von Willebrand Factor (vWF), fibrinogen and vitronectin through
the surface glycoprotein GP IIb/IIIa and GP Ib [35]. Once bound a series of com-
plex reactions take place often resulting in the secretion of various biologically active
compounds such as platelet factor 4 (PF4), adenosine diphosphate (ADP), serotonin
and P -selectin, a cell-surface glycoprotein. All of these biologically active agents go
on to further propagate platelet activation, coagulation and inflammation. This for-
eign body induced platelet aggregation is felt even more severely in the case of small
calibre grafts due to the increased surface to volume ratio and reduced blood flow
rates. Further, thrombus formation has a greater impact on the flow of blood in small
diameter blood vessels.
In addition to platelet aggregation, the coagulation cascade can lead to the formation
of fibrin clots through the chemical cross linking of Factor VIIIa [34]. The coagulation
cascade acts via two complementary pathways: the intrinsic and extrinsic pathways
(fig 1.3). The extrinsic pathway, or tissue factor (TF) pathway, becomes activated
when plasma comes into contact with cells expressing TF. In the presence of Ca2+,
TF activates Factor VII forming TF-FVIIa complexes, which then cleave Factor X
producing Factor Xa – a common component in both the intrinsic and extrinsic
pathways. Thrombin is then generated through the prothrombinase complex which
is able to cleave fibrinopeptides, from the plasma protein fibrinogen, forming the
29
CHAPTER 1. CARDIOVASCULAR DISEASE AND TREATMENTS
fibrin monomer. Fibrin is then able to cross link with Factor VIIIa forming fibrin
clots, which express an RGD tripeptide motif, allowing it to bind to the surface
glycoprotein GP IIb/IIIa of activated platelets; further amplifying thrombosis [36].
The intrinsic pathway generates Factor Xa through a cascade of reactions beginning
with the activation of Factor XII which goes on to convert prekallikrein into kallikrein
resulting in the activation of Factor XI. Factor XIa activates Factor IX, which in
conjunction with Ca2+ and Factor VIIIa, activates Factor X which proceeds to form
stable, fibrin clots, or thrombus.
Figure 1.3: The coagulation cascade summarising the role of the intrinsic and extrinsic
pathways in forming fibrin clots and stable thrombus
Intimal Hyperplasia
In the long term, tissue IH is the major cause of failure for surgical interventions to
treat atheroscelrosis, whether by PTA or bypass grafting. IH causes the narrowing or
stenosis of grafts due to the growth and thickening of the tunica intima of the blood
vessel and is the result of a series of events involving the invasion and proliferation of
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vascular SMC, fibroblasts and extracellular matrix (ECM) deposition [37]. The de-
velopment of intimal hyperplasia is multifactorial, and its aetiology is not completely
understood; however, it always involves some damage to the endothelium. The IH
area is usually composed of about 20% of SMC which migrate from the media to the
intima where they proliferate and deposit ECM components. The ECM components
make up about 60-80% of the IH area. Other components include macrophages and
lymphocytes. A multitude of growth factors and signalling molecules have been im-
plicated in the development of IH resulting from damaged EC.
Initially the excessive SMC proliferation takes place in the medial layer. At the site
of damaged endothelium, thrombosis forms reducing the capacity of EC to produce
nitiric oxide (NO), heparan sulphate and other inhibitors of SMC proliferation. This
effect is coupled with damaged EC producing more PDGF, basic fibroblast growth
factor (bFGF) and transforming growth factor β (TGFβ); all of which promote SMC
proliferation thus shifting the balance towards excessive SMC proliferation [38, 39].
Furthermore, the SMC found at sites of IH appear to be of a synthetic phenotype
which have a proliferation rate 10% higher than contractile SMC and produce 4 to 5
times more ECM [40]. The second stage of IH involves the migration of SMC from
the medial layer to the intima. This is primarily caused by degradation to the ECM,
which prevents SMC migration, by the overexpression of tissue-type plasminogen ac-
tivator (tPA) and urokinase-type plasminogen activator (uPA) which also activate
matrix metalloproteinase (MMP) [41]. SMC migration usually starts 4 days after in-
jury and can continue for up to a month. Finally, the third wave of intimal expansion
occurs through a combination of SMC accumulation through proliferation, continued
migration, and copious ECM synthesis.
The sequence of events in the development of IH is the same for all forms of IH, PTA
or vascular graft induced; however, the events initiating the start of IH and speed
of development are different. IH in bypass grafting is commonly found on the arte-
rial floor near the anastomosis and/or at the heel and toe around the anastomosis.
After grafting, blood flow patterns tend to change drastically leading to the local
anastomotic region experiencing an altered haemodynamic environment (fig1.4) [42].
Turbulence, flow separation and zones of high/low shear stress around the anastomo-
sis can damage EC and lead to platelet activation and adhesion resulting in a release
of growth factors mentioned previously promoting SMC proliferation [43, 44]. Wall
shear stress (WSS) is the product of the wall shear rate, the radial derivative of axial
velocity, and the local blood viscosity. Shear stress can be calculated using Poiseuilles
31
CHAPTER 1. CARDIOVASCULAR DISEASE AND TREATMENTS
law:
τ =
4µQ
pir3
 1.1
where µ is blood viscosity, Q is the volume flow rate and r is the internal vessel
Figure 1.4: Spatial distribution of blood flow patterns and IH in arterial bypass graft
anastomosis
radius. WSS has been shown to be an important determinant in the release of several
vasoactive molecules from EC [44]. Arteries tend to change their radius in order
to maintain a mean WSS value roughly in the range of 1.5Nm−2, with IH readily
observed in areas of low WSS, such as bifurcations, wall curves, and the stagnation
point on the arterial floor opposite the anastomosis, where flow divides proximally
and distally [45, 46]. Normal vessels respond to low WSS levels by constricting – a
process not possible with synthetic grafts. Therefore, the correlation between low flow
and IH may be an attempt by EC to maintain WSS levels within physiological range.
However, low WSS does not explain the formation of IH at the heel and toe regions
of anastomosis. Spatial and temporal gradients in WSS have been found at the site
of IH and it is the oscillations in WSS that appear to be the major determinants
in IH [47, 48]. Furthermore, at the heel of an anastomosis, rapid fluctuations in
direction of WSS – shear stress changing from positive to negative – tends to occur
during the systolic phase of the flow cycle [49]. Termed the oscillatory shear index
(OSI), it was devised to account for the cyclic departure of the WSS vector from its
predominantly axial alignment [50]. In a haemodynamic investigation conducted in a
canine model, WSS, WSS gradients and OSI were all evaluated and it was found that
the exponential function of OSI correlated best with IH formation [48]. This leads to
the production of ECM components and an invasion of SMC into the intima – the
hallmarks of IH. How the EC transmit these biomechanical signals into a biochemical
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response is still unclear with several mechanisms being proposed [48,51,52].
1.6 Overview of Thesis
This thesis presents a clinical viable alternative to currently available prosthesis for
vascular reconstructions. Given the clear clinical need, the general aim was to design
and construct a prosthetic small calibre conduit which can be used as an arterial
replacement in bypass surgery. By making use of a nanocomposite biomaterial with
improved biostability, mechanical properties and anti-thrombogenicity, it was antici-
pated that the grafts would have improved mechanical and interfacial properties in an
effort to minimise IH and thrombosis, without the need for complex cell therapies. In
chapter 4, a novel extrusion-phase separation, fabrication method, to produce small
calibre grafts was developed and optimised, which was reproducible and scalable.
The resultant grafts were then evaluated for their mechanical behaviour in chapter
5. The interfacial properties of the luminal surface were characterised extensively in
chapter 6 in order to better understand the blood-material interactions which were
investigated in chapter 7. Chapter 8 dealt with developing a stringent sterilisation
process which does not inadvertently harm material properties. Finally, the results
of a long term in vivo study is presented in chapter 9, which aims to investigate the
efficacy of using POSS-PCU grafts as bypass conduits.
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Replacement Blood Vessels: Concepts,
Progress and Future Challenges
Despite the long-standing clinical need, there have been few alternatives to autologous
vessels for bypass grafting. The ideal blood vessel substitute must overcome a myriad
of difficulties; principle amongst them is that blood vessels contain an interface with
blood, and with the exception of a fully functioning endothelium, no other substance
known to man is completely anti-thrombogenic. This presents the rather formidable
challenge of blood clotting when exposed to alternative surfaces, particularly in the
low flow, small diameter positions. The second challenge facing researchers is to
develop a conduit with the required radial strength which can withstand the, not
insignificant, arterial blood pressures. With mean arterial blood pressures approxi-
mately 100 mmHg, any implantable device must be robust enough to withstand the
constant pulsatile, shearing forces generated. Common with any other implantable
device, any developed graft must be resistant to infection and non-immunogenic.
Additionally, any replacement artery would have to be readily mobilisable for use in
emergency procedures, easy to handle and suture and available in a range of sizes
depending on the clinical need.
With such a challenging design criteria it is easy to see why success in finding al-
ternative prosthetic grafts has been limited. A wide range of strategies have been
proposed and investigated, which usually fall into two categories: biological grafts
which generally have better healing characteristics, and synthetic grafts with better
mechanical and functional properties.
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The ideal small calibre bypass graft
Biocompatible Safe, nontoxic and resistant to infection; graft does not
induce thrombosis or a severe inflammatory response
Healing character-
istics
Able to sustain a fully functioning endothelium and
integrate into the wider vasculature without a hyper-
plastic response
Mechanical proper-
ties
Viscoelasticity comparable to native vessels so as to
minimise the compliance mismatch between graft and
vessel; kink resistant
Durable Resistant to biodegradation, radial dilation and
aneurysm formation; bursting pressures in excess of
systolic pressures
Handling charac-
teristics
Easy to sterilise safely and suture and readily available
in a range of sizes
Table 2.1: Properties for the ideal small bore arterial substitute
2.1 Importance of Compliance Matching
As long ago as the 1960’s, it was suggested that the elastic properties of vascular
grafts may be an important parameter in determining long term patency of small
calibre grafts. However, this was merely an empirical observation as few controlled
studies were able to establish a clear correlation between graft performance, as mea-
sured by patency rates, and the mismatch in elastic properties between graft and host
artery.
The lack of reliable controls is a major problem in investigating the compliance mis-
match hypothesis. Studies have sought to compare the patency rates of a variety of
conduits with different elastic properties including PET grafts, veins grafts and arte-
rial grafts; however, these studies fail to take into consideration the different surface
properties, graft tearing, and wall thicknesses that each conduit exhibits. More re-
cently, the importance of compliance in determining graft patency was investigated in
a canine model whereby common carotid artery autografts were treated with gluter-
aldehyde, in a variable manner to differentially alter compliance, and then implanted
end to end with the femoral artery [53]. The compliance of grafts and arteries were
either 10% matched or 60% mismatched, resulting in patencies of 85% and 37% at
90 days respectively providing a clear link between graft compliance and patency.
These results were corroborated by a separate study where 36 femoropopliteal recon-
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structions were performed in 18 sheep with autologous venous grafts [54]. Dacron
mesh was used to surround the venous graft to achieve a state of compliance mis-
match and lumen adaptation. A clear correlation was found between compliance and
thickness of the hyperplastic intima that formed at the distal anastomosis 8 months
post-implantation. The study was initiated with autologous grafts and so influences
of exogenous materials were discounted; with it being assumed that the mechanisms
effecting prosthetic and autologous grafts are the same.
Whilst the mechanism remains elusive, clinical evidence suggests that patency rates
of small calibre grafts is significantly improved by matching graft and arterial com-
pliance. For this reason, compliance matching is now thought to be an essential pre-
requisite for the successful design of a vascular graft. However, combining strength
and elasticity is a difficult challenge to meet. Neither of the current industry standard
biomaterials, PTFE or PET, displays the elastic properties to be used as conduits in
small calibre reconstructions.
2.2 Biological Grafts as Arterial Substitutes
The central aim of biological grafts is to mimic the structure and function of the
native vessel (fig 1.1). The intima consists of a confluent layer of EC which is an-
tithrombogenic, nonimmunogenic and resistant to infection. Thereafter, the medial
layer, which is also the thickest, consists of SMC, collagen and elastin. The SMC are
arranged concentrically around the vessel and are surrounded by ECM proteins. As
has been mentioned, the medial layer is primarily responsible for the vessels mechan-
ical strength and maintaining structural integrity, with dilation and constriction the
result of SMC response to external stimulus. The re-creation of the properties of the
intimal and medial layers is thought to be vital for a functioning arterial graft that
is antithrombogenic and maintains structural integrity. A number of paradigms have
been proposed to engineer vascular tissue most of which involve a scaffold, cells and
a bioreactor. The central hypothesis is that cells are cultured on the scaffold; which,
over time, results in the deposition of ECM and spatial reorganisation of cells into
continuous tissue formation. Whilst the concept is simple, many decisions are re-
quired over cell sourcing, culture conditions and the types of scaffolds. Furthermore,
two opposing concepts have been pursued, each yielding promising results; namely,
the engineering of arteries in vitro or regenerating the artery in vivo.
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2.2.1 Scaffolds
The primary function of the scaffold is to provide support for the cells to adhere,
grow and organise themselves into functional tissue. A range of materials have been
exploited including degradable synthetic polymers, decellularised tissue and biopoly-
mers. The basic premise of using synthetic polymers is that they will provide the re-
quired mechanical support and stimulus for the cells to grow and remodel. Over time,
the synthetic material would then biodegrade leaving behind load bearing, functional
tissue. The use of synthetic materials has some distinct advantages; the polymer
chemical composition can be carefully controlled to manipulate the microstructure,
physical properties and degradation rates of the polymers in effort to optimise tissue
formation.
Polyglycolic acid (PGA) is perhaps the most popular synthetic material due to
its FDA approval and current widespread use in surgery as sutures. Polyglycolic
acid (PGA) degrades through hydrolysis of its ester bonds, with glycolic acid being
metabolised and eliminated as water and carbon dioxide. However, PGA is rapidly
absorbed and loses its mechanical strength in as little as 4 weeks raising the possi-
bility of a failure of the cells to produce sufficient amount of ECM before polymer
degradation. Copolymerising PGA with a range of other polymers, poly-L-lactic acid,
polyhydroxyalkanoate and polyethylene glycol (PEG) to name a few, can improve its
mechanical properties and adsorption rates [72, 73]. PGA scaffolds were coated with
poly-4-hydroxybutyrate (P4HB) to produce a scaffold on which myofibroblasts and
EC were seeded and cultured before implantation in the pulmonary artery of a lamb
model. By investigating the up-regulation of key enzymes, the authors were able to
show matrix remodelling on their grafts [74].
Alternatively, an elastomeric biodegradable polyester, Poly(glycerol-sebacate) (PGS),
has also been suggested for vascular tissue engineering [68]. PGS was shown to sus-
tain both EC and SMC growth, with the expression of vWF and alpha-smooth muscle
actin, respectively, being confirmed by immuofluorescence. Further, PGS demon-
strated considerably improved haemocompatibility with platelet adhesion, IL-1β and
TNFα release being considerably less than reference materials [69]. Further, the
PGS scaffold was shown to induce SMC characteristics from bone marrow mononu-
clear cells, in conjunction with platelets and plasma [70].
Whilst the use of biodegradable synthetic polymers, such as PGA, has yielded some
promising results there is evidence to suggest that the scaffold degradation products
may cause IH [75]. PGA remnants were found to change SMC phenotype from con-
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tractile to synthetic, with the latter being associated with IH in intermediate to late
graft occlusion [76].
The use of biopolymers is highly appealing as the resultant construct would be a
completely biological graft minimising problems associated with exogenous materi-
als. Collagen, an ECM protein and the most abundant mammalian protein, was used
in the pioneering work of Weinberg and Bell who demonstrated that dissociated cells
can be used to generate functional tissue [77]. Collagen appears to be the best placed
biopolymer for successfully TEBV as it is the collagen fibres that limit the high strain
deformations of blood vessels that prevent rupture [78]. Due to the ubiquitous na-
ture of collagen it tends to induce a minimal inflammatory and antigenic response
from the host [79]. Furthermore, collagen expresses integrin binding receptors on its
surface allowing for cellular adhesion and endothelialisation. The major drawback
to using collagen is its inadequate mechanical strength. Weinberg and Bell reported
nominal burst pressures of 90 mmHg. In recent years that has been improved upon
drastically through SMC alignment, cross linking with polysaccharides and proteins
and shear preconditioning; however, the mechanical properties of collagen scaffolds
still remain inadequate [80–82].
Composites of biopolymers and degradable synthetic materials have been developed
in a bid to improve mechanical properties. An elastin/polycaprolactone (PCL) con-
struct was produced via electrospinning resulting in a bilayered graft whereby the
luminal side was composed of elastin and the outer layer was a elastin/PCL hy-
brid. The multilayer construct demonstrated improved mechanical durability and
low thrombogenicity, both in vitro and in vivo, in a small scale rabbit carotid inter-
position model [61]. Alternatively, autologous fibrin with a biodegradable polylactide
mesh support has been fabricated into a vascular graft. Seeded with SMC and fi-
broblasts and then lined with EC, the construct was attached to a bioreactor and
mechanically conditioned for a period of 21 days [62]. The resultant graft appeared
to be mechanical robust and capable of sustaining EC growth; it was thus implanted
in a carotid artery of a sheep for a period of 6 months [63]. With the exception of
one graft, which experienced severe stenosis, the fibrin/polylactide constructs were
fully patent with the complete absence of thrombus formation on the luminal surface
of grafts and no evidence of aneurysm formation or calcification.
The use of decellularised tissue has some distinct advantages as it is almost entirely
composed of ECM giving it numerous advantages in terms of biocompatibility. The
critical step in decellularised tissue is the removal of the cellular components with
40
2.2. BIOLOGICAL GRAFTS AS ARTERIAL SUBSTITUTES
detergents, enzyme inhibitors, and buffers whilst keeping the biological scaffold in-
tact [83]. The scaffold can then be implanted into a host without any cells present
under the premise that they will provide optimal cell anchoring sites and thus will
be recellularised by host cells following implantation. The drawbacks of decellularis-
ing are that the mechanical properties, tensile strength and compliance, often suffer
severely during the extraction process [84]. Shrinkage, possibly due to the loss of
proteoglycans, is often observed as well as aneurysm, infection and thrombosis [85].
The residual antigenicity is also problematic as it can impair endothelialisation [86].
The tissue used for decellularising can be vascular in origin or non-vascular. Small
intestinal submucosa (SIS) has been successfully decellularised resulting in a scaffold
composed primarily of collagen (type I), fibronectin, growth factors, glycosaminogly-
cans, proteoglycans, and glycoproteins [87]. Patency rates, in a canine model, of SIS
grafts are comparable with saphenous vein with cellular infiltration being observed
at the midportion of the graft [88]. Alternatively, human umbilical arteries were de-
cellularised using the detergent CHAPS and sodium dodecyl sulfate buffers followed
by incubation in endothelial growth media-2. The decellularised umbilical arteries
supported EC growth and remained functional following an 8 week implantation in a
rat model [89]. Xenogenic tissue has also been investigated for decellularisation. An
ovine carotid artery was decellularised and seeded with mesenchymal stem cell (MSC)
derived smooth muscle and endothelial like cells and interposed into the carotid ar-
teries in an ovine host model [90]. The authors report the constructs to be patent,
anti-thrombogenic, and mechanically stable for 5 months in vivo.
2.2.2 Cells
All biological grafts require a cell source. The cells used have to be non-immunogenic,
easy to harvest and expand, and have the ability to differentiate into specific cell
types. Autologous cells obtained from the patient tend to be difficult to retrieve in
any great number, have limited proliferative capacity or require excessive time periods
for expansion. Stem cells possess some distinct advantages which include excellent
proliferative and growth potential; and current technologies mean they are easily ac-
cessible. Table 2.3 lists provides a brief summary of some of the different stem cells
which have been used for tissue engineering a blood vessel.
Embryonic stem cells (ESC) offer the potential for unlimited expansion: ideal for
tissue engineering. Further, their pluripotent nature makes them amenable to any
number of applications, including vascular. ESC have been shown to differentiate into
both EC and mural cells, and can contribute to developing vasculature in vivo [91].
The use of VEGF aides in promoting EC whilst PDGF induces mural cells. ESC
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have been shown to integrate into the circulatory system, grow on synthetic materi-
als, and the mechanical cues regulating their behaviour are beginning to be under-
stood [92–94]. Whilst the differentiation of ESC down vascular lineages has been
described, the precise conditions by which this is achieved have not been discovered.
So far, it has not been possible to differentiate ESC down a single cell line. A variety
of culturing conditions have been investigated with no clear consensus arising as to
the optimum method for differentiation and purification [95, 96]. Before ESC can
become a clinical reality, a robust culturing protocol must be elucidated.
Induced pluripotent stem cells (iPSC) are a type of pluripotent stem cell derived
from non-pluripotent sources through the ‘forced’ expression of specific genes. In
many ways iPSC are similar to ESC and offer the opportunity to generate donor spe-
cific pluripotent cells without the controversial use of embryos. iPSC generated from
mouse fibroblasts and juvenescent cells from cord blood have been shown to different
down cardiovascular lineages [97,98]. iPSC can mitigate any immunogenic side com-
plications of cell therapy, patient specific iPSC were prepared for the treatment of
limb ischaemia, thus offering an ‘off the shelf’ treatment option for the treatment of
limb ischaemia [99]. iPSc have also been successfully combined with polymeric scaf-
folds [100]. In subcutaneous implantation of the iPSC seeded polylactide scaffold, the
cells maintained a SMC phenotype, offering up the possibility of personalised tissue
engineering applications.
Mesenchymal stem cells (MSC) are primarily derived from bone marrow or adipose
tissue. They are easy to isolate, expand, have low immunogenicity and are multipo-
tent; a combination of properties making them promising for use in TE. MSC have
already found use in a clinical setting for orthopaedic applications [101]. The ability
of MSC to differentiate down a vascular lineage has been demonstrated on a number
of occasions [102]. MSC have also been seeded on PU grafts and implanted in Wistar
male rats. It was found that MSC restored the medial like thick wall and enhanced
endothelialisation of grafts [103]. Further, a bioreactor system was utilised to engi-
neer a blood vessel in vitro from bone marrow MSC and was found to be substantially
similar to a native vessel [104].
Amniotic stem cells (ASC) have also been demonstrated to be pluripotent and can
give rise to multiple lineages of all three embryonic germ layers. Further, they are
easy to isolate and expand. Their suitability for cardiovascular applications, amongst
others, has been demonstrated many times over [105, 106]. In addition to inducing
angiogenesis, ASC have been used to stimulate arteriogenesis through the secretion
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of mediators which are responsible for the stimulation and/or recruitment of host
reparative cells [107,108].
Endothelial progenitor cells (EPC) are a type of circulating CD34+ mononuclear cell
capable of attaining endothelial characteristics. Residing in the bone marrow and
circulating in low concentrations in peripheral blood, growth factors such as granu-
locyte colony-stimulating factor (GCSF) and VEGF as well as tissue ischemia and
vascular injury can mobilise EPC which proceed to stimulate re-endothelialisation of
injured blood vessel and repair function of ischemic organs [109,110]. EPC extracted
from human peripheral blood by the density gradient method have been cultured in
vitro and seeded onto vascular grafts [111, 112]. Studies indicate exceptional growth
characteristics suggesting they are a highly promising candidate for tissue engineering
purposes.
2.2.3 Bioreactors
Vascular cells, such as EC and SMC, are in a highly dynamic environment in vivo;
they are exposed to a range of mechanical forces which have been shown to influence
cell morphology, function and gene expression [113]. Indeed, mechanical forces have
been implicated as being critical to the tissue formation process [114]. In the tissue
engineering paradigm, ensuring proliferating cells adopt the correct phenotype is a
non-trivial task. In the vasculature, four distinct forces are known to regulate cellular
function, both in synergy and independently [115–117]:
1. Shear stresses: tangential frictional forces acting on EC and SMC due to blood
flow and transmural interstitial flow
2. Luminal pressure: cyclic normal force exerted by blood pressure
3. Mechanical stretch: cyclic circumferential strain also attributable to blood pres-
sure
4. Tension in the longitudinal direction
EC proliferation was shown to be shear dependant, with peak proliferative states at
∼5dynecm−2 (0.5 Pa) [118]. Both cyclic stretch and pulsatile hydrostatic pressure
further increased EC proliferation, with the proliferation rate being dependant on
both frequency of pressure and mean pressure [119,120]. In the case of SMC, as they
are not in direct contact with shearing forces, pulsatile distension is the dominant me-
chanical stimuli. Cultured statically, SMC dedifferentiated and proliferated rapidly
displaying a synthetic phenotype characterised by the production of large quantities
of ECM [121]. SMC with a contractile phenotype tend to have a cytoplasm rich in
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Cell type Cell source Comments Ref
Embryonic
stem cells
Derived from
the inner cell
mass of the
blastocyst
Pluripotent and unlim-
ited differentiation ca-
pacity, highly controver-
sial
[91–96]
Induced
pluripotent
stem cells
artificially de-
rived from a
non-pluripotent
cell
Pluripotent and similar
to ESC. Potential to
avoid immunogenic side
effects, reprogramming
could pose significant
risk.
[97–100]
Mesenchymal
stem cells
Derived from
bone marrow
and adipose
tissue
Multipotent, relatively
easy isolation and
expansion, low immuno-
genicity. Widely used
with a number of clinical
applications.
[101–104]
Amniotic stem
cells
Amniotic fluid Multipotent, non-
controversial, easy to
isolate and expand.
[107,108]
Endothelial
progenitor
cells
Derived from
bone marrow
Can differentiate into
EC, easy to isolate and
expand, low numbers in
circulation.
[109–112]
Table 2.3: Summary of cells available for tissue engineering a blood vessel
myofilaments. The change from contractile – present in the medial layer of healthy
arteries – to synthetic phenotype is seen in atherosclerosis and IH lesions. An im-
portant parameter in ensuring a contractile phenotype is the exposure to pulsatile
stretch; this is borne out by numerous studies suggesting mechanical preconditioning
is vital, prior to implantation, for the correct functioning of vascular cells cultured in
vitro [71].
To expose cells to the necessary mechanical stimuli, a range of bioreactors have been
developed. Bioreactors are laboratory tissue culture devices that aim to provide a
controllable, mechanically active environment for tissue culture. Whereas some biore-
actors expose only one aspect of the cardiovascular environment, such as shear force
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or cyclic distension; other more intricate systems, mimic the entire vascular envi-
ronment [122,123]. All such systems have demonstrated their ability to improve cell
proliferation, ECM synthesis and tissue growth. In addition to transmitting, mechan-
ical stimuli, bioreactors have been developed to improve the cell seeding density and
homogeneity by making use of convective mixing and flow [124,125].
2.2.4 Tissue Engineering a Blood Vessel
Tissue engineering a blood vessel refers to the complete engineering of a functional
vessel in vitro before implantation. This concept usually involves the culture of cells
on an appropriate scaffold in a bioreactor which provides the necessary perfusion of
nutrients and mechanical stimulus.
Perhaps the most impressive demonstration of tissue engineering a blood vessel in
vitro is the cell sheet approach, whereby no scaffold or any other exogenous mate-
rial was used to produce a fully functioning blood vessel [126]. Sheets of SMC were
cultured in the presence of elevated levels of ascorbic acid to induce collagen pro-
duction, which was then wrapped around a tubular support to produce the media
of the vessel. In the same manner, a sheet of fibroblasts were grown and wrapped
round the media to produce the adventitia. After several weeks of maturation the
construct was placed in a bioreactor designed to provide both luminal flow of culture
medium and mechanical support. Finally, EC were seeded by cannulating the ends
of the constructs and filling with EC solution and rotating slowly overnight.
Whilst the constructs were antithrombogenic and the mechanical properties were
impressive, the SMC did not exhibit circumferential alignment which is believed to
confer the artery with its unique mechanical properties [127]. The engineered blood
vessel was more compliant than ePTFE but not as compliant as the arteries it aims
to replace. Additionally, the production period took a total of 3 months, making it
unsuitable for emergency revascularisation purposes. The extended periods of cell
culture increase the chance of contamination and malignant dedifferentiation of the
cells. The TEBVs have been used for haemodialysis access on 10 patients with the 6
months results not wholly encouraging [128]. 3 grafts failed in the safety phase, one
patient died due to unrelated reasons, and another patient was withdrawn from the
study due to severe gastrointestinal bleeding. Of the remaining 5 patients, a further
surgical intervention was required on one patient to maintain secondary patency.
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2.2.5 A Regenerative Medicine Approach
The regenerative medicine approach has found favour amongst some researchers as it
eliminates the need for complex culturing conditions and bioreactors. Here the cell
seeded scaffold is directly implanted into the patient, where the body is allowed to
act as a natural bioreactor to induce tissue formation, with the scaffold gradually
degrading over time. In this strategy, the role of the scaffold is critical as it must
be mechanically robust enough to transport blood, and withstand systolic arterial
pressures, before tissue formation. Further, the scaffold should guide and support
continuous tissue formation in a homogeneous manner providing the necessary chem-
ical and mechanical stimuli for the cells to produce proteins, remodel the tissue and
organise their environment.
The in vivo approach has probably yielded the clinically most successful TEBV. A
scaffold composed of polyglycolic acid fibres coated with a 50:50 copolymer of poly-
lactic acid and polycaprolactone was seeded with autologous bone marrow derived
mononuclear cells and inserted as an intrathoracic inferior vena cava (IVF) interpo-
sition graft in a juvenile lamb model [66]. The graft was monitored using magnetic
resonance imaging (MRI) and remained patent whilst increasing in size over time, in
a symmetrical manner, proportional to the increase in size of the surrounding vas-
culature, indicating growth and remodelling as opposed to aneurysmal dilation. The
TEBV was then used to repair an occluded pulmonary artery in a 4 year old girl –
the first successful clinical application of a tissue engineered graft [129]. Based on
the successful results in both animals and humans a clinical trial took place whereby
the TEBV was implanted into 25 patients who underwent extracardiac total cavopul-
monary connection modified Fontan surgery [67]. 1 year after implantation there
were no graft related deaths, with only one complication reported – a partial mural
thrombosis, which was successfully treated with coumadin. 5 to 7 years after im-
plantation and all grafts were patent and intact; however, 4 grafts developed stenosis
requiring angioplasty.
Whilst the progress in tissue engineering vascular grafts is encouraging and has helped
to elucidate some of the fundamental remodelling mechanisms at play; it should be
noted, however, that the grafts were implanted in the low-pressure pulmonary cir-
culation where pressures are approximately 20-30 mmHg during systole, which is
considerably less demanding than systemic or coronary circulation where pressures
reach 100-140 mmHg during systole. The arterial circulation is far more demanding
and requires constructs with considerable radial strength to prevent rupture and/or
aneurysm formation. Currently, tissue engineered constructs, after scaffold degrada-
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tion, do not have the necessary mechanical strength to survive in the arterial circu-
lation.
2.3 Synthetic Grafts as Arterial Substitutes
Whilst there is no doubt that there has been significant progress in the field of tissue
engineering a blood vessel since the pioneering work of Weinberg and Bell 25 years
ago, there is still no clinically viable conduit for arterial replacements. The lack
of radial strength to withstand systolic pressures coupled with practical drawbacks,
such as insufficient length of conduit produced by current bioreactor technologies,
and expensive and time consuming cell culture protocols have meant that no TE
substitute has been translated to clinical practice. At the same time, the need for
small calibre grafts is increasing at an alarming rate. To meet this clinical need,
improvements to synthetic grafts have been sought. A range of strategies have been
explored to counteract the problems of thrombosis and IH; the two primary causes
of small calibre graft failure. These include the development of novel biomateri-
als, surface modifications and functionalisation with either anti-coagulant bioactive
agents or molecules which promote spontaneous endothelialisation; and optimising
graft mechanical properties in a bid to produce more elastic grafts thus minimising
the compliance mismatch between graft and artery.
2.3.1 Cell seeding
The most common problem in tissue engineered blood vessels tends to be insuffi-
cient radial strength resulting in excessive dilation and aneurysmal formation, and
in severe cases construct failure under systolic pressures. With this in mind, the
idea of a biologically active ‘hybrid’ graft was mooted whereby a fully functioning
endothelium would be seeded onto the luminal surface of synthetic vascular grafts.
The endothelium would alleviate many of the problems associated with exogenous
materials coming into contact with blood; namely, thrombosis and, to a degree, IH.
The synthetic graft, meanwhile, would provide the mechanical support and radial
strength that fully tissue engineered constructs lack.
Initially, EC were isolated from a subcutaneous vein segment, or usually from venipunc-
ture, and were immediately seeded onto the graft lumen. Clinical results, however
were largely disappointing with a lack of a confluent endothelium reported 14 weeks
after bypass surgery [130]. A further trial revealed that after 30 months the patency
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of a EC seeded ePTFE graft was significantly worse compared to a vein graft – 38%
vs 92% [131]. These disappointing results were put down to insufficient initial cell
density, poor adhesion under flow, and failure to achieve a confluent EC monolayer.
Undeterred by the poor clinical results, an improved cell seeding procedure was de-
veloped which involved EC being extracted from the vein or artery of a patient and
cultured ex vivo before seeding, resulting in an increase in cell density upon a 3-4
week cell culture period [132]. Clinical results with the two stage procedure are a lot
more encouraging with 9 year patency rates of 65% for EC seeded ePTFE grafts in
the femoropopliteal position [133]. Furthermore, 14 patients received autologous EC
seeded, 4mm ePTFE grafts as conduits for coronary artery bypass grafting of which
91% were patent at 28 months [134]. Mechanical preconditioning further enhanced
cell retention by inducing structural changes and adaptation of EC cultured on syn-
thetic vascular grafts [71].
Whilst conceptually promising, care must be taken when seeding grafts with cells. EC
grown on prosthetic surfaces may alter phenotype and display a pro-coagulant phe-
notype promoting thrombosis rather than inhibiting it. Activated EC may increase
growth factor production, encouraging SMC proliferation leading to IH. Cell sourcing,
attachment and retention during pulsatile flow continues to be a problem. Possible
solutions continue to be found with new cell sources, such as peripheral blood, bone
marrow, omentum and subcutaneous fat being reported [135–137]. Adhesive proteins
including fibronectin, collagen and RGD (Arg-Gly-Glu) have been investigated with
the aim to improve cell adhesiveness [138]. Whilst the clinical results for the 2 stage
seeding of grafts are very promising; it is highly time consuming and can not be
used in acute cases. The cell culture process is very costly, highly specialised, labour
intensive and carries the risk of infection.
2.3.2 Biofunctionalised materials
Considerable research effort is taking place in modifying current, commercially avail-
able, vascular grafts. One way in which patency rates can be increased is through
coating or binding commonly used anticoagulants, such as heparin and hirudin, to the
lumenal surface of the graft. Modified ePTFE and PET grafts are both commercially
available. The Gore-Tex Propaten graft, an ePTFE graft with heparin anchored to
the luminal surface via a proprietary end-point attachment mechanism, underwent
a prospective non-randomized clinical trial to evaluate its efficacy [139]. The one
year patency rate was 82%; 84% in the above knee position, 81% below the knee and
74% for the femorocrural position. This would suggest an improvement in the overall
48
2.3. SYNTHETIC GRAFTS AS ARTERIAL SUBSTITUTES
patency of the heparin anchored graft; however, it should be noted that there was
no control arm in the study and a prospective randomized controlled trial is really
needed to determine the exact effectiveness of this treatment.
An alternative method to enhance the anti-thrombogenicity of biomaterials is the
introduction of nitric oxide (NO) releasing molecules. NO has been shown to be
a powerful inhibitor of platelet activation and adhesion, bacterial cell adhesion and
SMC proliferation associated with restenosis and intimal hyperplasia [140]. A num-
ber of NO donors have been investigated from the exogenous diazeniumdiolates to
the endogenous S-nitrosoglutathione and S-nitrosocysteine (fig 2.1). Diazeniumdio-
lates are NO donors formed by the reaction of secondary amine structures with NO
under high pressure. The major advantage of using diazeniumdiolates is that they
are stable solids, the half-life of NO release can be tailored to the specific need and
NO release can be easily triggered in an aqueous environment [141]. A number of
NO releasing grafts have been developed: NO releasing polyethylene-amine , PU and
ePTFE grafts [142–144]. All grafts displayed NO releasing characteristics for a period
of time ranging from one week to two months. Platelet deposition and SMC prolifer-
ation was seen to be diminished and EC growth was enhanced in vitro. Patency rates
of NO releasing grafts, in arteriovenous shunt models, was much improved. However,
there were some significant drawbacks. The incorporation of an NO donor into the
graft impacted on the mechanical properties of the graft changing the compliance
profile and thus compromising the medium to long term graft patency [142]. Even
more worryingly, it was shown that some of the diazeniumdiolate leaches out of the
polymer matrixes and form measurable levels of nitrosamines, a well-known carcino-
gen [143]. Further, the finite nature of the released NO calls into question their ability
to coat long-term implants [145]. Liberating NO from endogenous sources may be
a more fruitful approach. By immobilising L-cysteine on graft surfaces, NO can be
released through the free thiol group undergoing NO exchange reactions [146]. The
major advantage of this type of material is the unlimited source of NO which can be
generated locally when blood comes into contact with the implant.
With the success of drug eluting stents in mind, sirolimus and paclitaxel (two com-
monly prescribed antiproliferative drugs) coated ePTFE grafts have been examined
in vivo in a bid to minimise the proliferative capacity of SMC in IH. A porcine il-
iac artery bypass model was used to test the sirolimus coated ePTFE graft with
the authors reporting a statistically significant reduction in cross-sectional narrowing
compared with the untreated and adhesive treated graft [147]. Paclitaxel was exam-
ined in a porcine arteriovenous model, and whilst the haemodynamic environment is
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(a) diazeniumdi-
olate
(b) S-nitroso-L-
glutathione
(c) S-nitroso-L-cysteine
Figure 2.1: The structure of NO donors
very different from an arterial bypass, stenosis was greatly reduced compared to the
control [148].
We have discussed the presence of cells with endothelial characteristics circulating
in peripheral blood already. A large body of work in developing synthetic grafts for
small calibre applications is concerned with the capture and adherence of these cells
to the lumen of the graft in an effort to endothelialise in vivo, thus providing a non-
thrombogenic interface with circulating blood. The principle strategy for synthetic
vascular grafts to capture EPC from circulating blood has been the immobilisation
of capture molecules on the graft surface [149]. As there is a low concentration of
EPC in peripheral blood, the ideal capture molecule must have a high affinity, se-
lectivity and specificity to EPC. Even a weak affinity for other cell types present in
blood can be fatal, as the cells or proteins present in higher concentrations, will com-
pete for the binding site and cover the graft surface preventing the adhesion of EPC.
Numerous peptides, derived from the ECM, have been postulated as effective EPC
capture molecules including YIGSR, REDV and RGD [144, 150]. RGD is a binding
sequence found on integrins present on the surface of cells. It is implicated in sig-
nal transduction events regulating numerous cell functions such as proliferation and
migration and is responsible for connecting cells to themselves and the ECM. RGD
functionalised grafts not only displayed an improved endothelialisation potential, but
also improved cell retention when exposed to shearing forces [151, 152]. However,
the long term safety and efficacy of RGD coated surfaces, and their effect on cell
phenotype, is unclear. It should also be noted that RGD is not exclusively found on
EPC but is a rather common binding integrin found on numerous plasma proteins
including fibronectin, fibrinogen, vWF, collagen, laminin and vitronectin. Of these
proteins, only vWF is synthesised in any great quantity by EPC whilst all the other
proteins can be found on a multitude of leukocytes and platelets. The non-specificity
of RGD has the potential to cause a thrombogenic or inflammatory response and
should therefore be viewed critically.
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Much more specific capture molecules are antibodies. EPC express a number of cell
specific surface markers, including CD34, VEGFR-2, CD31 and VE-cadherin, which
can be identified using labelled monoclonal antibodies. Anti-human CD34 mono-
clonal antibodies were attached to ePTFE grafts and evaluated in a porcine model of
arteriovenous graft failure [153]. Histological examination appeared to demonstrate
complete endothelialisation of the graft with 95% coverage after day 3 compared to
less than 5% of the bare ePTFE graft. However, in spite of the rather impressive and
rapid endothelialisation, significantly increased levels of IH at the venous anastomosis
was observed. A number of explanations have been proposed for the increase in IH.
CD34 is a haematopoietic stem cell marker, with CD34+ cells capable of differenti-
ating into a number of different cell types including SMC. Therefore, it is possible
that the CD34+ cells adhered to the graft still had the potential to differentiate
into cell types other than EC including SMC. Alternatively, the differentiated EC
on the graft could have adopted an alternate phenotype resulting in the secretion of
pro-SMC growth factors and cytokines. The lack of compliance of an ePTFE graft
could have contributed. It is difficult to draw any significant conclusions from this
study as the adhered cells were insufficiently characterised – lectin, a surface antigen
common in many blood borne cells including monocytes, was used to characterise EC.
The major drawback in this strategy is the low concentration of EPC in the circu-
lation. Strategies to boost the mobilisation of EPC from the bone marrow and into
the circulation are required. Furthermore, a deeper understanding of the factors con-
trolling EPC differentiation on synthetic materials is required to get a firmer grasp
of factors influencing cell phenotype, growth factor and cytokine release.
2.3.3 Biomimetic materials
By utilising advances in nanotechnology, a new generation of biomaterials are be-
ing developed that can mimic the structure and biological functions of the natural
ECM. The cellular microenvironment largely dictates its fate; the natural ECM is
not a smooth structure but rather it contains nanostructured grooves, ridges, pits
and pores and fibrillar networks composed mostly of collagen and elastin fibres, with
diameters ranging from 10-300nm, providing topographical cues to regulate cell be-
haviour. Nanopatterning of the luminal surface of a vascular graft can increase its
cellular adhesiveness. Poly(lactic-co-glycolic) acid (PLGA) was chemically etched
with sodium hydroxide to produce a nano-scale surface that exhibited an increased
affinity for endothelial cells [154]. Cellular function was also shown to improve as cells
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grown on nano-structured surfaces were observed to have long filopodia protruding
from the cell body allowing the cell to sense the surrounding area and interact with the
nanometre structures [155]. Furthermore, an increase in matrix metalloproteinases,
enzymes linked to cell movement and adhesion to substrata was observed from the
supernatant of EC cultured on nano-structured surfaces.
A highly versatile and inexpensive method of mimicking the native ECM fibrous net-
work is through electrospinning [156, 157]. In this method (Fig 2.2), an electrostatic
force is applied between the positively charged polymer solution and the substrate.
When the electrostatic charge overcomes the surface tension of the droplet, a polymer
jet is formed (Fig 2.2A), which then elongates and thins. As the solvent evaporates
from the jet, an electrically charged polymer is left behind. These solidified fibres are
then collected on a grounded surface (Fig 2.2B). Due to the simplicity of this method,
electrospinning has been widely used by a variety of research groups. A range of ma-
terials - biodegradable and non-biodegradable, synthetic and natural polymers - can
be electrospun, ranging from silk fibroin and collagen to PU and polyesters. This
technique allows for the control of thickness, composition and porosity of nanofibre
meshes with a relatively simple experimental set up. Fibres with a diameter of a few
micrometers down to as small as 3nm can be developed, resulting in significantly
larger surface areas [158]. Porosities in excess of 90% and pore sizes ranging from
a few microns to tens of microns can be produced resulting in effective cellular in-
filtration and allowing mass transport of nutrient and waste products to and from
cells [159,160]. Blends of different materials can be used to augment the mechanical
and/or biological behaviour of the scaffold. Furthermore, the fibres can be function-
alised with a wide range of ECM proteins and bioactive agents resulting in a scaffold
which has ECM like physical and biochemical properties. Through providing a more
biomimitec environment for cells to grow upon; cell adhesion, proliferation, migra-
tion and differentiation were all shown to improve on electrospun fibres [161]. Cells
orientate in the direction of the fibres, which is particularly pertinent for EC as it
mimics the morphology of EC in vivo under blood flow.
A number of vascular grafts have been manufactured through electrospinning hoping
to benefit from the improved substrate topography; however, these constructs are
often limited by the size in which they can be manufactured leading to poor burst
strengths [162]. By aligning the nanofibres, greater mechanical strength and mod-
ulus of nanofibre can be achieved and some degree of control over direction of cell
growth can be administered [163, 164]. Further functionalization of the graft with
ECM proteins such as gelatin and collagen, appeared to improve EC and SMC ad-
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Figure 2.2: Schematic diagram of the electrospinning process for the production of poly-
meric nanofibres. A polymer solution is held in a syringe and pumped through a metal
needle. A high voltage supply is connected to the needle, producing a fine jet of polymer
solution (A). This dries out in transit, resulting in fine fibres which are collected on an
earthed target (B)
hesion, growth and functionality [165]. The expression of EC specific markers such
as vWF, CD31, CD54 and CD106 indicate normal cell function is maintained in
vitro [166]. Electrospinning can be further utilised to overcome the inherent prob-
lem of cellular infiltration into scaffold pores, by concurrently electrospraying cells
whilst electrospinning the polymer [167]. SMCs were uniformly integrated into the
graft both radially and circumferentially using this technique. The graft appeared to
be strong and flexible with reasonable dynamic compliance and burst strength values.
An alternative method to achieve the ECM like morphology is through self assembly
of peptides. Molecular self-assembly is unique in its simplicity and ability to form
a wide range of diverse nanostructures. It involves the spontaneous organisation
of molecules into more energetically stable conformations favoured by hydrophobic,
Van der Waal and electrostatic interactions, as well as hydrogen bonding, result-
ing in a final supramolecular structure ordered on multiple length scales [168–170].
This technique allows for the molecular control of the materials whilst fabricating
three dimensional (3D) scaffolds providing the potential to mimic the complex sig-
nalling machinery of the ECM. An elegant example of collagen, a key component
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of the native ECM, self-assembly was demonstrated using peptide amphiphiles held
together in a staggered array by disulfide bonds [171]. The hydrophobic head of the
peptide amphiphiles formed the triple helical structure whilst the hydrophilic tail
reorganises and stabilises the self-assembled three dimensional structure of the scaf-
fold. Scaffolds can be functionalised with self-assembled peptide amphiphiles which
act as cell adhesive ligands such as Tyr-Ile-Gly-Ser-Arg (YIGSR) and Val-Ala-Pro-
Gly (VAPG) [172]. The attachment of these peptides can significantly increase the
adhesion, spreading and proliferation of EC. It was also found that these particular
ligands reduced platelet adhesion compared to collagen controls, which for vascular
applications, is highly desirable.
The mechanical behaviour of the graft is important not only in terms of compliance
and improving graft patency, but recent evidence also suggests that substrate me-
chanics play a pivotal role in cell behaviour [173]. Substrate stiffness, in terms of
compressibility, has been shown to affect the mechanical properties of the cell itself
with EC cultured on stiff collagen gels being twice as rigid [174]. Further, in re-
cent studies with SMC, substrate stiffness was the determining factor in dictating
cell shape rather than the density of adhesive ligand to which the cell binds [175].
Whilst EC attach to substrates with a modulus less than 1000 Pa, they do not
spread and there is a lack of stress fibres and other actin bindles [176]. When cul-
tured on substrates with a modulus of 3200 Pa or more, stress fibres were abundant.
Cytoskeletal tension and cell shape have been implicated as critical in determining
stem cell fate [177].
2.3.4 Polyhedral oligomeric silsesquioxane
Polyhedral oligomeric silsesquioxanes (POSS) is a caged silsesquioxane molecule (fig
2.3). Silsesquioxanes are structures with the stoichiometric formula RnSinO1.5n with
the inner inorganic framework made of silicone and oxygen, whereas the outer organic
covering consists of substituent groups that can range from purely hydrocarbon to an
alkyl, alkene, aryl or arylene group. The molecular architecture of silsesquioxanes can
be classified into two categories: caged and non-caged. A closed cage silsesquioxanes
results in POSS molecules with the formula of (RSiO1.5)n where n=8,10,12. A typical
POSS molecule with the silica-like core (0.53 nm in diameter), externally covered by
eight organic corner group with the general sizes ranging from 1 to 3 nm in diame-
ter, can be thought of as the smallest possible particles of silica [178]. The hybrid
organic-inorganic framework renders POSS thermally and chemically robust; so much
so, that it has been shown to be resistant to atomic oxygen oxidation resulting in
POSS based polymers being used in orbiting space vehicles [179, 180]. Further, the
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inner framework of POSS, consisting of Si-O and Si-C bonds is analogous to silicone, a
favoured option in biomaterials due to its inert nature and low inflammatory response.
Figure 2.3: Molecular structure of POSS
Despite the promising mechanical properties, the drawback of conventional PU as
implantable biomaterials has been discussed previously; namely, degradation due
to oxidation and hydrolysis. With POSS known to be chemically robust and non-
inflammatory, combining the beneficial effects of POSS with PU would yield a highly
promising biomaterial. When used as filler, POSS tends to aggregate into larger
agglomerates due to its small size and to minimise its high surface energy [178].
Therefore, the Seifalian lab aimed to covalently attach the POSS molecule to the
4,4-methylenebis(phenylisocyanate) (MDI), PU hard segment; which was then re-
acted with poly(1,6-hexamethylene carbonate) diol, the soft segment in the PU. This
resulted in a pre-polymer which was chain extended with ethylenediamine in dimethy-
lacetamide (DMAc) forming the end polymer – polyhedral oligomeric silsesquioxane
poly(carbonate-urea) urethane (POSS-PCU, fig 2.4) [181].
POSS-PCU was shown to be more resistant to degradation and biostable, both in
vitro and in vivo [182, 183]. No changes in strength, toughness or elasticity were de-
tected after incubation with a range of degradative solutions for a period of 10 weeks;
thereby preserving the compliant properties of the parent PU. Following implanta-
tion in a sheep model for 3 years, no signs of degradation or inflammation were noted.
The POSS moiety is known to migrate to the surface of the polymer matrix, this
coupled with its high surface area, allows minimal quantities of POSS to be added to
the polymer whilst still exerting a significant influence over the material surface and
bulk properties. The amphiphilic, lipid-like, nature of the POSS-PCU nanocomposite
resulted in it having anti-thrombogenic properties by both repelling platelet surface
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adsorption and lowering the binding strength of platelets to the nanocomposite poly-
mer. Coupled with its potential to support EC growth, it is a promising candidate
for cardiovascular applications [184, 185]. POSS-PCU has already been used in the
development of heart valves and for stent coating applications; and its feasibility for
use in developing vascular grafts has been explored [186–188].
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3
Aims of Thesis
Previously, the Seifalian lab has developed a novel nanocomposite biomaterial which
displayed improved anti-thrombogenic and mechanical properties; making it a promis-
ing material for cardiovascular applications. It has already been used to develop range
of medical devices including stents and heart valves. The central aim of this thesis is
to develop a clinically viable, small calibre prosthetic graft for bypass surgery.
Multiple challenges need to be overcome in the creation of small calibre vascular
graft. A method to fabricate conduits, in a scalable and reproducible manner, to
a clinical standard with acceptable handling characteristics needs to be developed.
Thereafter, the functional behaviour of the grafts needs to be characterised and the
biocompatibility assessed. Before the graft can be considered for human use, it must
undergo a pre-clinical trial in vivo in a suitable animal model.
Therefore, the work in this thesis can be further broken down into four specific aims
as follows:
1. Develop and optimise a reproducible and scalable method for the
fabrication of POSS-PCU vascular grafts.
A novel extrusion-phase inversion method was developed and evaluated through
a qualitative assessment of handling characteristics and a quantitative assess-
ment of graft geometry and porosity. An automated extrusion machine was
commissioned to assist in the manufacturing and the scalability of the process.
The addition of a porogen to control graft pore size and porosity was inves-
tigated. The method was iteratively improved to manufacture fully scalable
grafts in a range of dimensions.
2. Achieve biomechanical properties similar to the native artery
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The tensile strength was evaluated as a measure of graft strength and its ability
to withstand systolic pressures in the circulation. Handling characteristics such
as suture retention were characterised to ensure that graft was clinically viable.
A flow circuit was developed to mimic the circulatory system to examine the
dynamic mechanical properties, such as compliance and viscoelasticity, of the
vascular grafts at physiologically relevant arterial pressures.
3. Characterise the biocompatibility of the grafts, in terms of the throm-
bogenic and immunogenic response as well as the potential for en-
dothelial cell growth to these surfaces in vitro
Biocompatibility was assessed through measuring the release of a range of cy-
tokines including PF4, IL-1β, IL-6. IL-10 and TNF-α. The presence of proteins
critical in the coagulation cascade was assessed as was platelet and mononuclear
cell adhesion. The expression of surface of markers (CD14, CD69 and CD86)
were examined and the ability to sustain endothelial cell growth evaluated. Sur-
face properties of the grafts were characterised in order to get a more complete
understanding of graft surface structure and functional properties especially
with regards to interface with blood.
4. Investigate healing and functional properties of POSS-PCU grafts in
vivo in a large animal model
Implant POSS-PCU vascular grafts for an extended period of time in a large
animal model following GLP protocols as per FDA guidelines. Monitor im-
planted grafts for their perfusion efficiency. Upon explantation histologically
evaluate grafts to get an idea on the healing characteristics upon prolonged
implantation.
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Fabrication of Vascular Grafts Using an
Extrusion-Phase Inversion Method
Developing a facile method that is able to meet the numerous structural requirements
for a small calibre vascular graft is a non-trivial task with multiple design considera-
tions to take into account. A major challenge in developing any load-bearing device is
balancing the conflicting interests between material porosity and mechanical strength.
The graft must be mechanically robust to withstand systolic arterial blood pressures
whilst having a porous graft wall. Porosity has been deemed an essential prerequisite
for the successful healing of a vascular graft [189]. It is essential to anchor the neoin-
tima in position and for the mass transport of nutrients and the removal of metabolic
waste products. Further, porous graft walls have been demonstrated to improve en-
dothelialisation of the constructs [190]. The challenge is further complicated as there
are no clearly defined criteria for the porosity of vascular substitutes or, indeed, me-
chanical properties of arterial replacements.
Any fabrication process for the manufacture of vascular grafts must also be able to
produce grafts in a range of dimensions. For the treatment of coronary or carotid
occlusions, grafts rarely require a length of more than 150 mm; however, for the treat-
ment of PAD, particularly from the above knee femoral position to the dorsalis pedis
or posterior tibial artery, requires grafts of approximately 1 m in length. Furthermore,
there should be a uniform wall thickness throughout the prosthesis and it should be
defect free as any imperfection could be fatal. Finally the fabrication method must
be fully reproducible and scalable. The ability to control the structural elements of
graft design is important as it is these properties which will essentially dictate the
mechanical and, along with the nature of the material, the biological properties of
the graft.
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A number of different techniques have been proposed and utilised which range from
electrospinning and salt leaching to excimer laser ablation [191]. In this work, an
extrusion phase inversion method was developed with the aim to produce grafts in a
reproducible manner in a range of dimensions. Phase inversion involves the immersion
of a thin layer of polymer solution in to a liquid non-solvent in which the polymer is
immiscible. The exchange of solvent from the polymer solution with the non-solvent
from the coagulation bath produces thermodynamic instabilities which are resolved
by the separation into polymer-rich and polymer-lean phases. The polymer-rich phase
forms a solid membrane matrix while the polymer-lean phase leaves a porous struc-
ture by leaching out of the system. The rates of solvent/non-solvent demixing and
polymer precipitation during phase separation are two primary influencers of the
membrane morphology [192]. Fine tuning factors which influence these twin proper-
ties provide a means with which grafts with a range of structural properties can be
produced. Additionally, a porogen can be added to the system which is then leached
out during the phase inversion step. The addition of the porogen allows greater con-
trol over macropore formation with the porosity effectively controlled by the quantity
of porogen added, and the pore size of the structure can be adjusted independently
of the porosity by using particles of different sizes.
In this study, we developed and optimised a phase inversion method to produce
vascular grafts in a range of dimensions from the previously discussed POSS-PCU
biomaterial. An automated extrusion machine was designed to produce grafts to a
clinically viable standard. The influence of manufacturing parameters on the graft
structure were investigated in order to get a fuller understanding of the phase sepa-
ration process.
4.1 Materials and Methods
4.1.1 Polymer preparation
POSS-PCU synthesis
The reaction scheme for the synthesis of POSS-PCU is shown in fig 2.4. Polycarbon-
ate polyol, 2000 MWt,(Bayer MaterialScience GmbH) and trans cyclohexanechloroy-
drinisobutyl silsesquioxane (Hybrid Plastics Inc) were placed in a 250 ml reaction
flask equipped with mechanical stirrer and nitrogen inlet. The mixture was heated
to 135◦C to dissolve the POSS cage into the polyol and then cooled to 70◦C. Flake
MDI was added to the polyol blend and then reacted, under nitrogen, at 75◦C-85◦C
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for 90 minutes to form a pre-polymer. DMAc was added slowly to the pre-polymer to
form a solution; the solution was cooled to 40◦C. Chain extension of the pre-polymer
was carried out by the drop wise addition of a mixture of ethylenediamine and di-
ethylamine in DMAc to form a solution of POSS-PCU in DMAc. Unless otherwise
stated, all chemicals and reagents were purchased from Aldrich Limited, Gillingham,
UK.
POSS-PCU/NaHCO3 preparation
Sodium bicarbonate (NaHCO3, 40µm particle size, Bruner Mond, Cheshire, UK) was
dispersed into an 18% (w/w) solution of POSS-PCU in DMAc containing Tween 80
surfactant. The mixture was dispersed and degassed in one process using a Thinky
ARE 250 mixer (Intertonics, Oxfordshire, UK) resulting in a viscous slurry. The
quantity of NaHCO3 used was altered to manufacture graft of varying porosities.
Polymer rheology
Rheological evaluation of POSS-PCU and POSS-PCU/NaHCO3 was undertaken us-
ing a Bohlin CVO Rheometer (Malvern Instruments, Malvern, United Kingdom) at
ambient temperatures of 25◦C. The viscosity of the samples was obtained over a shear
rate range of 0-250 s−1 using a cone and plate geometry configuration for samples.
4.1.2 Graft fabrication
Design of automated extrusion machine
Previously, we have developed a bench top extrusion machine capable of producing
grafts with a maximum 10 cm length (fig 4.1). A mechanical arm descended vertically
through a stainless steel chamber. The stainless steel chamber contains the polymer
solution, so that when the mechanical arm was driven through it, it would be coated
with a layer of polymer. A column of distilled water was placed directly below the
chamber into which the mechanical arm would be driven into and left undisturbed
for a period of 20 minutes. The formed tube was then removed from the mechanical
arm by gentle agitation. Whilst this experimental set-up worked reasonably well and
allowed the optimisation of the phase separation method, the grafts produced were
neither reproducible nor scalable. Further problems with the eccentricity of the grafts
led to inconsistent mechanical properties due to the unevenness of the graft walls.
Further, the addition of the polymer to the chamber via a syringe led to copious
trapped air bubbles which would cause inconsistencies and mechanical weak points
63
CHAPTER 4. FABRICATION OF VASCULAR GRAFTS USING AN
EXTRUSION-PHASE INVERSION METHOD
in the graft wall structure.
Figure 4.1: Digital images of bench top extrusion used for manufacturing vascular grafts.
An improved extrusion machine was designed and manufactured in conjunction with
industrial partners (W. Bibby Ltd, Neston) with the aim of eradicating the drawbacks
of the previous machine (fig 4.2). The principles behind the extrusion machine is the
same; a mandrel is driven through a polymer chamber and die and into a water bath.
The mandrel and die are interchangeable and have a range of dimensions allowing
the fabrication of grafts with a range of wall thicknesses and internal diameters. The
internal diameter of the graft is governed by the diameter of the mandrel whilst
the wall thickness is principally controlled by the size of extrusion die. Horizontal
extrusion was preferred to minimise the effects of gravity in distorting the polymer
coating vertically and both the mandrel and die rotate to prevent any eccentricity
forming in the polymer coating. The mandrel is pulled through the polymer chamber
by a second distal die which also acts to stabilise the 1 m long mandrel ensuring
a smooth coat of polymer is applied. The polymer is placed in a piston pump and
is dispensed onto the mandrel at controlled rates. A bleed valve just proximal to
the die helps to dissipate any trapped air bubbles which may cause imperfections
in the graft wall. Following extrusion, the mandrel is left in the water bath for a
period of 30 mins whereupon solvent exchange with distilled water takes place and
the polymer crystallises. Thereafter, the grafts are removed from the mandrel and
placed in de-ionised water for a period of 48 hrs followed by air drying for a further
48 hours.
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Figure 4.2: (a) Novel extrusion machine designed to manufacture grafts. (b) Proximal and
distal die showing the early stages of graft extrusion (c) The latter stages of graft extrusion
with phase separation taking place and the graft becoming more opaque (d) Distal die at
the latter stages of graft extrusion (e) A closer image of the proximal die, which determines
the wall thickness of the graft, and of a fully phase separated graft (f) Digital images of
vascular grafts following p complete phase separation and removal from mandrels
Manufacture of vascular grafts
Vascular grafts were manufactured using the modified extrusion machine previously
discussed. An 18% solution of POSS-PCU in DMAc was placed in the piston pump
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and dispensed at a speed of 0.07 mms−1. A mandrel with diameter 5 mm was used to
extrude grafts through a 7 mm die, at a speed of 3 mms−1, applying a 1 mm thick wet
coating of polymer. Both the extrusion die and mandrel rotate at a speed of 3rpm.
The graft is extruded into a water bath at room temperature and left undisturbed
for a period of 30 minutes. A number of variations were made in order to optimise
the extrusion conditions which included:
Temperature The temperature of the coagulant water bath was adjusted from a
minimum of 0◦C to a maximum of 50◦C in 10◦C increments. The remaining condi-
tions were kept constant. The effect of temperature on the morphology of the phase
separated membrane was evaluated.
Mandrel and die size Mandrels size was varied in an effort to produce graft with
a range of internal diameters. Mandrels of diameter 2, 3 and 4 mm were utilised in
addition to the standard 5mm mandrel. Mandrels were extruded through die’s with
diameters of 4, 5 and 6 mm respectively ensuring that the wet coating was of the
same thickness.
Use of porogen NaHCO3 was utilised as a porogen and combined with POSS-
PCU as detailed above. The concentrations of NaHCO3 used are described in table
4.1. Additionally, POSS-PCU/NaHCO3 composite was extruded through die’s of 8
mm and 9 mm diameter in order to form wet film coatings 1.5 and 2 mm thick.
POSS-PCU/% NaHCO3/% Tween 80/%
63 35 2
53 45 2
43 55 2
Table 4.1: Porogen:polymer formulations used to manufacture grafts. Values are displayed
as percentages of the total weight. POSS-PCU is an 18% solution in DMAc
4.1.3 Graft evaluation
DMAc liberation
The exchange of solvent during the phase separation process was monitored via gas
chromatography–mass spectroscopy (GCMS) (i2 Analytical services, Watford, UK).
Samples from the water bath were taken after 1, 12, 24, 36 and 48 hours and analysed
via GCMS for DMAc.
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NaHCO3 leaching
Inductively coupled plasma optical emission spectrometry (ICP-OES) (Warwick An-
alytical Services, Coventry, UK) was utilised to ensure all the NaHCO3 was leached
out of the grafts. Samples of grafts produced from POSS-PCU/NaHCO3 were taken
at 0, 1, 6, 12, 24, 36 and 48 hours after extrusion and exposed to inductively coupled
plasma detecting for electromagnetic radiation characteristic of Na+ as an indica-
tor of the presence of NaHCO3. The intensity of the emission is indicative of the
concentration of the element within the sample.
Differential scanning calorimetry
DSC analysis was undertaken to investigate whether the phase separation process
effects the crystallinity of the sample. 3 by 3mm samples of POSS-PCU and the
phase separated POSS-PCU were subjected to heat-flux DSC (Shimadzu DSC Ltd,
Japan) at a heating rate of 10◦Cmin−1. All samples were weighed pre and post-test
to confirm that there was no change in mass after melting. Analysis was done in
duplicates.
Gel permeation chromatography
GPC was carried out on POSS-PCU before and after phase separation to in order
to ensure that the phase separation process does not alter the molecular weight of
the material. Solutions of both samples were prepared by adding 15 mL of DMF
to 30 mg of sample and left to dissolve on a roller mixer over night. The samples
were analysed using a PL-GPC 50 system equipped with PLGel column guard and
3 PLGel 5m mixed bed-C columns (300×7.5mm). The measurement was carried
out at 50oC in DMF and the eluent was pumped at the constant flow rate of 1.0
mL/min. The system was calibrated by performing Universal Calibration with single
PL-polystyrene standard and a set of PL-EasyVial PS-H polystyrene standards of
known molecular weights. The detection was done using PL-BV 400RT viscometer
and PL-RI differential refractometer. The data has been collected and analysed using
Varian ‘Cirrus Multi detector’ software. Analysis was done in duplicates.
Wall thickness
Digital images were taken and image analysis software (Carl Zeiss KS 400 version
3.0) was used to measure the uniformity of wall thickness at 72 points distributed
equally around the circumference.
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Tensile Strength
Samples were cut longitudinally into a dogbone shaped specimen, 20 × 4 mm, using
a sharp cutter and mechanical press ensuring a clean cut with no flaws or stress
aggregation. However, due to the random nature of pore size and porosity in the
coagulated samples, variability is to be expected. Sample thickness was recorded using
an electric micrometer. Stress-strain profiles were characterised using a uniaxial load
testing machine (Instron 5565, UK) and the ultimate tensile strength (UTS) recorded
(n=6).
Porosity
The porosity of foams was calculated on the basis of their apparent density (ρ) and
bulk density (ρo) according to the following equation:
Porosity(%) =
(
1− ρo
ρ
)
× 100
 4.1
ρ values were measured gravimetrically on the basis of their dimensions and weights
and ρ0 is equal to 1.15 gcm
−3 for non-porous virgin POSS-PCU (n=3).
Pore size and surface area
Mercury porosimetry was performed on the grafts to evaluate pore size and surface
area using a Poremaster automated mercury porosimeter (Quantachrome UK). Grafts
(n=3) were weighed, sealed in penetrometers and subjected to porosimetry analysis.
For the purposes of data analysis, the surface tension of mercury and the intrinsic
contact angle with polymer, regardless of the sample, was taken to be γHg = 480Nm
−1
and θ = 140◦ respectively.
Scanning electron microscope
Graft samples (n=6) were washed with several changes of phosphate buffered saline
(Oxoid) and post fixed using 1% osmium tetroxide/1.5% potassium ferricyanide for 1
hour. The samples were then washed with distilled water and dehydrated through a
degrading acetone series (30%, 50%, 70%, 90% and 100% HPLC grade) washing twice
for 15 mins each. After dehydration the samples were transferred to tetramethylsilane
for 10 mins and then allowed to air dry. Finally, the samples were attached to
aluminium stubs with double sided sticky tabs (TAAB) and coated with gold using an
SC500 (EMScope) sputter coater for electrical conductance. The stubs were examined
and photographed using a Philips 501 scanning electron microscope. Images were
captured from random areas and were representative of the entire surface.
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4.2 Results
4.2.1 Graft fabrication
Empirical observations of the manufacturing process suggest that altering the tem-
perature or mandrel/die sizes did not significantly affect the extrusion or phase sepa-
ration process: grafts were successfully manufactured with internal diameters of 2,3,4
and 5mm (fig 4.3). However, upon storage and drying the grafts produced via phase
separation were found to be structurally unstable resulting in them shrivelling up and
collapsing (fig 4.4).
Figure 4.3: Digital image of POSS-PCU vascular grafts fabricated via extrusion-phase
separation method in a range of internal diameters.
Figure 4.4: Digital image of POSS-PCU vascular grafts before and after dehydration.
Graft is unable to maintain structural integrity resulting in deformation and shrinkage.
NaHCO3 was introduced to the system as a porogen which would be leached out
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in the phase separation process. Preparing the POSS-PCU/NaHCO3 dispersions
became increasingly more challenging as the quantity of NaHCO3 was increased.
There were minimal differences in viscosity for up to 45% NaHCO3 (fig 4.5); however,
concentrations in excess of 55% were highly viscous and were difficult to handle and
extrude therefore, it was not possible to manufacture grafts. Using 55% of NaHCO3
resulted in a viscous slurry however it was still possible to extrude and manufacture
grafts. The extrusions of the dispersions were successful and upon the drying the
grafts were found to be stable and maintain their shape and size.
Figure 4.5: Viscosity of POSS-PCU/NaHCO3 dispersions. There were minimal changes in
viscosity following the addition of NaHCO3 up to 45%. 55% NaHCO3 was significantly more
viscous but still extrudable whereas 60% NaHCO3 was difficult to handle and not possible
to extrude.
4.2.2 Graft evaluation
DMAc liberation
The concentration of DMAc in the water bath was evaluated with GCMS over a
period of 48 hours. The complete removal of DMAc was confirmed after 24 hours as
no further DMAc was liberated from the graft (fig 4.6a).
NaHCO3 leaching
The complete removal of NaHCO3 was confirmed via ICP–OES. After 24 hours only
trace amounts of Na+, 0.08%(wt/wt), was detected (fig 4.6b).
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(a) DMAc released into the water bath (b) Na+ remaining in the graft
Figure 4.6: GCMS and ICP–OES analysis confirming that all solvent and porogen are
removed from the graft.
DSC
The thermal properties of the graft assessed following phase separation to ensure no
change in polymer crystallinity. Phase separation induced no changes in glass tran-
sition temperature (Tg), which remained at -30◦C, suggesting polymer crystallinity
is not effected by phase separation.
Figure 4.7: Glass transition temperature (Tg) of cast and phase separated POSS-PCU
indicating no significant difference in the thermal properties of the polymer following phase
separation.
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GPC
GPC analysis of both POSS-PCU and the POSS-PCU graft formed through phase
separation was conducted to investigate whether any change in molecular weight took
place during the phase separation process. No significant changes were observed in
the number average molecular weight (Mn), weight average molecular weight (Mw)
or indeed the polydispersity (Pd) suggesting that phase separation does not adversely
affect the polymer chain structure (fig 4.8).
Figure 4.8: Molecular weight distributions of POSS-PCU and phase separated POSS-PCU
with the Mn, Mw and Pd values inset.
Wall thickness
Whilst the thickness of the wet polymer coating was the same in each case, the phase
separation process results in a contraction of the polymeric coating leading to a re-
duction in wall thickness. Both the temperature and the addition of NaHCO3 all had
a significant impact on the degree of contraction. At an extrusion temperature of 0◦C
the wall thickness was found to be 0.95 ± 0.04 mm which decreased significantly (p <
0.001, n=5) to 0.81 ± 0.02 mm at 10◦C. The reductions in wall thickness continued
with each incremental increase in temperature with the wall thickness being 0.56 ±
0.03 mm at 50oC. However, the severity of reduction decreased as temperature in-
creased with no significant difference detected between grafts formed at 30 and 40◦C
or 40 and 50◦C (fig 4.9a).
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With the extrusion temperature held constant at 25◦C, the addition of NaHCO3
significantly impacted the wall thickness of the grafts (fig 4.9b). The introduction
of 35% NaHCO3 resulted in a contraction twice the size of the NaHCO3 free graft.
Further addition of NaHCO3 resulted in a wall thickness of 0.42 ± 0.01 mm at 55%
NaHCO3.
(a) Effect of coagulant temperature on graft wall
thickness
(b) Effect of adding NaHCO3 on graft wall
thickness at a coagulant temperature of 25◦C
Figure 4.9: The impact of manufacturing conditions on the wall thickness of grafts extruded
via phase separation
Tensile strength
Figure 4.10 summarises the tensile properties of the vascular grafts produced via
phase separation. A gradual increase in UTS is seen for grafts as the coagulant
temperature is increased. Whilst no significant difference is observed between the
grafts produced between 0 and 30◦C there was a significant (p < 0.001) increase
in UTS for the grafts produced at 40 and 50◦C (fig 4.10a). The addition of 35%
NaHCO3, at a coagulant temperature of 25
◦C, significantly (p < 0.001) increased
the UTS to 3.21 ± 0.20 MPa. However, the further addition of NaHCO3 led to a
reduction in UTS with 45% NaHCO3 yielding a UTS of 2.38 ± 0.20 MPa and 55%
NaHCO3 exhibiting UTS values of 1.66 ± 0.30 MPa the latter being insignificantly
different to the graft produced with no NaHCO3 (fig 4.10b).
Porosity
SEM images of the cross sections of vascular grafts clearly indicate a porous structure
(fig 4.11). Phase separation of POSS-PCU produced large isolated pores sandwiched
between two skin layers. There appears to be a correlation between temperature and
cross section morphology of grafts. Phase separating at low temperatures produces
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(a) (b)
Figure 4.10: Ultimate tensile strength of POSS-PCU vascular grafts produced via phase
separation over (a) temperature range of 0 to 50◦ and (b) with or without NaHCO3
(*=p<0.001)
a highly porous graft with large isolated macrovoids. Increasing the temperature of
the water bath led to a, less porous, more compact membrane with smaller pore size.
This fact is borne out by the bulk density and porosity calculations (table 4.2) which
demonstrate that the bulk density doubles as you increase the temperature of the
water bath from 0◦C to 50◦C which manifests itself into a 20% reduction in porosity.
The introduction of NaHCO3 further dramatically altered the graft cross-sectional
morphology. The POSS-PCU/NaHCO3 grafts displayed a far more homogenous
structure composed of smaller, more evenly distributed, interconnected pores, in-
terdispersed amongst a fibrous network of polymer (fig 4.12). SEM images did not
display a visual difference between graft structure and concentration of NaHCO3;
a result which was confirmed with the bulk density and porosity calculations. The
addition of NaHCO3 did not alter the bulk density or porosity of the grafts signif-
icantly, compared to the grafts produced with no porogen and produced at room
temperature. Increasing the concentration of NaHCO3 did result in a slight increase
in porosity; however, a significant variation was only detected when 55% of NaCHO3
was used suggesting that the density and porosity ratio is relatively insensitive to the
concentration of NaHCO3 used.
Pore size
In order to obtain a more quantitative measure of graft pore size, mercury intrusion
porosimetry in the axial direction was conducted. Table 4.2 provides the modal pore
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(a) 0◦C (b) 10◦C (c) 20◦C
(d) 30◦C (e) 40◦C (f) 50◦C
Figure 4.11: SEM images of the cross section of grafts produced at a range of temperatures
between 0 and 50◦C. Magnification is ×80. Pore size and wall thickness reduce in size as
temperature increases.
Temp
(◦C)
NaHCO3
(%)
Bulk denisty
(gcm−3)
Porosity
(%)
Pore size
(µm)
Surface
area(m2g−1)
0 0 0.13 ± 0.02 88.70 ± 2.38 n/a n/a
10 0 0.16 ± 0.03 86.09 ± 3.19 n/a n/a
20 0 0.18 ± 0.05 84.35 ± 1.56 n/a n/a
30 0 0.19 ± 0.03 83.48 ± 2.78 n/a n/a
40 0 0.23 ± 0.05 80.02 ± 3.57 n/a n/a
50 0 0.27 ± 0.04 76.52 ± 3.39 n/a n/a
RT 35 0.15 ± 0.03 86.96 ± 2.19 15.21 ± 1.48 0.22 ± 0.04
RT 45 0.14 ± 0.03 87.83 ± 1.81 20.87 ± 1.87 0.50 ± 0.02
RT 55 0.11 ± 0.02 90.43 ± 1.33 30.75 ± 2.64 0.65 ± 0.04
Table 4.2: Mercury porosimetry and density measurements of grafts phase separated over
a temperature range of 0-50oC or fabricated with NaHCO3. Porosity is calculated from
equation 4.1. Mercury porosimetry and was not possible on the grafts produced with no
porogen. RT = room temperature.
diameters for the grafts produced with NaHCO3 with figure 4.12 displaying the pore
size distribution. Unfortunately, intrusion porosimetry could not be carried out on
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(a) 35% NaHCO3 (b) 45% NaHCO3 (c) 55% NaHCO3
Figure 4.12: SEM images of graft cross sections at ×10 magnification (top), ×160 mag-
nification (middle), and a distribution of pore sizes as obtained from mercury porosimetry
analysis (bottom).
grafts produced without NaHCO3 due to their closed-pore nature leading to excessive
torsion and compression of the sample. A significant (p < 0.001) increase in pore size
is evident with increasing concentration of NaHCO3. Whereas using 35% NaHCO3
results in a modal pore size of 15.21 ± 1.48 µm, 45% NaHCO3 yields a pore size
of 20.87 ± 1.87 µm which further increases to 30.75 ± 2.64 µm with 55% NaHCO3.
The increase in pore size further manifested itself in an increase in surface area. The
total surface area of the graft produced with 55% NaHCO3 is significantly higher (p
< 0.001) than the graft produced with 35% NaHCO3.
4.3 Discussion
The work in this chapter aimed at developing a facile method for the fabrication of
small diameter bypass grafts in a range of dimensions. An extrusion machine capable
of extruding 18% (w/w) POSS-PCU in DMAc was developed. Grafts with a range of
internal diameters, wall thicknesses and lengths can be fabricated in a reproducible
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manner. The versatility, simplicity and reproducibility of this production method are
major advantages.
In any extrusion process, viscosity of material is an important parameter. In this
instance the polymers behaviour was almost Newtonian with negligible variation in
viscosity over the shear rate range (fig 4.5) ensuring that the viscosity of the polymer
remains constant irrespective of the extrusion rate. Upon extrusion, a porous struc-
ture trapped between two skin layers was formed. SEM images of the cross section
(fig 4.11) suggested that the pores were isolated and large in size. This is likely due to
the almost instantaneous demixing when POSS-PCU is exposed to water. The ratio
of solvent outflow far exceeds that of non-solvent inflow resulting in large concentra-
tion gradients which leads to the diffusion process dominating polymer precipitation
initiating the formation of isolated macrovoids [193].
There appears to be a correlation between porosity and temperature of the water
bath (table 4.2). Increasing the temperature reduced the prominence of the large
tear shaped macrovoids; however, SEM images still display isolated and unconnected
pores. The lack of large pores and macrovoids translates itself into a reduction in
the overall porosity of grafts from approximately 90% to 75%. The principle effect
of an increase in the temperature of the water bath is an increase in the thermal
motion of the non-solvent and a reduction in surface tension of the water bath. The
combined effect of the two properties is likely to be an increase in diffusion of the non-
solvent through the skin, leading to an increase in the polymer crystallisation rate
resulting in fewer large macrovoids [194]. The combined effect of the two processes
is likely to prevent the development of the tear-shaped macroviods at an early stage.
This is also reflected by the high dimensional shrinkage with water bath temperature.
The closed pore structure is impermeable to water, solutes and cells and thus is likely
to inhibit the healing process by frustrating cellular attempt at successful integration
of the graft into its surrounding tissues due to the smooth surface providing no tether-
ing points which can result in the formation of a florid capsule around the graft. The
large pores also create structural weak points which can lead to excessive localised
dilation and even mechanical failure under pressure. Further, the grafts produced
were structurally unstable upon drying resulting in them shrivelling and collapsing.
It was postulated that the structural instability originated from the isolated nature of
the pores. Introducing solvents such as EtOH in the water bath have been shown to
produce graft with an interconnected pore morphology, however, in this instance, the
augmentation of the water bath rendered the graft unstable at the phase separation
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stage [194]. Therefore, in a bid to increase the interconnectivity of the pore structure,
a porogen (NaHCO3) was introduced into the system.
The introduction of NaHCO3 resulted in a minor increase in viscosity and led to the
suspension displaying pseudoplastic behaviour whereby the viscosity began to reduce
with increased shear rate. However, as the range of shear rates tested far exceeds
those applied by the extrusion machine, this reduction in viscosity is not likely to be a
problem. A maximum concentration of 55% (w/w) of NaHCO3 was used as anymore
porogen and the viscosity of the mixture became too great making extrusion very
difficult.
The addition of NaHCO3 resulted in a dramatic alterations in graft structure; the
graft wall became more homogenous with an interconnected pore structure (fig 4.12),
with a high level of pore interconnectivity been shown to improve cell viability [195].
It’s thought the increased interconnectivity is primarily due to the leaching of the
NaHCO3 out of the polymer matrix. However, NaHCO3 particle size is 40 µm whereas
the pore size, as determined by mercury porosimetry and visually via SEM, is consid-
erable smaller than 40 µm. The pore size also varies with concentration of NaHCO3
used indicating that NaHCO3 not only acts as a pore former, or leaching agent, but
also effects the phase separation process itself. The introduction of a fourth element
to the system (NaHCO3, POSS-PCU, DMAc and H2O) is likely to slow down the
overall membrane formation process favouring the precipitation of the polymer into
a porous membrane packed by arrays of interlinked crystallites [196]. The introduc-
tion of NaHCO3 resulted in a viscous suspension, which is likely to cause a kinetic
barrier to the diffusion process, thus slowing down the overall membrane formation
process which is likely to favour coagulation of the polymer rich phase [197]. Further,
the rate of demixing of the solvent and non-solvent is also likely to be reduced with
the introduction of an inorganic filler, which has been shown to also favour polymer
crystallisation [198].
The introduction of NaHCO3 appeared to stabilise the structure of the graft with no
distortions seen when dried. No chemical differences between the grafts were detected
despite the addition of NaHCO3 and surfactant. Graft morphology and wall structure
differ significantly with the addition of NaHCO3. Whether the stabilisation of the
graft structure is the direct consequence of the change in pore structure is difficult to
ascertain and requires additional study. However, it is possible more in-depth chem-
ical characterisation is required to confirm that the grafts produced with NaHCO3
are not chemically modified as even a small concentration of surfactants have been
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known to stabilise pore structures [199,200].
Increasing the concentration of NaHCO3 led to an increase in the modal pore size (fig
4.12) possibly due to the agglomeration of porogen resulting in a larger particle size.
Pore size plays a critical role in the successful healing of vascular grafts. In a previous
study, successful endothelialisation was demonstrated on grafts with pores 30 µm in
diameter within 8 weeks [201]. It is reported that the ideal pore size is between 10 and
45 µm as larger pores could result in excessive fibrous tissue infiltration resulting in
a profound loss of compliance and inadequate endothelial coverage [202]. The modal
pore size of the grafts produced with NaHCO3 for this study ranged from 15-30 µm
obtained via mercury porosimetry. It was not possible to evaluate the porogen free
samples via porosimetry due to their closed-pore nature leading to excessive torsion
and compression of the sample. Whilst porosimetry provides an indication of the
pore size, it should be noted that the values expressed here should not be thought of
as exact pore diameters. The Washburn equation used to convert intrusion pressures
into diameters assumes pores off a cylindrical geometry whereas SEM observations
clearly indicate that the pores are not cylindrical but are polygonal and intercon-
nected. The values are also likely to be slightly lower than the actual pore size due
to porosimetry mainly detecting the smaller contractions within the interconnections
between larger pores.
Whereas the pore size increased with increasing NaHCO3 concentration, there was
no significant change in the overall bulk density and thus porosity of the grafts which
remained between 85-90%. Porosity is defined as the percentage of void space in a
solid and can be measured as a ratio of bulk density of graft and density of material.
The negligible variation of porosity over the NaHCO3 concentration range is likely
due to the greater contraction of the grafts during the phase separation process. De-
spite a constant 1mm thick coating of POSS-PCU/NaHCO3 slurry being applied to
the mandrel for the manufacture of all grafts, the wall thicknesses varied significantly
(fig 4.9b) between each sample. The reduction in mass, due to additional void space,
would be negated by a reduction in volume leading to a near constant bulk density
and thus porosity of 85-90%. A bulk density of 0.1 gcm−3 and porosity in the range
of 85-90% may be the saturation point for low density polyurethane foams.
Whilst a high level of porosity encourages tissue ingrowth; it diminishes mechanical
properties thereby setting an upper limit for pore size and porosity. A slight increase
in tensile properties was detected for grafts produced at 40 and 50◦C which is likely
to be an effect of a significantly denser membrane. The bulk density of grafts pro-
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duced between 0 and 30◦C did not vary in any significant manner which corresponds
to no significant variations in UTS. The addition of NaHCO3 improved the UTS of
the graft samples significantly; however, subsequent increases in the concentration
of NaHCO3 reduced the UTS. The increase in UTS is most likely a consequence of
the more homogenous wall structure of the graft and fewer large macrovoids in the
cross-section (fig 4.12). As the bulk density and thus the overall porosity does not
vary significantly between the samples produced with NaHCO3, the increase in pore
size may be responsible for the observed reduction in UTS. Larger pores would result
in a smaller apparent cross sectional area upon which force is applied compared to
the measurable cross sectional area resulting in lower UTS values. It should be noted
however, that due to the extraordinarily high UTS of the virgin POSS-PCU material
(approx 60MPa) the UTS of all the grafts produced exceed those of a number of
porcine and human arteries [203,204].
The phase separation process was able to produce porous membranes with suitable
mechanical strength to be used as vascular grafts. The complete removal of solvent
(DMAc) and porogen (NaHCO3), for those grafts produced with a porogen, was con-
firmed via GCMS and ICP-OES ensuring a contaminant free graft is produced. A
combination of GPC and DSC analysis was conducted to investigate whether the
polymer processing affects any of the bulk material properties. GPC analysis was
utilised to investigate changes in molecular weight distributions to determine any
physical damage to the polymer via either the extrusion or phase separation process.
No change in molecular weight distributions between the grafts and virgin POSS-PCU
were detected, thus confirming that the manufacturing process does not damage the
polymer. Similarly no difference was detected in the thermal properties of phase sep-
arated POSS-PCU as determined via DSC. Molecular weight and thermal properties
are important in determining many physical properties which determine the perfor-
mance, end use and processability of materials. With no change in bulk properties
being detected, it can be concluded that phase separation does not adversely effect
the biomaterial.
4.4 Conclusions
Graft properties are primarily dependant on the nature of the biomaterial and the
fabrication process. In this chapter, an extrusion phase separation fabrication method
is described for the production of vascular grafts from POSS-PCU polymer. The
phase separation method does not adversely affect material properties. The porosity,
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pore size and pore interconnectivity are evaluated and optimised for tissue ingrowth
and graft healing. Finally, the UTS was assessed to ensure the grafts are mechanical
robust enough to endure the harsh conditions of the vasculature.
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5
Mechanical Optimisation of Small Calibre
Vascular Grafts
Poor long term patency has, in part, been attributed to physical determinants in
biomechanical design of grafts [205]. The ideal graft should have viscoelastic prop-
erties comparable to those of the native vessel, circumferential strength capable of
withstanding arterial pressures, tensile and shear strength to withstand fraying and
tearing out of sutures and a degree of flexibility and kink resistance. Currently
available biomaterials meet many of these requirements which has led to the devel-
opment of a range of large calibre grafts; however, for the treatment of small calibre
vessels, viscoelasticity, and more specifically, compliance is critical [53, 54]. The cur-
rently available grafts, namely PTFE and PET, fail to meet this crucial requirement
resulting in poor functional patency rates when used for small calibre (<6 mm) re-
constructions [206].
The mismatch in compliance and its role in the progression of IH, the principal cause
of small calibre graft failure, has been discussed in detail previously. Additionally,
if one considers the Hagen-Poiseuille equation whereby the pressure drop (∆P ) is
proportional to the length of tube (L), flow rate (Q), viscosity (η) and inversely pro-
portional to the fourth power of the internal radius (r4) and pi is the mathematical
constant (equation 5.1); and substituting the Ohm’s law (P=QR) analogy where R
is impedance, then the impedance to flow is drastically increased with any reduction
in graft calibre (equation 5.2). The increase in impedance results in a decrease in
flow rate which is highly likely to cause an increase in the probability of stasis thus
promoting thrombogenicity.
∆P =
8ηLQ
pir4
 5.1
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R =
8Lη
pir4
 5.2
A number of assumptions are present in the equation, namely that flow is lami-
nar, viscous and incompressible and flow is through a constant circular cross section.
However, blood vessels are not rigid pipes, they display complex compliant behaviour
with intrinsic and extrinsic mechanisms to vary compliance and shape. The disten-
sion of the vessel wall in response to pulsatile flow and pressure is viscoelastic in
nature. That is to say that whilst vessels return to their original shape upon removal
of an external force, the response to force is not instantaneous but is time depen-
dant. The purpose of the viscoelasticity is to convert the pulsatile ejection of blood
from the heart into continuous flow [207]. Energy is stored in the vessel wall dur-
ing systolic distension, which is then responsible for the elastic recoil during diastole
ensuring continuous anterograde blood flow. Additionally, the elastic component is
responsible for minimising the arterial systolic pressure whilst increasing the diastolic
pressure ensuring that the mean arterial pressure remains high and the pulsatility low.
Meanwhile, the viscous component of the vessel wall is responsible for dissipating
energy due to the highest frequency components of the incident pressure and flow
waves and the amplitude of any reflected waves. Further, mechanical damage to the
vessel wall can be reduced by eliminating high frequencies that could cause early
fatigue. Plotting pressure against diameter during one cardiac cycle results in a hys-
teresis being observed with the area of the loop being equal to the energy lost in each
cycle. Additionally, the phase angle (δ) between the diameter and pressure wave can
be calculated, as a quantitative measurement of the viscous component of the vessel
wall, using equation 5.3 [208].
sin(δ) =
a
∆F
 5.3
Where a is the separation between the ascending and descending limbs of the hys-
teresis at mid-cycle and ∆F is the total excursion of hysteresis (fig 5.1).
For practical purposes, when measuring the viscoelastic properties of vessel walls
and vascular grafts, it is convenient to use a single parameter which expresses the
mechanical behaviour under living conditions, rather than the well established for-
mulations and constitutive equations, which increase dramatically in complexity as
the number of dimensions increases (1D to 3D), and anisotropy and non-linearity is
introduced. Several parameters have been suggested and are often used which in-
cludes the pressure-strain elastic modulus (Ep) and compliance (C); both of which
give a measure of the functional stiffness of the vessel wall i.e. its effectiveness as an
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Figure 5.1: Lissajous plot of pressure (P(t)) and diameter (d(t)) resulting in a hysteresis
from which the phase angle can be calculated using equation 5.3
elastic reservoir.
Ep =
∆PDd
∆D
 5.4
C =
∆D
∆PDd
× 104
 5.5
Where P is pressure and Dd is equal to the diastolic diameter. A significant advantage
of these models is that measurements can be made non-invasively and routinely; only
the pressure-diameter data at a specific pressure level is required. However, these pa-
rameters are structural and express the stiffness or distensibility of a blood vessel or
graft but do not represent the inherent elastic properties of the wall material, which
is still calculated from the elastic modulus.
In addition to the viscoelasticity and inherent graft mechanical properties, a clinically
viable graft must meet a number of handling characteristics such as suture retention
and kink resistance. The graft wall must be strong enough to withstand tearing of
sutures. Sutures tend to apply stress on the graft wall over small areas resulting
in the graft being exposed to high levels of localised force which could lead to graft
failure [209]. Graft kinking is where bending the graft results in a dramatic reduction
in its diameter resulting in stenosis (fig 5.9). The formation of kinks in the arterial
circulation has been known to lead to a range of ischaemia related incidences includ-
ing angina and stroke [210]. Treatment of kinking grafts is rather limited, and can
include angioplasty, stenting or a repeat of invasive bypass surgery.
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Figure 5.2: Digital images of kink formation in a graft.
In this chapter the inherent mechanical properties (ultimate tensile strength, elonga-
tion to break and Youngs modulus) of the graft material were characterised through
uniaxial tensiometry. This was followed by investigating the functional dynamic me-
chanical behaviour of the grafts. A bespoke physiological flow circuit was constructed
which allowed the simultaneous collection of pressure and diameter, thus allowing the
calculation of compliance over an arterial pressure range, and the phase angle at one
reference pressure. Results were directly compared with previously published data
for a range of arteries in vivo. Three different wall thicknesses (0.5, 0.7, 0.9 mm) and
three concentrations of NaHCO3 (35, 45, 55%) were evaluated in an effort to elucidate
the influence of wall thickness and porosity on the functional mechanical properties of
the grafts. Further, handling properties such as suture retention and kink resistance
were characterised using methods outlined in the British Standard ISO 7198:1998. A
method for externally reinforcing vascular grafts as a measure against kinking was
also developed and assessed for compliance.
5.1 Materials and Methods
Graft fabrication
Grafts were produced as outlined in chapter 4. POSS-PCU grafts with no porogen
were produced, with an internal diameter of 5 mm, at three different wall thicknesses:
0.5, 0.7 and 0.9 mm. Additionally, grafts with 35, 45, 55% NaHCO3 were also pro-
duced with wall thicknesses of 0.7 mm. This allowed the comparison of both the
wall thickness and the effect of porosity on the mechanical behaviour of grafts. All
grafts were manufactured at room temperature using the extrusion phase separation
method outlined extensively in the previous chapter.
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Tensiometry
Grafts were cut open longitudinally and a dogbone shaped specimen, 20 × 4 mm,
prepared using a sharp cutter and mechanical press ensuring a clean cut with no flaws
or stress aggregation. However, due to the random nature of pore size and poros-
ity, variability between samples is to be expected. Specimens were cut in both the
longitudinal and circumferential direction to test for isotropy. Stress-strain profiles
were characterised using a uniaxial load testing machine (Instron 5565, UK). The
maximum tensile strength, initial Youngs modulus (between strains of 0 and 25%)
and elongation at break were obtained (n=6).
Suture retention
Test pieces, 30 mm in length, were prepared from grafts using a scalpel, and a suture
(6.0 Prolene) was passed through the graft wall 2mm from the end. The graft was
placed in the top grip of the uniaxial load machine (Instron 5565) and the free end
of the suture was placed in the bottom grip. The specimen was pulled at a speed of
50 mmmin−1 until either the suture ripped or the graft failed. The force required to
pull the suture through the prosthesis or cause the wall of the prosthesis to fail was
recorded (n=6).
External reinforcement
An external reinforcement of PCU fibres was incorporated onto the grafts using tex-
tile braiding techniques. A 1/1 maypole braiding method (Cobra 250, Cheshire, UK)
was used to braid POSS-PCU grafts (0.7 mm wall thickness, 0% NaHCO3, n=3).
Three different gear ratios were used (0.4, 0.6, 1) to produce three different braiding
angles (45, 50, and 60◦) (fig 5.3).
Thereafter, an isocyanate prepolymer bioadhesive was sprayed onto the surface of the
grafts using an ultrasonic atomisation spray machine (Sono-Tek, USA) in an effort
to attach the braiding to the surface of the graft. Grafts were placed on a mandrel
rotating at 115 rpm and driven laterally at a speed of 25 mms−1 with the prepolymer
being sprayed at a rate of 0.3 mLmin−1 and atomised at a power setting of 1.20
W. Two layers of the bioadhesive were applied after which the grafts were placed in
distilled H2O.
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Figure 5.3: Digital image of POSS-PCU vascular grafts following external reinforcement
with PCU fibres. Three different braiding angles were evaluated ranging from 45-60◦.
Kink resistance
The purpose of this test is to determine the length of curvature required for the grafts
to kink. The ends of the vascular grafts, 100 mm in length, are slowly brought into
contact with each other until the graft buckles and begins to kink. The distance that
separates the two ends of the graft is then recorded as the distance required for kink
formation. The smaller the separation distance, the more resistant the graft is to
kinking. Tests are conducted at ambient pressure.
Pressure-diameter analysis
A physiological flow circuit was constructed to accurately recreate the haemodynamic
environment of pulsatile arterial blood flow in vitro (fig 5.4). 10 cm lengths of graft
(n=8) were prepared and individually connected with a 10% longitudinal stretch to
a phantom pulse generator (Harvard Apparatus Model 1421) set at a frequency of 1
Hz and a pulse pressure of 60 mmHg. Clinically expired human blood was collected
from the Royal Free blood bank and held in a reservoir at 37◦C, with the mean
pressure of the circuit determined by the height of the reservoir, and pumped using the
previously mentioned pulse generator. A size 2F Millar Mikro-tip catheter transducer
(model SPC-320, Millar Instruments Inc, Houston, USA) was placed within the graft
and connected to pressure transducer control unit. A 50 mm 7.5 MHz linear array
probe connected to a Doppler ultrasound machine (Picus, Pye Medical) was clamped
perpendicular to each graft along its longitudinal axis. Wall tracking software (Pie
Medical Wall Track System II) was used to monitor the distension of the inner wall
for 20 mmHg increments of mean pressures in the physiological range (30-100 mmHg)
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by sampling the radiofrequency signal generated by the vessel wall over a 4 second
period (fig 5.4c). This set-up allowed the simultaneous recording of the real time wall
distension and pressure (fig 5.4d).
(a) (b)
(c) (d)
Figure 5.4: Diagramatic representation (a) and digital image (b) of the physiological
flow circuit constructed to characterise the dynamic functional behaviour of small calibre
vascular grafts. An example of radiofrequency signal generated by vessel wall (c) and the
corresponding pressure and diameter waveform (d) generated over a period of 4 seconds.
5.2 Results
Tensiometry
The inherent tensile properties of the grafts wall were evaluated using a uniaxial ten-
siometer. The effect of porosity, through varying the concentration of porogen, wall
thickness and the anistropy were all assessed, the results of which are presented in
table 5.1.
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Figure 5.5 displays the stress strain curve of grafts produced with varying concentra-
tion of NaHCO3. There is a significant reduction (p < 0.001) in the tensile strength
and elongation at break as the concentration of NaHCO3 is increased. However, the
stiffness of the graft wall was not so sensitive, with no significant differences detected
in the Youngs Moduli between samples produced with 45 and 55% NaHCO3. How-
ever, both had significantly reduced Youngs moduli than the graft produced with
35% NaHCO3.
Figure 5.5: Effect of porogen concentration on tensile properties of POSS-PCU grafts.
Inset is the region over which the Youngs modulus was calculated, 0-25% strain.
No significant differences were detected in the tensile properties (tensile strength,
elongation at break or Youngs Moduli) of grafts with wall thicknesses of 0.5 mm,
0.7 mm or 0.9mm (fig 5.6). Further the tensile properties were found to be isotropic
with no significant difference in tensile properties detected in the longitudinal and
circumferential direction (fig 5.7).
Suture retention
Suture retention is a critical factor in the design of a vascular graft as it directly relates
to the success of the implant. With the continued addition of NaHCO3, the suture
retention strength systematically decreases from 4.46 ± 0.32 N for 35% NaHCO3 to
2.33 ± 0.23 N for grafts produced with 55% NaHCO3 (fig 5.8a). Reductions in wall
thickness had a similar effect; grafts with walls 0.9 mm thick exhibited significantly
higher (p < 0.01) suture retention strengths than those with walls 0.7 or 0.5 mm
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Figure 5.6: Effect of graft wall thickness on tensile properties. Inset is the region over
which the Youngs modulus was calculated, 0-25% strain.
Figure 5.7: Tensile tests in the longitudinal and circumferential direction of POSS-PCU
grafts. Inset is the region over which the Youngs modulus was calculated, 0-25% strain.
thick (fig 5.8b).
Kink resistance
The distance at which a kink forms in 100 mm long grafts, at ambient pressure’s,
was examined. Figure 5.9 displays the relationship between NaHCO3 concentration,
wall thickness and graft kinking. Additionally, the effect of adding an external re-
inforcement, in the form of PCU braiding, is examined for its efficacy in preventing
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Sample Tensile
strength/MPa
Elongation/% Youngs Mod-
ulus/MPa
cast 59.67 ± 5.48 856 ± 53 17.03 ± 0.30
35% NaHCO3 3.21 ± 0.20 547 ± 18 0.99 ± 0.05
45% NaHCO3 2.38 ± 0.20 450 ± 27 0.69 ± 0.09
55% NaHCO3 1.66 ± 0.25 416 ± 20 0.66 ± 0.04
0.5mm 2.27 ± 0.23 459 ± 22 0.70 ± 0.08
0.7mm 2.32 ± 0.32 473 ± 19 0.67 ± 0.07
0.9mm 2.67 ± 0.29 528 ± 17 0.70 ± 0.08
Longitudinal 1.92 ± 0.35 397 ± 18 0.77 ± 0.08
Circumferential 1.84 ± 0.32 382 ± 21 0.79 ± 0.08
Table 5.1: A summary of the inherent tensile properties of phase separated POSS-PCU.
The tensile strength, elongation at break and Youngs Modulus are presented for samples
comparing porosity, wall thickness and anistropy.
(a) (b)
Figure 5.8: The effect of NaHCO3 concentration (a) and wall thickness (b) on suture
retension strength
kink formation. Increasing wall thickness appears to significantly (p < 0.01) improve
the kink resistance of the vascular grafts with the distance separating the two ends
of the graft smallest for the 0.9 mm thick graft. Neither the addition of NaHCO3,
nor the concentration, had any significant impact on kink resistance. By applying an
external reinforcement, there is a significant initial improvement in kink resistance of
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the grafts irrespective of braiding angle. However, at extreme curvatures (very short
distances between graft ends) the braiding came apart from the graft which resulted
in the graft kinking.
Figure 5.9: Separation distance resulting in kink formation. The shorter the distance
separating the two ends of the graft, the more resistant the graft is to kinking. Wall thickness
appears to be an important determinant in kink formation as an increase in wall thickness
results in significantly improved kink resistance. The addition of NaHCO3 appears to have
a negligible effect on kinking whilst the addition of an external reinforcement caused a
significant improvement irrespective of braiding angle. n=3, p<0.01.
Pressure-diameter analysis
The pressure-diameter plots of POSS-PCU vascular grafts were plotted as shown in
fig 5.10, and the phase angle between pressure and distension was calculated from
equation 5.3. No significant difference was recorded between the phase angle of thick
and thin grafts demonstrating that the viscous component of the graft wall was in-
dependant of wall thickness (fig 5.11a). Similarly, NaHCO3 concentration had a
negligible effect on the phase angle which remained a constant 16 ± 1◦ (fig 5.11b).
Compliance, on the other hand, was heavily dependant on both the wall thickness
and concentration of NaHCO3. The thin walled graft (0.5 mm) was significantly (p
< 0.001) more compliant than the thick walled grafts (0.7 and 0.9 mm, fig 5.12).
There was no significant difference between the compliance of grafts at 0.7 and 0.9
mm. Further, whereas the compliance of thick grafts was independent of the mean
arterial pressure at a near constant value of 5.9 ± 0.4 %mmHg−1 × 10−2; the thin
walled graft displayed behaviour that was heavily pressure dependant. At a pressure
of approximately 30 mmHg the compliance of the thin walled graft was 6.6 ± 0.3
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Figure 5.10: Representative pressure diameter plot for POSS-PCU vascular graft display-
ing a hysteresis due to the viscoelastic nature of the graft.
(a) (b)
Figure 5.11: Phase angle between the pressure and distension waveforms of vascular grafts
as a function of (a) wall thickness and (b) NaHCO3 concentration.
%mmHg−1 × 10−2 which increased to 12.5 ± 0.6 %mmHg−1 × 10−2 at a pressure of
100 mmHg.
The grafts produced with NaHCO3 were fabricated with walls 0.7 mm thick. The
addition of 35% of NaHCO3 does not appear to have significantly altered the com-
pliance averaged over the pressure range compared to grafts with no NaHCO3 (6.1
± 0.9 v 5.9 ± 0.4 %mmHg−1 × 10−2); however, it is now dependant on the pressure
with significant differences between the compliance at 30 mmHg and 100 mmHg (fig
5.13). The continued addition of NaHCO3 not only increased the absolute compliance
values but also increased the pressure dependence with the slope of the best fit line
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Figure 5.12: Effect of wall thickness on POSS-PCU vascular graft compliance over the
mean arterial pressure range. The compliance of thin walled grafts appears to be higher
and pressure dependant compared to the two thicker grafts which do not differ significantly
(n=8, p<0.001).
of the graft produced with 55% NaHCO3 significantly higher than that of the graft
produced with 45% (0.04 v 0.06).
Figure 5.13: Effect of NaHCO3 concentration on compliance over the mean arterial pres-
sure range of POSS-PCU vascular grafts with 0.7 mm wall thickness. An increase in NaHCO3
concentration results in an increase in compliance with the compliance values further de-
pendant on the pressure (n=8, p<0.001.
Through the addition of an external reinforcement for anti-kinking purposes, the
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compliance of the grafts suffered a significant decrease. A braiding angle of 45◦
produced grafts with the tightest braid resulting in the most severe loss of compliance
compared to equivalent graft without braiding (0.8 ± 0.3 v 5.9 ± 0.4 %mmHg−1 ×
10−2, fig 5.14). The subsequent loosening of the braid through a reduction in the
braiding angle at higher gear ratios, resulted in a minor increase in compliance to
an average value of 1.4 ± 0.2 %mmHg−1 × 10−2. The braiding at 60◦ resulted
in the loosest reinforcement, and whilst the compliance of the graft was severely
compromised at low mean arterial pressures (1.1 ± 0.3 %mmHg−1 × 10−2 at 30
mmHg), it was found to significantly increase (p < 0.001) as the pressure was also
incresed (3.2 ± 0.2 %mmHg−1 × 10−2 at 100 mmHg).
Figure 5.14: Effect of external reinforcement on vascular graft compliance (n=3).
5.3 Discussion
Blood vessels are constantly under continuous and intermittent mechanical stress
which includes pulsatile shearing forces, cyclic stretching, longitudinal tension and
compression. Any successful vascular substitute must be able to withstand the harsh
mechanical environment that it is exposed to in the vasculature. In contrast to many
other tissue engineering applications, such as cartilage, liver etc, the function of the
scaffold is not merely to support and direct cell proliferation but the scaffold must
also successfully fulfil its primary role as a conduit for the transportation of blood
round the body. A great number of tissue engineering paradigms rely on mechanically
weak biodegradable scaffolds, which may successfully support cellular activity, but
do not have the required radial strength to be used in the arterial circulation.
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This thesis has examined the use of POSS-PCU for the fabrication of vascular sub-
stitutes as it has excellent mechanical properties which include UTS in excess of 60
MPa. A phase separation method was developed in chapter 4 to produce cylindrical
conduits with the required UTS and a degree of radial elasticity to be used in the
arterial circulation. The use of NaHCO3 as a porogen was investigated to impart a
greater degree of porosity to the grafts. In this chapter the functional mechanical
behaviour of the grafts is examined through tensiometry to evaluate graft wall be-
haviour, suture retention, kink resistance and viscoelasticity. The influence of wall
thickness and pore size was elucidated. Three different wall thicknesses (0.5, 0.7 and
0.9 mm) and three different concentrations of NaHCO3 (35, 45, 55%) were examined.
Whilst porosity is a necessary prerequisite for the successful healing and tissue in-
growth of vascular grafts, it diminishes mechanical properties thereby setting an upper
limit for pore size and porosity. This was seen with the POSS-PCU grafts whereby
UTS decreased as the percentage of NaHCO3 increased (fig 5.5). It was interesting
to note, however, that the addition of 35% NaHCO3 improved the UTS considerably
compared to the vascular graft produced with no NaHCO3. This is most likely due
to the more homogenous wall structure and smaller pore size exhibited by the graft
produced via porogen leeching. The stiffness of the graft wall suffered a slight re-
duction with the addition of 45% or more NaHCO3. Whilst a degree of elasticity in
the graft wall is vital, there is a considerable risk of excessive dilation and aneurys-
mal formation if the graft wall is not stiff enough. Wall thickness appears to have
a negligible effect on the mechanical properties of the graft wall. This should come
as no surprise as stress is calculated as force per unit area, therefore, measurements
taken are suitably adjusted for dimensional changes. Similarly, the graft walls were
found to be isotropic with no significant change in the mechanical properties in the
circumferential or longitudinal direction, therefore there is no directional dependence
on the strength of POSS-PCU. Irrespective of the porosity or wall thickness of graft,
the UTS of the grafts is well in excess of native human arteries [203,204].
Similarly, the suture retention values were well in excess of the generally accepted
value of 2N for all the grafts tested. As expected, the increase in NaHCO3 concentra-
tion results in a decrease in the amount of force required for the graft to fail. This is
likely to be a direct consequence of the diminishing mechanical properties of the graft
wall as porosity is increased. In contrast to the tensiometry testing, suture retention
was dependant on graft wall thickness. The sequential increase in graft wall thickness
manifested itself in significantly improved suture retention forces. As suture reten-
97
CHAPTER 5. MECHANICAL OPTIMISATION OF SMALL CALIBRE
VASCULAR GRAFTS
tion measures the load at failure (N), as opposed to stress (Nmm−2), suture retention
is heavily dependent on graft wall thickness – with thicker grafts more resistant to
failure.
Thicker grafts also appeared to be more kink-resistant. Kink formation in vascular
grafts is a major problem particularly for below-knee bypasses. Upon knee flexion
resulting in bending of the graft, the outer convex wall is under tension resulting
in lengthening of the graft wall which, at its maximum, can cause the graft cross
section to take on an oval form. Meanwhile the inner concave wall is compressed and
shortened resulting in deformations and creating folds which then protrude into the
lumen. Whilst minor graft kinks can result in acute ischemia, lumen encroachment
of 50% or more results in graft occlusion and requires immediate treatment [211].
Graft wall thickness appears to be a critical parameter in determining the propensity
of grafts to kink. Whilst it is clear that thin grafts are prone to kinking, the addition
of NaHCO3 does not have any impact on kink formation with no significant changes
detected between the different concentrations of NaHCO3 or the equivalent grafts
produced with and without NaHCO3.
An external radial support is one method by which kink prevention can be achieved.
By utilising commercially available braiding techniques, an external support consist-
ing of PCU fibres was applied to the POSS-PCU grafts. Three different braiding
angles were evaluated with the highest angle, 60◦, producing the tightest braid whilst
a braiding angle of 45◦ produced a loose braiding. Thereafter, an isocyanate based
pre-polymer was sprayed onto the surface of the grafts in an effort to adhere the
external reinforcement to the surface of the vascular grafts. The pendant isocyanate
groups of the pre-polymer are activated by residual moisture, resulting in the for-
mation of reactive amines. After which the amines react with remaining isocyanate
groups resulting in the curing of the pre-polymer and fixation of the braid to the
graft. Whilst the external reinforcement improved the kink resistance of the grafts
significantly, the braiding appeared to detach itself from the body of the graft at
extreme curvatures. This is likely due to the extreme localised stress placed on both
walls of the graft, but in particular the concave wall. The driving force behind kink
formation was greater than the adhesive force of the isocyanate pre-polymer resulting
in the localised detachment of the braiding from the graft, which then led to kink
formation. However, the principle behind the external reinforcement appears to be
sound with no kink being observed whilst the braiding remains attached to the graft.
The role of the artery is more than just to transport blood from one part of the circu-
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lation to another. The complex viscoelastic nature of the vessel wall is responsible for
the energy efficient transmission of pulsatile blood flow whilst simultaneously damp-
ing excessive pressure fluctuations [207]. Additionally, viscoelasticity has also been
shown to reduce the wall stress and strain during a sudden increase in mechanical
loading, such as in acute hypertension [212]. The introduction of a stiff prosthetic
graft introduces a degree of impedance into the circulation diminishing flow pulsatil-
ity and perfusion efficiency, and in small calibre, low flow, situations may lead to flow
stagnation and graft thrombosis.
The viscous component of the vessel wall, which results in a force-deformation hys-
teresis loop, is thought to be important in filtering out instantaneous changes in
loading which may lead to mechanical failure. Previously, it has been demonstrated
that the phase angle between stress and strain is approximately 12.6 ± 4.4◦ for an
iliac artery [213]. Whilst POSS-PCU vascular grafts exhibited generally higher phase
angle’s (fig 5.11), there is no significant difference between the grafts or iliac artery.
It is worth noting, however, that the standard errors in the measurements are ap-
proaching 30% in some cases, therefore, any meaningful comparison is negated by
the large errors in data collection.
In the native vessel (fig 1.1), the medial layer is primarily responsible for maintaining
vasomotor tone in response to pressure. At low pressures elastin is the primary load
bearer, responsible for imparting a degree of elasticity to the vessel, allowing it to
stretch during systole and resuming its normal shape once load is removed in dias-
tole. However with increasing pressure, the stiffer collagen becomes the dominant
load bearer resulting in a stiffer artery and imparting a degree of non-linearity to the
vessel wall. The distension and constriction in response to pressure is termed com-
pliance. A mismatch in compliance has been implicated in the aetiology of IH [53].
A stiff graft causes pulsatile stretching at the site of anastomosis damaging EC and
stimulating SMC proliferation [214]. Variations in cyclic stretching forces can alter
the SMC phenotype producing SMC with an increased proliferation rate which pro-
duce four to five times the amount of ECM components as regular SMC, resulting in
the increased proliferation and deposition of ECM components in the intima [215].
There is also evidence to suggest that a compliance mismatch can indirectly lead to
IH, and even contribute to thrombosis, through impeding the flow of blood causing
stagnation and resulting in an increase in residence times of chemotactic factors and
platelets [216, 217]. Furthermore, flow patterns are directly affected by the compli-
ance of the graft with inelastic grafts leading to flow reversal, vortex formation and
wall shear stress fluctuations which have been implicated in IH progression [218,219].
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POSS-PCU vascular grafts were found to be significantly more compliant than the
industry standard PET or PTFE grafts currently available [206]. Both wall thick-
ness and porosity had significant bearing on the compliance properties of the grafts.
Whereas grafts with walls 0.7 and 0.9 mm thick had compliance profiles independent
of pressure, grafts with walls 0.5 mm thick were heavily pressure dependant with the
compliance value more than doubling as the mean arterial pressure increased from
30 to 100 mmHg. Excessively compliant grafts would raise serious concerns over the
long-term mechanical robustness as they are likely to be prone to aneurysmal for-
mation and dilation. The addition of 35% of NaHCO3 did not significantly alter the
average compliance over the mean pressure range, compared to grafts produced with
no NaHCO3 and equivalent wall thicknesses. However, the compliance profile was
no longer independent of pressure with significant differences being observed between
compliance at 30 mmHg and 100 mmHg. The pressure dependence of compliance
increased with the continued addition of NaHCO3. The compliance pressure depen-
dence as a result of thinner graft walls or increased graft porosity is likely due to a
reduction in the mass of polymer that pressure is exerted against. Thinner graft walls
are unable to resist strain, particularly at high mean arterial pressures. Whereas an
increase in NaHCO3 concentration results in a reduction in apparent bulk density of
graft which transpires into a less stiff graft wall characterised by a significant reduc-
tion in Youngs modulus between grafts produced with 35% NaHCO3 and 45+%. The
reduction in stiffness manifests itself in the form of a more compliant graft at high
pressures.
By introducing an external reinforcement, the possibility of compromising the radial
expansion of grafts is always likely. Whilst the external reinforcement was successful
in administrating an additional degree of kink resistance to the grafts, they dramat-
ically reduced the compliance properties of the graft, irrespective of braiding angle.
The relatively loose braiding, produced with a braiding angle of 60◦, can be seen to
be expanding at increased pressures; however, the braiding produced at angles of 45
and 50◦, which are tighter in nature, compromises the compliance properties of the
graft throughout the pressure range. The PCU fibres are considerably stiffer than
the phase separated graft walls therefore it is no surprise to see them impacting on
the compliance properties of the grafts.
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5.4 Conclusions
The biomechanical properties of any vascular substitute play a decisive role in deter-
mining it’s patency. In this chapter, the functional mechanical properties of POSS-
PCU grafts were evaluated. The role of wall thickness and porosity was evaluated
and the feasibility of an external reinforcement explored. POSS-PCU grafts were
found to be viscoelastic in nature with tensile strengths and suture retention forces
that are able to withstand the harsh conditions found in the arterial circulation. A
physiological flow circuit was developed to assess the dynamical mechanical proper-
ties whereupon grafts were found to be compliant and able to propagate the flow
waveform.
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Surface Characterisation of POSS-PCU
Vascular Grafts
For all implanted biomaterials and devices, the central characteristics are biofunc-
tionality and biocompatibility. Whereas the previous chapter discussed at length the
mechanical behaviour of POSS-PCU grafts, the aim of this chapter is to investigate
the parameters which influence biocompatibility. Whilst there are differing opinions
on the precise definition of biocompatibility, it usually refers to the safety, and lack
of adverse interactions of the implant, over its intended lifetime in the body [220].
For blood contacting devices, such as stents, heart valves and vascular grafts, blood
compatibility is effectively the tolerance of blood to the implant. As the surface of
the biomaterial is the first component of the device that comes into contact with
blood, it is the surface properties, such as wettability, flexibility, morphology and the
surface chemical composition, which determine the degree of biocompatibility [221].
The chemical composition of a material often dictates many of its properties; however,
surface chemistry tends to be rather complex with the exact nature of the chemical
constituent interacting with blood difficult to ascertain. It is widely recognised that
surface polarity and energy influence cell-substrate interactions [222]. Polar, hy-
drophilic surfaces, with a greater degree of surface wetting, are thought to improve
cellular adhesion. The wettability of a liquid refers to the ease with which a fluid
spreads across a solid surface and can be measured quantitatively by determining
the contact angle of a droplet of liquid, usually water, in thermal equilibrium on a
horizontal surface. Contact angle, θ, is defined as the angle formed by the liquid at
the three phase boundary where the liquid, gas and solid intersect (fig 6.1).
Whilst wettability is an example of surface chemistry and the role of intermolecular
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Figure 6.1: Diagrammatic representation of liquid wetting on horizontal surfaces. A high
contact angle, θ>90◦, signifies poor wetting ability of the surface indicative of a hydrophobic
surface (A). Low values of contact angle, θ<90◦, indicates a hydrophilic surface on which
the liquid spreads well (B).
forces in influencing bioadhesion; physical determinant such as surface topography
and surface morphology have been of great interest recently, as factors which influence
cellular behaviour. As discussed in section 2.3, cells in their native microenvironment
interact with a complex milieu of topographic cues which range from the nano- to the
micro-scale [223]. Whereas the underlying molecular mechanisms controlling these
interactions have yet to be elucidated, their role in influencing biocompatibility is
beyond doubt. Factors such as porosity and surface roughness have proven to be
influential parameters to consider in the design of biomaterials [224]. For example,
it has been consistently demonstrated that a number of different cell types tend to
align and elongate over grooved substrates [225]. The dimensions of the features are
critical with cells responding to grooves with depth as little as 35 nm with the ef-
fect diminishing when the feature size becomes negligible (<35 nm). Neonatal rat
ventricular myocytes cultured on grooves 50 nm in depth led to highly anisotropic
cell arrays guided by the underlying nanoridges [226]. Filopodial extension in the
groove results in adhesion proteins and actin filaments becoming aligned parallel to
the groove direction; with the organisation of actin filaments or microtubules being
identified as the first step in contact guided cell alignment. In a similar manner; pits,
pores and protrusions have been shown to influence cell behaviour [227].
Topograpahy and surface chemistry are well established factors which influence cell
behaviour and have been systematically investigated. More recently, substrate me-
chanics have emerged as another important factor worth considering in the design of
biomaterials [173]. The underlying substrate stiffness is known to influence the cell
contractile forces and related cellular functions, such as motility, cytoskeletal orga-
nization, and differentiation regardless of whether the substrate is autologous tissue
or a synthetic substrate [173, 228, 229]. For example, substrate mechanics have been
found to play an important role in determining cell phenotype during the process of
wound healing [230]. Fibroblasts are known to differentiate into myofibroblasts in
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response to injury, and are responsible for replacing and repairing damaged ECM. As
ECM is deposited, the elastic modulus of the cell microenvironment increases, with
the myofibroblast deactivating and undergoing apoptosis when the desired modulus
is achieved [230]. If de-activation is misregulated and the myofibroblast phenotype
persists, ECM secretion would continue and the increasing modulus would affect fi-
brosis [231].
To be able to investigate the biocompatibility and cellular behaviour of the POSS-
PCU vascular grafts, a careful assessment of the vascular graft surface is required.
Whilst the surface properties of POSS-PCU have been investigated previously; the
aim of this chapter is to evaluate the surface properties of the phase separated mem-
branes from which the vascular grafts are fabricated from. The surface chemical,
topographical and mechanical properties were characterised and any differences fol-
lowing phase separation was assessed. The influence of adding a porogen, NaHCO3,
on the interfacial properties was evaluated.
6.1 Materials and Methods
Sample preparation
A cast sheet of POSS-PCU which would serve as a control to compare the surface
properties of the phase separated membranes was produced by casting a 18%(w/w)
solution of POSS-PCU in DMAc onto a glass petri dishes and left in an oven at 60◦C
overnight. The solvent would evaporate resulting in a solid sheet of polymer for fu-
ture experiments.
The phase separated membranes were produced in a similar manner to the vascular
grafts in chapter 4; however, flat membranes were produced as opposed to cylindrical
conduits for ease of analysis. POSS-PCU solution and POSS-PCU/NaHCO3 sus-
pension was cast on to a stainless steel sheet and placed in distilled water at room
temperature. The polymer sheets were left immersed in distilled water for a period of
48 hours to ensure complete removal of solvent and NaHCO3. The membranes were
then removed from the steel support and air dried for a further 48 hrs before use
in downstream experiments. The POSS-PCU/NaHCO3 suspension was prepared as
previously stated in chapter 4: 35, 45 and 55% of NaHCO3 was used as per chapter
4. Analysis took place on the luminal surface which is expected to be in contact with
blood.
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SIMS
Secondary ion mass spectroscopy (SIMS) analysis was undertaken using a Millbrook
MiniSIMS instrument (SAI Ltd) equipped with a 5kV gallium ion source in static
SIMS mode. Positive and negative ion SIMS spectra were obtained from sample
discs 16 mm in diameter. Fragments detected were ascribed chemical species and
their relative intensities referenced against the common organic fragments m/z =41
(C3H
+
5 ) and m/z = 13 (CH
−) in positive and negative spectra respectively. Images of
principal ions were collected from areas of approximately 2mm × 2mm of the sample
and over-laid as three colour maps.
ATR-FTIR
Samples were subjected to attenuated total reflectance Fourier transform infer-red
(ATR-FTIR) spectroscopy (JASCO FT/IR 4200) to evaluate any alterations in the
surface chemical functional groups. A total of 30 scans were taken for each sample
between 600 and 4000 cm−1 (n=6).
Contact angle
Contact angle analysis was carried out using a goniometer (DSA100E, Kruss, Ham-
burg, Germany) equipped with a high speed framing video recording system with a
CCD camera. A 3 µL Milli-Q water drop was placed on the surface of each sample,
in air, at room temperature. Manufacturer provided drop shape analysis software
was used to determine the air-water contact angles over a period of 10 seconds. A
minimum of 10 droplets were examined for each sample (n=6).
SEM
Graft samples (n=3) were washed with several changes of phosphate buffered saline
(Oxoid) and post fixed using 1% osmium tetroxide/1.5% potassium ferricyanide for
1 hour. The samples were then washed with distilled water and dehydrated through
a degrading acetone series (30%, 50%, 70%, 90% and 100% HPLC grade) washing
twice for 15 mins each. After dehydration the samples were transferred to tetram-
ethylsilane for 10 mins and then allowed to air dry. Finally, the samples were attached
to aluminium stubs with double sided sticky tabs (TAAB) and coated with gold us-
ing an SC500 (EMScope) sputter coater for electrical conductance. The stubs were
examined and photographed using a Philips 501 scanning electron microscope. Rep-
resentative images of the surface were captured at random.
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For the purposes of surface porosity analysis, ImageJ software was used to measure
the surface pore size distributions. 50 measurements were taken for each image and
a total of four images were analysed for each sample.
AFM
Samples (n=6) were examined using a commercial atomic force microscope (XE 100,
Park Systems) operating in contact mode. Discs (16mm in diameter) were positioned
on a metallic disc and magnetically mounted in the AFM chamber. Surface images
for quantitative analysis were obtained from 5×5 µm scans at a scan rate of 0.8Hz.
Roughness was quantified by the deviation of the real surface from its ideal form.
Two different indices were evaluated (equations 6.1, 6.2): the arithmetic average of
absolute values (Sa) and the root mean squared (SRMS).
Sa =
1
n
n∑
i=1
|yi|
 6.1
SRMS =
√√√√ 1
n
n∑
i=1
|y2i |
 6.2
Where n is the number of points and yi is the vertical distance from the mean plane
to the ith data point. The area surface roughness values of the scans were calculated
using XEI analysis programme (Park Systems Corp).
Substrate stiffness
Nanoindentation tests were carried out using an AFM in force-displacement mode to
measure the substrate stiffness (S) and reduced modulus (Er) of the samples (n=6).
An aluminium-coated, silicon AFM tip of 150 kHz resonance frequency and 4.5 Nm−1
nominal spring constant(NSC12 tip-C; MikroMasch, Tallinn, Estonia) was driven into
the sample at a rate (dz/dt) of 0.25 µms−1 and the sample deformation measured by
piezo displacement. Multiple points, typically 12, on each sample were measured and
the results averaged to ensure reliability and the load versus the specimen deforma-
tion for each indentation was plotted and used for data analysis. All measurements
were conducted at room temperatures.
The S and Er were determined from force-displacement curves using the Oliver and
Pharr model [232]. Stiffness was defined as the resistance of the material to in-
dentation by an externally applied force and was determined from the slope of the
unloading force-displacement curve (S = dF/dh) where F is force and h displacement.
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The stiffness is then related to Er through equation 6.3
S = Erβ2
√
A/pi
 6.3
where A is the cross-sectional contact area, and β is a variable, which takes into
account non-axisymmetry of the indenter and large strains. Being close to unity, β
has only a small influence compared to the overall experimental inaccuracy, and is
therefore neglected in the present work [232].
6.2 Results
SIMS
Table 6.1 provides a list of the mass to charge ratios and the ascribed chemical species
with their relative intensities for each sample provided in figure 6.2. POSS fragments
(28, 73) on the positive SIMS fragments are significantly more intense on the cast
sample as opposed to the phase separated POSS-PCU. Further, the fragment at 35
on the negative SIMS is also significantly higher on the cast sample than the phase
separated. Fragment with a mass to charge ratio of 35 is attributed to chlorine
which is present as on the POSS further reinforcing the belief that the POSS moiety
is present in greater numbers on the cast sample. Meanwhile, the negative SIMS
fragments indicate that oxygen and nitrogen containing heteroatom fragments are
far more prevalent in the phase separated sample indicative of far greater presence of
the ethylenediamine, MDI and the polycarbonate soft segment on the surface of the
membrane. Figure 6.3 provides a spatial distribution of Si and Cl fragments which are
indicative of the POSS distribution on the surfaces of the cast and phase separated
samples. The images corroborate the quantitative data by clearly displaying a greater
abundance of Si and Cl ions on the cast sample.
ATR-FTIR
Attenuated total reflectance fourier transform infrared (ATR-FTIR) spectroscopy
was used to analyse surface chemical composition of the different substrates with the
results summarised in figure 6.4. The peak assignment was as follows: 1100 cm−1
(Si-O-Si), 1240 cm−1 (urethane C-O-C), 1400 cm−1 (C-C aromatic ring), 1540 cm−1
(N-H and C=N), 1589 cm−1 (C=C aromatic), 1632 cm−1 (NH2), 1736 cm−1 (C=O).
The process of phase separation appears to result in a significant reduction in the
amplitude of the Si-O-Si peak at 1100 cm−1 belonging to POSS, but an increase
in intensity of the carbonyl peak at 1736 cm−1 due to the carbonate and urethane
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Positive SIMS fragments Negative SIMS fragments
m/z+ Fragment m/z- Fragment
27 C2H3 28 CO
28 Si 35 Cl
29 CHO 39 CHCN
39 C3H3 42 OCN
43 CONH 43 C2H3
45 CHO2 54 C2H2N2
55 C3H3O 59 C2H3O2
73 (CH3)3Si 60 SiO2/CO3
Table 6.1: Positive and negative ion SIMS fragments and their corresponding mass to
charge ratio (m/z).
moiety. However, the addition of NaHCO3 did not result in any significant changes
in the peak intensitie of the ATR-FTIR spectra.
Contact angle
The results of static contact angle tests are presented in figure 6.5. The contact
angle of the cast sheets of POSS-PCU was found to be 105◦ and was consistent over
the time period. Upon phase separation, the contact angle decreased to 94◦ and was
found to decrease further over time, to 83◦ after 10 seconds. The addition of NaHCO3
resulted in a significant increase in contact angle to 100◦. Whilst the concentration
of NaHCO3 did not have any significant effect on the initial contact angle, it was a
significant factor in determining the temporal behaviour of the water droplet on the
different samples. Contact angle dropped to 80, 72 and 63◦ for samples produced
with 35, 45 and 55% NaHCO3 respectively.
SEM
SEM images of the surfaces of the different POSS-PCU samples are displayed in
figure 6.6. The cast sheet of POSS-PCU appears to be a smooth surface with little
else observable through SEM. Upon phase separation, the surface becomes very rough
and textured, empirically visible from the SEM image; however, no surface pores are
detected. A quantitative measure of the surface roughness is provided via AFM. The
addition of NaHCO3 resulted in openly visible surface pores on each of the three
samples. A histogram of the pore sizes is provided adjacent to each SEM image. The
sample produced with 35% NaHCO3 resulted in a mean pore size of 5.3 ± 2.2 µm.
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(a) Positive SIMS fragment peak intensities
(b) Negative SIMS fragment peak intensities
Figure 6.2: Peak intensities of mass to charge fragments produced by SIMS analysis on
cast and phase separated POSS-PCU
Increasing the concentration of NaHCO3 to 45% led to an increase in the mean pore
size to 6.1 ± 2.7 µm, which increased further with 55% NaHCO3 to a mean pore sizes
of 7.0 ± 2.9 µm.
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(a) Distribution of Si (m/z 28+) on cast POSS-
PCU
(b) Distribution of Si (m/z 28+) on phase sep-
arated POSS-PCU
(c) Distribution of Cl (m/z 35−) on cast POSS-
PCU
(d) Distribution of Cl (m/z 35−) on phase sep-
arated POSS-PCU
Figure 6.3: SIMS images of cast and phase separated POSS-PCU samples obtained over a
2×2 area. The images display the distribution of Si and Cl ions (white) associated with the
POSS moiety. POSS is clearly more abundant on the cast sample as opposed to the phase
separated.
AFM
Both 2D and 3D images of the POSS-PCU surface are provided in figure 6.7 and the
quantitative roughness measurements are presented in table 6.2. The cast sheet of
POSS-PCU has a Sa of 75.3 ± 9.8 nm and a SRMS roughness of 84.2 ± 8.6 nm which
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Figure 6.4: ATR-FTIR analysis of surface chemical functional groups on POSS-PCU
samples. A magnified image of the changes in the POSS peak at 1100 cm−1 and carbonyl
peak at 1736 cm−1 are also displayed.
increased significantly (p < 0.01) to 198.1 ± 7.9 and 215.2 ± 12.8 nm respectively for
the phase separated sample. There was a further significant rise in roughness with
the addition of 35% NaHCO3 which increased Sa to 278.4 ± 14.2 and SRMS to 294.6
± 11.2 nm. The subsequent addition of NaHCO3 resulted in further increases in both
Sa (45%: 323.9 ± 21.3 nm, 55%: 376.4 ± 28.7 nm) and SRMS (45%: 376.4 ± 28.7
nm, 55%: 404.2 ± 29.8 nm).
Sample Sa (nm) SRMS (nm)
Cast POSS-PCU 75.3 ± 9.8 84.2 ± 8.6
Phase separated POSS-PCU 198.1 ± 7.9 215.2 ± 12.8
35% NaHCO3 278.4 ± 14.2 294.6 ± 11.2
45% NaHCO3 323.9 ± 21.3 361.6 ± 19.8
55% NaHCO3 376.4 ± 28.7 404.2 ± 29.8
Table 6.2: The arithmetic average surface roughness (Sa) and root mean square surface
roughness (SRMS) of POSS-PCU samples examined with AFM (n=6, p<0.05).
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Figure 6.5: Digital images of the water droplet on the different polymer samples over
10 seconds. The static contact angles, determined via the sessile drop method, of the five
POSS-PCU samples examined are summarised in the graph.
Substrate stiffness
Figure 6.8 displays a representative force-indentation curve and the reduced modulus
of POSS-PCU samples. The cast sheet of POSS-PCU displayed a modulus value of
0.59 ± 0.09 GPa whereas the phase separated samples had stiffness values of 0.55 ±
0.06 GPa. There did not appear to be any significant differences between any of the
samples.
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Figure 6.6: SEM images of sample surfaces displaying a smooth surface for the cast sheet
of POSS-PCU (A). The phase separated sample appears to be highly textured and rough
(B). The addition of NaHCO3 resulted in the formation of surface pores (35% (C), 45% (D)
and 55% (E)). The pore size is displayed for each sample in the form of a histogram.
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Figure 6.7: AFM images, both 2D and 3D, of the surface of POSS-PCU samples. The
arithmetic mean average (Sa and root mean square (SRMS) average surface roughness values
are provided in table 6.2
6.3 Discusion
In order to engineer vascular grafts with optimal biocompatibility, a thorough un-
derstanding of the surface properties and how such properties affect the response of
certain cell types is vital. These surface properties can be ascribed to three main
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(a) (b)
Figure 6.8: (A) Representative image of the force-displacement curve generated by AFM
indentation. (B) Reduced modulus (Er) values generated via AFM and equation 6.3 of the
POSS-PCU membranes.
physiochemical categories: chemical, mechanical and structural. All three surface at-
tributes have been demonstrated to modulate interactions between biological matter
and biomaterial surfaces. The aim of this chapter was to provide a full characteri-
sation of the surface properties of phase separated substrates, with or without the
use of NaHCO3, and compare and contrast with the cast sheet of POSS-PCU which
served as a control.
It is clear to see phase separation resulted in significant variations in the chemical,
mechanical and structural surface properties of POSS-PCU. Further, the addition of
NaHCO3 resulted in significant changes to the surface morphology and topography
but did not have any great impact on the chemical or mechanical behaviour of the
phase separated membranes.
By utilising SIMS, any differences in surface chemistry, following phase separation
were elucidated. SIMS is a surface analytical technique which makes use of a fo-
cussed beam of primary ions which induce secondary ions to be released from the top
two monolayers (up to 2 nm) of the surface. Secondary ions are analysed by a mass
spectrometer to form mass spectra and selected mass images of the surface (fig 6.2
and 6.3). Phase separation appears to reduce the presence of the POSS moiety at the
surface. This result is further corroborated by ATR-FTIR analysis which also dis-
played a reduction in peak intensity at 1100cm−1 which is associated with POSS. It is
thought that the low surface energy, non-polar, POSS moiety migrates to the surface
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in a manner analogous to a number of additives used in the coatings industry [233].
This is validated by the high content of POSS found on the surface of the cast sheet of
POSS-PCU via SIMS, and the intensity of the POSS peak on the ATR-FTIR spectra.
However, upon phase separation; a highly porous, low density POSS-PCU foam is
created which exhibits a dramatically increased surface area. As the surface area is
increased but the concentration of POSS remains constant, it is expected that there
would be fewer POSS moieties at any given location on the surface of the membranes.
With fewer POSS moieties at the surface of the phase separated membranes, it is
expected that the underlying polyurethane would be exposed to a far greater degree.
A closer look at the ATR-FTIR results indicate an increase in peak intensity at ap-
proximately 1740cm−1 which can be attributed to carbonyl peaks associated with
the polycarbonate polyol soft segment. Again, SIMS analysis appears to validate
these findings. The negative SIMS spectra, which contains many of the nitrogen and
oxygen containing heteroatom fragments associated with polyurethanes, is far more
abundant for the phase separated sample giving rise to the belief that the first few
nanometres of the phase separated sample is predominantly polyurethane in nature.
The reduction in the number of non-polar POSS groups at the surface of the phase
separated samples also manifested itself into a significant reduction in surface contact
angle (fig 6.5). Contact angle measurements are used to determine the wettability of
the substrate with wetting surfaces associated with high surface energy and nonwet-
ting ones with low surface energy. The level of wetting is represented by the contact
angle formed at the interface between a solid and a liquid. Whilst phase separation
resulted in a significant decrease in the initial contact angle, the addition of NaHCO3
led to a minor increase. This is likely due to the increased surface roughness of the
membranes (fig 6.7). In addition to surface chemical constituents, contact angle is
known to be highly sensitive to surface heterogeneity and roughness, and an increase
in surface roughness is likely to lead to an increase in surface contact angle. Contact
angle, however, was not sensitive to the concentration of NaHCO3 as no significant
change was noted between samples produced with 35, 45 or 55% NaHCO3.
The wetting behaviour of the samples was noted to change over time. The contact
angles formed appear to reduce dramatically on the phase separation samples. Fur-
ther, the higher the concentration of NaHCO3 the more dramatic the decrease in
contact angle. The likely cause of this observation is the increased swelling potential
of the porous membranes produced with NaHCO3. As the concentration of NaHCO3
increased to a maximum of 55%, the bulk pore size also expanded to approximately
117
CHAPTER 6. SURFACE CHARACTERISATION OF POSS-PCU VASCULAR
GRAFTS
30 µm (fig4.12). Consequently, the volume of free space for water absorption will also
increase resulting in the dramatic reduction in contact angle due to the liquid being
swollen by the membranes [234].
Whereas mercury porosimetry reported bulk pore sizes in the range of 15-30 µm, it
is clear to see from the surface SEM images (fig 6.6) that the surface pore size is
significantly less. Whilst there was a general trend of increasing pore size with an
increase in NaHCO3 the differences were not significant and the surface pore size
of the membranes produced via phase separation and NaHCO3 ranges from as little
as 1 µm to approximately 15 µm. This is in contrast to the membrane via phase
separation alone, with no NaHCO3, which does not appear to have a porous surface
at all, with a thin skin layer forming at the surface. The fact that the pore size is
significantly smaller than the diameter of NaHCO3 would appear to further validate
the hypothesis discussed in chapter 4 that the NaHCO3 does not act as a leaching
agent, but in fact, fundamentally alters the dynamics of the phase separation process;
the result of which, in this case, is to inhibit the formation of a skin. If the NaHCO3
acted as a conventional porogen, one would expect the pore size to be more uniform
and correspond to NaHCO3 diameter. As that is not the case, it is likely that the
addition of NaHCO3 has a significant influence on the thermodynamic and kinetic
properties of the quaternary system. It is likely that the addition of an inorganic filler
to the system reduces the build-up of interfacial polymer concentration inhibiting the
formation of a dense skin layer.
Recently, the rigidity and roughness of the surface have become important parame-
ters in the design of vascular grafts [235]. Having control over the morphological and
mechanical surface properties at the nanoscale could help to aid in the design of more
anti-thrombogenic surfaces capable of endothelialisation. The addition of NaHCO3
resulted in a significant increase in the surface roughness of membranes (fig 6.7),
reaching a maximum SRMS value of 404.2 ± 29.8 nm for the membrane produced
with 55% of NaHCO3 as measured via AFM.
AFM in indentation mode was utilised to measure the surface stiffness of the mem-
branes. No significant differences were seen between the cast, phase separated or
phase separated with NaHCO3 samples. This is in sharp contrast to the bulk stiff-
ness measurements obtained via more conventional means, such as uniaxial tensiom-
etry, whereby there are marked differences in the mechanical properties of the cast
and phase separated samples. The Youngs modulus is almost 20 times as stiff as
the phase separated membranes [186]. The second surprising feature of the nanoin-
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dentation tests was the values of the Youngs relaxation modulus. Whereas tensile
testing returned values in the MPa range, AFM produced values in the GPas. How-
ever, this is not a unique observation; a number of previous investigations have
found significant discrepancies between the bulk stiffness and surface stiffness of
polyurethanes [236, 237]. Further, there are several reports of the surface stiffness
of polyurethanes, measured via AFM indentation, being in the GPa range [238–241].
Polyurethanes are multiphase samples with complex morphology. The bulk modulus
values will be dependent on volume fractions, morphology of phases and interphase
crystal connectivity with the tensile characteristics are determined via physical aver-
aging processes. The surface stiffness measured with AFM indentation is a measure
of the surface stiffness, at a depth of a few hundred nanometres, in isolated locations.
Therefore, surface fractions are the primary determinants of the surface stiffness, with
significant variations in stiffness between the hard and soft segments of polyurethanes
being reported. Furthermore, in the case of POSS-PCU, POSS is a highly ordered,
symmetrical, silica cage which is known to migrate to the surface. Stiffness values
of POSS have been measured in the range of tens of GPa, which is likely to further
exacerbate the surface stiffness of POSS-PCU, causing a further divergence of bulk
and surface stiffness [242].
It should be noted that this chapter dealt with studying the bare surface on the lu-
minal side of the graft - the surface that will be in contact with the blood. However,
upon immediate exposure to blood, the surface properties are likely to dramatically
alter due the immediate adsorption of proteins. It is this interfacial protein layer
that will mediate the cellular adhesion and biocompatibility of any implanted de-
vice. Whilst the underlying surface porosity and substrate stiffness are not likely
affected, properties such as surface topography, surface energy and contact angle are
likely to alter significantly following protein adhesion. Further, the type, concentra-
tion and confirmation of the adhered proteins will modulate the downstream cellular
behaviour. The adhesion and confirmation of proteins is itself dependent on the sur-
face properties of the biomaterial. Previous studies on POSS-PCU found it to bind
fibrinogen irreversibly in a competitive binding assay with albumin [243]. Adsorbed
fibrinogen molecules mainly took the dominant trinodular structures in monomeric
and dimeric forms [244]. In addition, net positively charged long α chains were prone
to being hidden beneath the D domains whilst γ chains predominantly remained ex-
posed. Protein adhesion is a key intermediary process influencing cellular adhesion,
gaining further insight on the behavior of proteins on surfaces can help in the design
of improved biomaterials.
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6.4 Conclusions
Biocompatibility of medical devices and implants is, to a large degree, determined by
the interfacial characteristics of the biomaterial. In this chapter, a detailed descrip-
tion of the surface chemical, morphological and mechanical properties of POSS-PCU
is provided and discussed. Three quite distinct surfaces were investigated: the virgin
POSS-PCU, phase separated POSS-PCU and phase separated with NaHCO3 POSS-
PCU. Following phase separation, the surfaces were significantly rougher with fewer
POSS moieties at the surface. The addition of NaHCO3 led to a more porous mem-
brane. No differences were found between the surface mechanical properties which
is in marked contrast to the bulk mechanical properties which displayed some quite
obvious and significant differences. With the exception of surface roughness, the con-
centration of NaHCO3 did not appear to significantly influence the surface properties
of the membranes, which again, is in contrast to the bulk properties which were quite
heavily influenced by the concentration of NaHCO3.
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Blood Material Interactions of POSS-PCU
Vascular Grafts
Vascular grafts are, by their very nature, blood contacting devices; and as such, in-
teractions between graft surface and blood are essential in determining graft patency.
Blood is a multicomponent fluid, which delivers required substances to the body, such
as nutrients and oxygen, whilst simultaneously removing waste products. It is com-
posed of 55% plasma and 45% formed elements. Plasma constitutes approximately
90% water with the other 10% consisting of plasma proteins, electrolytes and nutri-
ents. The formed elements component of blood is composed of a number of cell types
which includes red blood cells (RBC), white blood cells (WBC) and platelets. The
WBC can be further subdivided into five different and diverse cell types: monocyte,
lymphocyte, basophil, eosinophil and neutrophil.
When an exogenous material is exposed to blood, a complex series of events is ini-
tiated which begins with protein adsorption resulting in the activation of the coag-
ulation cascade, which regulates thrombosis via the intrinsic pathway (fig 1.3) [34].
Factor XII is activated by adsorption which then goes onto convert prekallikrein into
kallikrein initiating a cascade of reactions resulting in prothrombin being cleaved into
thrombin. Thrombin converts the soluble plasma protein, fibrinogen, into insoluble
strands of fibrin which then forms a mesh resulting in a haemostatic plug or clot in
conjunction with platelets. The mesh forms a transient provisional matrix in and
around the biomaterial which provides the structural, biochemical and cellular com-
ponents required for modulating WBC behaviour [245].
The adhesion, survival and phenotype of WBC is dependent on the type, level and
surface conformation of adsorbed proteins, which in turn are dependent on the surface
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properties of the biomaterial. An inflammatory response results in the migration of
monocytes to the biomaterial surface and differentiating into macrophages, express-
ing various surface markers such as CD14, CD69 and CD86, essential for presenting
antigens necessary for T cell activation [245]. Activated macrophages can modulate
their behaviour through the release of cytokines, such as IL-1β, IL-6, IL-8, IL-10
and TNF-α, which are chemical messengers mediating the immune response [246].
Eventually macrophages fuse together forming multi-nucleated foreign body giant
cells (FBGC) which remain at the tissue-implant interface for the lifetime of the de-
vice [247]. If the biomaterial is larger than 10µm, as is the case with vascular grafts,
then the FBGC is incapable of undergoing phagocytosis and thus release oxygen free
radicals, degradative enzymes and acid in a bid to degrade the foreign body. En-
suring that the biomaterial invokes a minimal macrophage response, and is durable
enough to withstand the degradative solutions, is essential for successful long term
implants. The release of cytokines, growth factors and chemoattractants provides a
rich environment of activating and inhibiting substances capable of regulating the cell
populations in the inflammatory and wound healing responses.
Parameters such as chemical composition, electrical charge, surface texture and poros-
ity, discussed extensively in the previous chapter, all modulate the behaviour of im-
planted device [248]. Hydrophobic head groups such as –CH3 and –CF3 were found to
be significantly less thrombogenic than more ionic head groups (–COOH and –SO3H)
with the least thrombogenic surface being the hydrophobic silastic tubing which had
a water in air contact angle of 108◦ [249]. In an alternative study conducted on PU
catheters, the opposite trend was apparent [250]. The more hydrophilic PU, with
increased number of carboxylic groups, led to a decrease in platelet and fibrinogen
uptake. Meanwhile, it was reported that a rough, textured surface leads to an in-
crease in the number of adhered platelets and thus poor haemocompatibility [251].
However, this too was contradicted with it being reported that sub-micron texturing
of polyurethanes reduce platelet adhesion due to the minimal surface area available
for interacting with blood [252]. A similar response was noted on porous substrates
where highly porous grafts displayed much improved blood compatibility due to a
reduced surface area for platelets to interact with [251].
Human monocytes are equally vulnerable to the material surface affecting their be-
haviour. When cultured upon hydrophilic and anionic surfaces, monocytes expressed
reduced level of the pro-inflammatory cytokine IL-8 and increased levels of the anti-
inflammatory cytokine IL-10 compared to monocytes cultured on hydrophobic and
cationic surfaces [253]. The same authors also discovered that hydrophilic and anionic
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surfaces inhibit monocyte adhesion and IL-4 mediated FBGC formation leading them
to conclude that hydrophilic and anionic surfaces promote an anti-inflammatory re-
sponse by dictating the cytokines produced by adhered monocytes and macrophages.
In vitro studies, using titanium surfaces with a range of roughnesss, found that the
rougher surfaces promoted the secretion of pro-inflammatory cytokines (Il-1β, IL-6
and TNF-α) and chemokines (monocyte chemoattractant protein-1 and macrophage
inflammatory protein-1α) from murine macrophage-like cells, in a time dependant
manner [254]. Meanwhile, a separate study with polyethylene implants, suggested
that a coarse surface induced a lesser tissue reaction compared with the smoother
surface [255].
It is clear from the literature that no clear consensus exists on the optimal parameters
for blood contacting devices. The contradictory reporting of the effects of biomate-
rials on the thrombogenic and immunogenic response is indicative of the complex,
interwined nature of blood-material interactions. The aim of this chapter is to in-
vestigate the biocompatibility of POSS-PCU surfaces by studying the interactions
of various components of blood with the phase separated membranes in vitro. The
activation of plasma proteins, platelet adhesion and activation, mononuclear cell ad-
hesion and activation and the endothelialisation potential were all explored in this
study. HUVECs and EPCs were both used to assess endothelialisation with cell vi-
ability measured with Alamar Blue assay. The impact of phase separation, with or
without NaHCO3, on the biological performance of POSS-PCU was assessed.
7.1 Materials and Methods
7.1.1 Isolation of blood components
Blood samples were collected following consent from healthy adult human volun-
teers. Samples were collected by venepuncture in citrated blood tubes constituting
3.8% citrated whole blood at 1:10 v/v, pH 7.4 (Sarstedt, UK). Samples were exposed
to density gradient centrifugation within an hour of collection (fig 7.1).
Plasma and platelets
Blood was layered onto Ficoll-Paque (GE Health care Bio-science, Sweden) density
gradient in a 1:1 ratio and centrifuged at 200g for 15 mins resulting in the red blood
cells at the bottom and platelet rich plasma (PRP) at the top separated by the density
gradient, Ficoll-Paque. The PRP was separated and further centrifuged at 2000g for
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(a) Before centrifugation (b) After centrifugation
Figure 7.1: Images of human blood layered on Ficoll-Paque before and after centrifugation.
Centrifuging splits the blood into four layers: plasma, mononuclear cell fraction, Ficoll-Paque
and red blood cells.
20 mins resulting in a pellet of platelets at the bottom of the container and a plasma
layer. The plasma was collected in a flask and the platelets were resuspended in
sterile PBS at a concentration of 1×106 per mL.
Mononuclear cells
The mononuclear fraction of the blood was also isolated by centrifugating a 1:1 ratio
of blood and Ficoll-Paque at 400g for 30 mins at room temperature. The mononuclear
fraction was separated from each tube and the samples pooled in 30 mL universal
tubes (Falcon, UK). 10 mL of Hanks Balanced Salt Solution (HBSS, Invitrogen,
UK) was then added slowly to each tube and the contents mixed and centrifuged
at 250g for 10 mins at room temperature. The cells were washed three times with
HBSS, resuspended in 10% fetal bovine serum (FBS) and counted for downstream
experiments.
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7.1.2 Thrombogenicity evaluation
Plasma kallikrein assay
Presence of kallikrein in plasma supernatant following incubation with polymer discs
was measured spectrophotometrically by a chromogenic kallikrein substrate (H-D-
But-CHA-Arg-pNA, Diapharma). Polymer discs (16mm in diameter, n=4) were in-
cubated with 1mL plasma (diluted 1:5 with TrisHCl, pH 7.8) for a period of 60 mins
in a 24 well plate. In 96 well plates, 100µL of the incubated plasma was mixed with
200µL of the kallikrein substrate and incubated at 37◦C for 30 minutes. 25µL of
50% acetic acid was used to terminate the reaction and optical densities were read
at 405nm (Anthos 2010) giving a measure of kallikrein concentration. A calibration
curve was constructed following manufacturers instructions using known concentra-
tions of kallikrein diluted in 100µL of sterile PBS.
Platelet adhesion
A 24 well plate was lined with polymer discs (16 mm in diameter, n=4) and incubated
in PBS for 1 hour. 1mL of platelet solution was added and incubated at 37◦C
for 1 hour. The supernatant was then removed and immediately counted using a
haemocytometer. The number of attached platelets was calculated from platelet
counts before and after incubation with polymer, and expressed as a percentage of
platelets adhered (P ) using equation 7.1
P =
Pi − Pf
Pi
× 100
 7.1
where Pi represents the initial platelet concentration and Pf the concentration of
platelets in the supernatant after adsorption.
Platelet activation
Platelet activation was determined using direct enzyme linked immunosorbent assay
(ELISA). Polymer membrane samples (16mm in diameter, n=4) were incubated in
24 well plates with 1mL platelet solution for a period of 1 hour. The supernatant was
removed and the concentration of PF4 in the plasma was determined using an ELISA
kit (Human CXCL4/PF4 DuoSet ELISA Kits, R & D Systems, Abingdon, UK) fol-
lowing standard, manufacturer provided protocols (Catalogue Number: BBE6 and
human CXCL4/PF4, Catalogue Number: DY795, R&D systems). Platelet adsorp-
tion morphology was observed using SEM. Glutaraldehyde solution (2.5% v/v) was
used to fix samples which were then dehydrated with ethanol/distilled water (10%
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ethanol increments) at 41◦C. This was followed by freeze-drying for 48h before sub-
jecting them to SEM observation.
7.1.3 Inflammatory evaluation
PBMC culture and immunostaining
Isolated PBMCs, concentration of 1×106 cells/mL, were cultured on 24 well plates
coated with polymer samples (n=6). RPMI 1640 (Gibco, UK) supplemented with
2mM glutamine and 10% FBS was used as cell culture medium. The cultured cells
were collected from the graft samples for immunostaining after 24 hrs and 7 days. Fol-
lowing washing with sterile PBS, cells were subsequently stained for surface markers
including, CD14-PerCP, CD86 Fluorescein, HLA-DR-PE and CD69-APC (all from
R&D Systems, Abingdon, UK). The cells were incubated at 4◦C for 30 mins then
were washed with PBS, re-suspended in 100µL of 4% paraformaldehyde, and were
acquired on a FACS Calibur.
Cytokine release
Supernatants were collected from the cells cultured on the different substrates and
were freezed and stored at -20◦C for quantitative immunoassay. Cytokines, namely
Interleukin-1 (IL-1β/IL-1F2), IL-6, IL-10, and Tumour Necrosis Factor (TNFα) were
identified using specific ELISA kits (Quantikine, R&D System, Abingdon, UK) fol-
lowing the protocol provided and the optical density of each sample was determined
using a microplate reader (Anthos 2010) set to 450nm. Concentrations of each cy-
tokine was determined from calibration curves produced using known quantities of
cytokine.
7.1.4 Endothelialisation potential
HUVECs
HUVEC isolation HUVECs were isolated from a fresh human umbilical cord col-
lected from the Royal Free hospital Labour Ward. The cord was inspected for any
clamp marks, needle holes or any other damage; clamp marks were cut and the cord
was then clamped to allow manipulation. The vein of the cord was cannulated with
a 4 cm length sterile nasogastric tubing at both ends and tied firmly in place with
sterile silk thread. The clamps were removed from the vein and placed on the tub-
ing. A syringe was then used to flush the vein with sterile PBS until all clotted
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blood was removed from the vein. The vein was then filled with collagenase solution
(12.5 mg Collagenase A in 25 mL of basic medium) which was filter sterilised before
use. The basic medium consisted of 96% M199 medium, 3% NaHCO3, and 1% Peni-
cillin/Streptomycin Solution (Penicillin 10000 U/mL streptomycin 10 mg/mL). The
vein was placed in an incubator at 37◦C for a period of 10 minutes. Following incuba-
tion, the cord was massaged to loosen the EC, and the collagenase solution emptied
into a centrifuge tube. The cord was then washed with PBS collecting the washings
in a centrifuge tube. The collagenase solution was neutralised with complete medium
consisting of basic medium supplemented with FBS and L-glutamine. Cell solutions
were centrifuged at 300g for 7 minutes, the medium was removed and the cell pellet
was resuspended in complete medium and transferred to a culture flask and placed
in an incubator. After 24 hrs the RBC were removed by washing with PBS and the
cells were fed with fresh complete medium. At confluence, cells were removed using
0.25% trypsin-EDTA and split in a 1:2 ratio. Confluent cultures at passage three
were used in all experiments.
HUVEC culture 16 mm discs of polymer samples (n=6) were prepared and ster-
ilised through autoclaving and placed in 24 well plates. Polymer samples were seeded
with 2×105 cells in 1 mL of medium (M199 supplemented with 20% foetal bovine
serum (FBS) and penicillin/streptomycin), and cultured for a period of 14 days. Cells
cultured on tissue culture plastic (TCP) served as a positive control.
EPCs
The isolated PBMCs were suspended in cell culture medium (M199 supplemented
with 20% fetal bovine serum (FBS) and penicillin/streptomycin) and cultured on
polymer discs (n=6) in 24 well plates at a concentration of 5×105 cells per well in 1
mL of medium. Cells were cultured for a period of 14 days with TCP cultured cells
serving as a control.
Cell viability
Cell metabolism was assessed by AB assay at day 1, 3, 5, 7, 10 and 14 for HUVECs
and 5, 7, 10 and 14 for EPCs. Medium was removed from the wells and 1ml 10% AB
in cell culture media added. After a 4 hour incubation, AB samples were removed and
0.1 ml was measured on a Fluroskan Ascent FL (Thermo Labsystems, UK) fluorescent
plate reader (excitation 530nm, emission at 620nm).
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Statistical data analysis
The data is presented as means and standard deviations. One way analysis of variance
(ANOVA) with Tukey post hoc test was used to examine the significance between
the samples with p<0.05 considered to be statistically significant. Two way ANOVA
was utilised where indicated for analysing two independent variables.
7.2 Results
Thrombogenicity evaluation
Plasma kallikrein assay The presence of kallikrein in plasma following incuba-
tion with the polymer samples was measured spectrophotometrically using a spe-
cific kallikrein substrate (H-D-But-CHA-Arg-pNA) and are presented in figure 7.2.
Kallikrein activity was lowest on the cast sheet of POSS-PCU polymer rising signifi-
cantly (p<0.001) on the phase separated samples. Samples produced with NaHCO3
induced a greater degree of kallikrein than the sample produced with no NaHCO3;
however the concentration of NaHCO3 had no effect on the level of kallikrein produc-
tion.
(a) Calibration curve (b) Kallikrein concentration in supernatant
Figure 7.2: Significant differences in concentration of kallikrein was recorded from plasma
supernatant following one hour incubation with the cast, phase separated and phase
separated/NaHCO3 samples. No significant differences were detected between the differ-
ent concentrations of NaHCO3(p<0.001, N.S = not significant, n=4)
Platelet adhesion Figure 7.3 summarises the percentage of platelets adhered to
each polymer sample. The cast sheet of POSS-PCU adhered the least platelets (8.0
± 3.8%). Phase separating POSS-PCU resulted in it adhering significantly (p<0.001)
more platelets compared to the cast sheet (26.3 ± 3.7%); however, the addition of
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NaHCO3 reduced the percentage of platelets adhered to 19.96 ± 3.12%. There was
no significant difference between the sample prepared with 35% NaHCO3 and 45%
but increasing the concentration of NaHCO3 to 45% reduced the number of platelets
adhered to 14.82 ± 2.06%.
Figure 7.3: Percentage of platelets adhered to polymer samples after incubation with
platelets in for 1 hour (N.S = not significant, n=4)
Platelet activation The concentration of PF4 released into the supernatant was
used as an indicator of the extent to which the polymer samples activate platelets. No
significant differences were detected between any of the samples with the exception of
phase separated POSS-PCU produced with no NaHCO3 which induced a significantly
(p<0.001) greater degree of PF4 release (fig 7.4).
In addition to PF4 concentration, the morphology of the adherent platelets was ob-
served through SEM images (Fig 7.5). On the cast sheet of POSS-PCU, platelets
appear spherical in shape and there is no evidence for any pseudopodia emanating
from the rounded cells 7.5a. Platelet morphology changes drastically on the phase sep-
arated POSS-PCU. Large aggregates of platelets are present on the surface which are
flat and highly spread, with protruding pseudopodia, indicative of activated platelets
7.5b. Platelets on the phase separated samples, produced with NaHCO3, are rela-
tively quiescent 7.5c, d, e. There are minor aggregates but little or no evidence of
pseudopodia protrusion or flattening and spreading out; the hallmarks of activation.
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(a) Calibration curve (b) concentration of PF4 supernatant
Figure 7.4: Concentration of PF4 released into the supernatant by platelets following one
hour incubation with polymer samples. * = p<0.001, n=4.
Inflammatory evaluation
PBMC culture and immunostaining PBMC were cultured on the different sub-
strates and labelled with antibodies for four inflammatory cell markers (CD14, CD69,
CD86 and HLA-DR) and analysed using a fluorescence activated cell sorter (FACS)
at two time points: after 24 hours and 7 days (Fig 7.7). FACS analysis displayed
a significantly higher (p<0.001) number of CD14 positive cells on phase separated
POSS-PCU; however, after 7 days culture that difference dissipated and all 5 sam-
ples exhibited the same number of CD14+ cells. CD86 expression was least on the
cast POSS-PCU both after 24 hours and 7 days. In contrast the phase separated
POSS-PCU induced the most CD86 expression after 24 hours. Following 7 days of
culture, CD86 expression equilibrated between the phase separated samples with no
significant differences being detected. No significant difference in CD69 expression
was detected between the phase separated samples; however, cast POSS-PCU consis-
tently had fewer CD69+ cells after 24 hours and 7 days. Phase separated POSS-PCU
also induced a greater degree of HLA expression, after 24 hrs, than the other 4 sam-
ples; however, there was no difference after 7 days of culture. Interestingly, there was
no significant change in HLA expression on the cast sample after 24 hours or 7 days.
Cytokine release Commercially available ELISA kits were used to measure the
concentration of four cytokines (IL-1β, IL-6, IL-10 and TNFα) released by PBMC
into the supernatant (fig 7.8). IL-6 appears to be unaffected by the substrate as no
difference was detected in its concentration on any of the samples after 24 hours or
7 days. IL-1β was significantly (p<0.001, marked * or # on figure 7.8) lower on
the cast sample than the phase separated; however, there was no difference in IL-1β
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(a) cast POSS-PCU (b) o% NaHCO3 (c) 35% NaHCO3
(d) 45% NaHCO3 (e) 55% NaHCO3
Figure 7.5: Representative images of platelets on polymer samples following 1 hour incu-
bation on polymer samples. Platelets on the cast sheet of POSS-PCU are spherical in shape
with no aggregates or evidence of pseudopodia protrusions. Large aggregates of platelets
with protruding pseudopodia are present on the phase separated sample with no NaHCO3.
Evidence of minor platelet aggregation on samples produced with 35% and 45% NaHCO3,
but platelets remain relatively spherical in shape. Fewer platelets found on the samples with
55% NaHCO3 with minimal aggregates and no spreading.
release between the different phase separated samples. Further, there were no differ-
ences in IL-1β concentration between the two time points on any of the five samples,
indicating that cytokine release was at its maximum very quickly after contact with
the foreign surface. Both IL-10 and TNFα appear to be heavily surface dependant.
There is a significant (p<0.001) reduction in IL-10 concentration on the phase sepa-
rated samples produced with 35 or 45% NaHCO3, compared to the samples with 0
and 55% NaHCO3 after both 24 hours and 7 days (marked * and ## on figure 7.8).
IL-10 concentration was at its highest on substrate produced with 55% NaHCO3 af-
ter 7 days. TNFα release profile was almost exactly the opposite of IL-10, whereby
samples produced with 35 or 45% NaHCO3 produced significantly higher concentra-
tions of TNFα than the samples with 0 and 55% NaHCO3 after 24 hours. The rate
of TNFα release over 7 days varied with each substrate. The sample produced with
35% NaHCO3 generated the most TNFα followed by a significant reduction in TNFα
on the sample produced with 45% NaHCO3 (marked #). There was no difference
between TNFα production on the samples produced with 0 and 55% NaHCO3; how-
131
CHAPTER 7. BLOOD MATERIAL INTERACTIONS OF POSS-PCU
VASCULAR GRAFTS
Figure 7.6: Representative SEM images of PBMC cultured on polymeric surfaces.
Figure 7.7: Surface receptor expression of PBMC at two time points: 24 hours and 7 days.
Surface receptors CD14, CD69, CD86 and HLA-DR were examined. *=p<0.01, # =p <0.01
in second time series, n=6
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ever, both produced significantly less than the 35 and 45% samples (marked ##).
The cast sample of POSS-PCU consistently had the least concentration of both IL-10
and TNFα after 24 hours and 7 days (marked ** and ###).
Figure 7.8: Concentration of cytokine release from PBMC supernatants after 24 hours and
7 days. Cytokines IL-1β, IL-6, IL-10 and TNFα were all examined. * indicates significance
for the 24 hour time period whereas # indicates significance for 7 days time period. p<0.01,
n=6)
Endothelialisation potential
HUVEC HUVECs were cultured for a period of 14 days with the results presented
in figure 7.9. After 24 hours, no significant difference existed between any of the
experimental samples, as determined by one way ANOVA, or indeed the control
TCP. After 3 days of culture; the number of viable cell, as determined via Alamar
Blue assay, increased however there was still no significant difference between the
samples or TCP. A growth in cell numbers was again observed after 5 days; however,
HUVECs on the sample with NaHCO3 appear to be growing significantly slower (2
way ANOVA, Bonferroni’s post test p<0.05). After 7 days, the samples produced
with NaHCO3 were still sustaining a significantly lower number of cells compared
to TCP. Following 14 days of culture, there were significant differences between the
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number of viable cells on TCP and all the test samples with the exception of the
substrate produced with 55% NaHCO3.
Figure 7.9: HUVEC culture for a period of 14 days. Cell viability is measured at discrete
time points via the AB assay. Samples were subjected to 2 way ANOVA to determine
significance, n=6)
EPC Results of EPC culture are presented in figure 7.10. Two way ANOVA deter-
mined significant differences in cell numbers at different time points. Whilst the initial
number of viable cells, after 5 days, is the same on both TCP and cast POSS-PCU;
the rates of growth vary significantly so that after 14 days TCP has significantly more
viable ECPs than cast POSS-PCU. The phase separated samples, with the exception
of the substrate produced with 55% NaHCO3, consistently exhibited a lower nuber of
viable cells than TCP. Despite having significantly fewer cells after 5 days, the rate of
cell growth on the 55% NaHCO3 sample continued to grow resulting in it sustaining
a significantly higher number of cells than the other test samples. The TCP control
clearly sustains a significantly higher number of viable cells throughout the 14 days.
7.3 Discussion
The success of any blood contacting, implantable device is based in its ability to
resist thrombosis and inflammation. This is particularly pertinent for vascular grafts
as thrombosis remains the primary cause of small calibre graft failure [256]. Throm-
bosis is usually the result when any exogenous material comes into contact with
blood. Whilst a truly non-thrombogenic surface does not exist; there have been some
successes in reducing protein adsorption and platelet adhesion and elucidating the
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Figure 7.10: EPC growth curves generated over a period of 14 days. The Alamar Blue
assay was utilised to measure cell viability. 2 way ANOVA was used to determine statistical
significance, n=6)
mechanisms by which exogenous materials activate the coagulation cascade and the
cellular components of blood [257,258].
The concentration of kallikrein present in plasma is a good indicator of the extent
of activation of the intrinsic pathway of the coagulation cascade [259]. Kallikrein
activation is known to be most prominent on negatively charged or polar, hydrophilic
surfaces. Whilst none of the POSS-PCU surfaces are negatively charged, the cast
POSS-PCU is the most hydrophobic and was found to induce the least kallikrein
activation. Meanwhile, the substrates produced via phase separation with NaHCO3
elicited more kallikrein production than the substrate produced via phase separa-
tion alone, despite being more hydrophobic. Whilst there was a modest increase
in contact angle between the respective samples, it is unlikely that a small increase
in contact angle would translate itself into modulating kallikrein activation. More
likely, the increase in activation could be due to the significant increase in surface
area. The membranes produced with NaHCO3 are porous surfaces which are signif-
icantly rougher translating into a dramatic increase in surface area. The increased
surface area would provide more of the polymer for the plasma to interact resulting
in plasma activation to a greater extent.
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A similar paradigm could be proposed for the interaction of platelets: increased
roughness would expose a larger area for platelet adhesion. However, this simplistic
view fails to take into consideration the scale of dimensions on the surface [260]. If
the dimensions are in excess of 2 µm (the dimension of a platelet) then the increased
roughness will simply result in more contact area for platelet surface adhesion, result-
ing in a more thrombogenic surface. Meanwhile, if surface features are below 75 nm,
then the surface structures are even smaller than the pseudopodia of platelets; thus,
they can be considered smooth with factors other than surface roughness dominating.
However, if the surface roughness dimensions are between 2 µm and 50 nm then the
contact area that platelets are in contact with may be reduced as platelets will only
be able to adhere to the top of the topographic features.
Accordingly, the smooth, cast POSS-PCU adhered the least platelets. As platelets
are insensitive to substrate rigidity and mechanical forces, it is thought the highly
hydrophobic nature of the surface repelled platelet adhesion [261]. Thereafter, there
appears to be a correlation with surface roughness and platelet adhesion for the phase
separated samples. The membrane produced with 55% NaHCO3 had a SRMS equal to
404.2 ± 29.8 nm (table 6.2) and adhered the least platelets (14.82 ± 2.06%); whereas
the graft produced with 0% NaHCO3 had a SRMS equal to 105.2 ± 12.8 nm and
adhered the most platelets (26.34 ± 3.69%).
Once adhered, the interaction and activation of formed elements, such as platelets
and cells, with a material surface is dependent on the nature of the surface and the
adsorbed proteins. Activation is instigated by an extracellular stimulus interacting
with the cell surface which usually involves a ligand binding with a specific surface
receptor. Various plasma proteins, including thrombin and fibrinogen, can absorb
onto material surface and provide the necessary activation. However, for plasma pro-
teins to be able to successfully provide the stimulus needed for activation, they need
to be in a suitable orientation and conformation for the correct presentation of an
epitope [244]. The orientation and conformation of proteins on material surface is
dependent on a number of factors including surface topography, porosity and surface
charge with adsorption distorting protein structure.
Platelet activation appeared to be insensitive to surface roughness as no significant
difference was detected in PF4 release - a key cytokine released from the α granules
of activated platelets - or platelet morphology between the cast POSS-PCU or any of
the phase separated with NaHCO3 samples. However, the phase separated membrane
with no NaHCO3 did induced a significantly higher level of PF4, after normalisation
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for platelet numbers, suggesting a greater extent of activation. SEM images of the
platelets on would appear to corroborate these findings with significant aggregation
and pseudopodia protrusion, indicative of platelet activation, readily visible on the
phase separated with no NaHCO3 sample. This is in sharp contrast to the spherical
morphology of platelets on the remaining four samples. The precise mechanism be-
hind this heightened state of activation is difficult to ascertain; however, it may be
due to the relative hydrophilicity of the sample, or indeed the surface features may
be in the correct size range to induce activation [262].
WBC are produced and derived from haematopoitic stem cells in the bone marrow.
Following centrifugation of blood samples, they are often found in the buffy coat,
a thin, typically white layer of nucleated cells (fig 7.1). The mononuclear compo-
nent of these cells includes lymphocytes, monocytes and macrophages. Lymphocytes
are primarily responsible for mediating the immune system whereas monocytes and
macrophages are concerned with foreign body response. Monocytes tend to migrate
from the blood stream and differentiate into macrophages which are then tasked with
the engulfment and digestion of exogenous materials. CD14 is a surface receptor
commonly expressed by monocytes/macrophages. After 7 days in culture, nearly all
the cells on the samples are CD14+.
CD69, CD86 and HLA-DR are all surface markers of activation of macrophages.
CD69 is one of the earliest inducible cell surface glycoproteins making it a useful
marker for early activation of PBMC [263]. The relatively high level of CD69 expres-
sion after 24 hrs (> 50%) suggests the phase separated samples induce early activation
of PBMC. Meanwhile, HLA-DR and CD86 are both surface receptors whos primary
role is to modulate T cell response [245]. An increased abundance of HLA-DR or
CD86 on the cell surface is often in response to stimulation and so can be used as a
marker for immune activation. The general trends appears to be slightly increased
expression, after 24 hrs, on the substrate prepared with 0% NaHCO3 compared with
the other samples. After 7 days culture, the expression levels appear to reach close
to 100% on all of the samples.
Cytokine release profiles were measured at two time points - 24 hrs and seven days- in
an effort to see if the different surfaces altered the functional behaviour of PBMC. can
modulate their behaviour through the release of cytokines, such as IL-1, IL-6, IL-10
and TNFα, which are chemical messengers mediating the immune response [245]. No
difference was observed between the release profiles of IL-1β and IL-6 on the different
samples after 24 hrs or seven days indicating an initial burst of pro-inflammatory
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cytokine release, possibly as a result of the early activation as witnessed by the high
levels of CD69 expression.
Despite a higher percentage of CD14, CD86 and HLA-DR positive cells after 24 hrs,
the phase separated sample with 0% NaHCO3 induced a lower level of TNFα than
the samples produced with 35 and 45% NaHCO3. This may be due to the increased
expression of IL-10. IL-10 is an anti-inflammatory cytokine known to inhibit pro-
inflammatory cytokine production, such as TNFα, possibly via inhibition of NFκB
activation [264]. It would seem the cast sample of POSS-PCU induces a minimal
level of cytokine secretion. Thereafter, the phase separated sample with 0% and 55%
of NaHCO3 induce the highest level of the anti-inflammatory IL-10 cytokine and the
lowest levels of the pro-inflammatory TNFα. The trends remained similar after seven
days. Whilst TNFα is potent pro-inflammatory, low levels have been implicated in
the healing process by encouraging angiogenesis and increasing macrophage produced
growth factors during wound healing [265].
Whilst its clear that the different substrates induced a contrasting immune response;
no distinct pattern was observed, suggesting a complex relationship between material
surface characteristics and cell behaviour. Recent studies investigating macrophage
response to material topography have reported similar findings: no distinct pattern
between surface feature size or shape and cell response being detected [266]. This
may be a response of the intrinsically dynamic, heterogeneous and complex nature of
the macrophage cell system. Further, the chemical composition of the surface and the
subsequent changes in surface energy was found to have no impact on macrophage
behaviour [267].
Native blood vessels have a thin layer of EC lining the luminal wall which forms an
anti-thrombogenic interface with blood. Its postulated that for any prosthetic graft
to be successful in the long term, a fully functional endothelium, capable of main-
taining vessel integrity, is a necessity. Studies of endothelialising grafts in vitro with
cultured EC have shown that a confluent endothelium can improve long term patency
of the graft by preventing thrombogenic complications [71, 130, 133, 208]. However,
the process of extracting and culturing ECs for in vitro endothelialisation of grafts
is labour intensive requiring a great deal of time and expertise making it expensive
and restricted to a few specialised clinics. Therefore, material which can sustain and
induce in situ endothelialisation are much sought after.
In this study, POSS-PCU was shown to sustain both mature EC and EPC growth
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on its surface. Over a period of 14 days, HUVECs appeared to grow best on the
highly porous and rough surface of the substrate produced with 55% NaHCO3, com-
pared to the other test substrates; with no significance difference was noted between
cell growth on TCP or POSS-PCU. EPC growth was found to be not as robust on
POSS-PCU as on TCP; however, the 55% NaHCO3 sample was capable of sustaining
significantly higher number of EPC than the remaining test samples. These findings
are in agreement with a number of previously published reports which have found
EC growth much improved on rough, textured surfaces with pore sizes smaller than
30 µm [154,155,202,224].
7.4 Conclusions
The success of any implantable device is dependent on the biological reactions in the
interfacial regions governed by physiochemical properties. In this chapter, the throm-
bogenic, immunogenic and endothelialisation potential of the different graft surfaces
was examined. By studying a wide range of factors which include cytokine release,
surface receptor expression on PBMC and the growth of platelets, HUVEC and EPC;
the aim of this chapter was to get an understanding of the biological response one
can expect upon implantation of a POSS-PCU vascular graft.
In this study, the highly porous and rough surface of the sample produced with 55%
NaHCO3 appear to perform better than the substrates produced with 35 and 45%
NaHCO3. Whilst the phase separated sample produced with 0% NaHCO3 did suffer
in its response to platelets, cytokine release was at a minimum and it did not activate
the coagulation pathway as severely as samples produced with NaHCO3.
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The Impact of Sterilisation on POSS-PCU
Up to 6% of prosthetic grafts can encounter difficulties with infection resulting in ap-
proximately $640m in healthcare costs in the USA alone [268]. In addition, there are
significant associated morbidity and mortality rates and in 17-40% of patients, graft
infection leads to death [268]. A rather common, and completely avoidable, method
in which a prosthetic graft can become infected is through directly implanting a graft
with microrganisms attached [269]. Staphylococcus aureus, the central pathogen re-
sponsible for graft infections, and coagulase-negative staphylococci possess virulence
factors that facilitate their adherence to the prosthetic materials [270]. The pros-
thetic device is coated with a biofilm consisting of ECM which contain the infective
microbes; protecting it from the hosts immune response.
For these reasons an effective sterilisation protocol is essential when developing biomed-
ical devices. Sterilisation usually involves physical or chemical treatment which re-
sults in the deactivation of organic macromolecules and/or microorganisms and can
be achieved in a number of ways including steam, gamma irradiation and ethanol.
Given the nature of their action, the sterilising techniques can also react with the
biomaterial. Steam sterilisation can lead to hydrolysis, softening and degradation of
the polymer due to the high temperature, pressure and humidity [271]. Gamma irra-
diation is known to cause chain scission and cross-linking which can adversely affect
material properties [272]. Furthermore, both steam and gamma have been known
to deform and yellow the polymeric materials. Immersing in ethanol is a milder
technique used in vitro to disinfect the polymer sample. It is particularly useful for
disinfecting biodegradable tissue engineering scaffolds, such as glycolic acid based
materials; which, by their very nature, tend to be fragile [273].
The propensity of PUs to degrade has been discussed often in this thesis. Mean-
141
CHAPTER 8. THE IMPACT OF STERILISATION ON POSS-PCU
while POSS-PCU has been shown to be resistant to biodegradation both in vivo
and in vitro through incubating with a range of oxidation, hydrolysis and enzyme
solutions [182]. However, the impact of sterilisation technique on POSS-PCU is as
yet unknown. Whilst a range of sterilisation techniques has been used in the past,
little thought given to the impact of each method on the material properties. Nu-
merous investigations have characterised microbial activity following sterilisation, as
a marker of efficacy, but the impact of sterilisation technique’s on the material bulk
and surface properties is often ignored; whereas it is often the material bulk and sur-
face properties which determine the effectiveness of the implant/device. The purpose
of this study was to evaluate the impact of the sterilisation technique on the bulk
and surface properties of POSS-PCU and POSS-PCU vascular grafts. The treat-
ments include 70% ethanol, steam and gamma irradiation. Changes to the molecular
weight, mechanical strength, surface chemistry and cytotoxicity were evaluated and
the efficacy of sterilisation determined through incubating in bacterial growth broth.
8.1 Materials and Methods
Sample preparation
The 18%(w/w) solution of POSS-PCU in DMAc was cast onto glass petri dishes and
left in an oven at 60◦C overnight to evaporate the solvent. The resulting solid sheets
of polymer were then sterilised accordingly and used for future experiments.
Alternatively, vascular grafts were manufactured as per the instructions in chapter 4
using a formulation consisting of 50% NaHCO3 and 2% Tween 80 surfactant. Fol-
lowing manufacture, the grafts were sterilised for future experiments.
Sterilisation
Gamma irradiation Samples were packed in sterilisation pouches and irradiated
with a dose of 28.4 kGy at room temperature, using a 60Co gamma-ray source
(Isotron, Berkshire, UK). Samples were exposed to the source on a continuous path
for a period of 10 hours.
Autoclave Auotclaving involves exposing the biomaterials to saturated steam at
121oC for a minimum of 15 minutes at pressures of 115 kPa. The samples were
autoclaved and then left overnight for cooling.
Ethanol Polymer discs were incubated with 70% (v/v) ethanol and left in a roller
mixer for 10 minutes or 24 hours. Samples were then washed (5×) in distilled water,
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and stored in distilled water until use.
Material characterisation
Mechanical test Samples were cut longitudinally into a dogbone shaped specimen,
20 × 4 mm, using a sharp cutter and mechanical press ensuring a clean cut with no
flaws or stress aggregation. However, due to the random nature of pore size and
porosity in the coagulated samples, variability is to be expected. Sample thickness
was recorded using an electric micrometer. Stress-strain profiles were characterised
using a uniaxial load testing machine (Instron 5565, UK) and the Youngs modulus,
ultimate tensile strength and elongation at break obtained (n=6).
ATR-FTIR The chemical structure of the polyurethane samples, following ex-
posure to the various methods of sterilisation, was evaluated via attenuated total
reflectance Fourier transform infer-red (ATR-FTIR) spectroscopy (JASCO FT/IR
4200). 30 scans were taken for each sample between 600 and 4000 cm−1 (n=6).
Gel permeation chromatography Solutions of both samples were prepared by
adding 15 mL of DMF to 30 mg of sample and left to dissolve on a roller mixer
over night. The samples were analysed using a PL-GPC 50 system equipped with
PLGel column guard and 3 PLGel 5m mixed bed-C columns (300×7.5mm). The
measurement was carried out at 50oC in DMF and the eluent was pumped at the
constant flow rate of 1.0 mL/min. The system was calibrated by performing Univer-
sal Calibration with single PL-polystyrene standard and a set of PL-EasyVial PS-H
polystyrene standards of known molecular weights. The detection was done using
PL-BV 400RT viscometer and PL-RI differential refractometer. The data has been
collected and analysed using Varian ‘Cirrus Multi detector’ software. Analysis was
done in duplicates.
Cytotoxicity
Endothelial Progenitor Cell (EPC) extraction Blood samples were collected
following consent from healthy adult human volunteers. 24 ml samples were collected
by venepuncture in EDTA blood tubes (Sarstedt, UK). Following collection samples
were mixed and used for cell isolation within one hour of collection.
The mononuclear fraction of the blood was isolated using Histopaque 1077 (Sigma-
Aldrich, UK). Briefly 3 ml of Histopaque 1077 was added to each of eight 12 ml
polystyrene centrifuge tubes (Falcon, UK). 3 ml of blood was carefully layered on
top. The tubes were then centrifuged at 400g for 30 minutes at room temperature.
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The mononuclear fraction was separated from each tube and the samples pooled in
30 ml universal tubes (Falcon, UK). 10 ml of HBSS (Invitrogen, UK) was then added
slowly to each tube and the contents mixed. The tubes were centrifuged at 250g
for 10 minutes at room temperature. The cells were washed twice by removing the
supernatant, resuspending in 10 ml HBSS and centrifuging at 250g for 10 minutes
at room temperature. Finally the isolated cells were resuspended in 5 ml cell cul-
ture medium: M199 supplemented with 20% FBS and penicillin/streptomycin (both
Invitrogen UK). Cells were then counted using a haemocytometer and seeded onto
polymer samples as below.
EPC culture Cells were seeded onto polymer discs (n=4) in a 24 well plate (Falcon,
UK) at a seeding density of 5×105 cells per well in 1 ml cell culture medium. Cells
were then cultured for seven days.
Alamar blue assay Cell metabolism was assessed by Alamar blueTM (AB) assay
at day 7. Medium was removed from the wells and 1ml 10% AB in cell culture media
added. After a 4 hour incubation, AB samples were removed and measured on a
Fluroskan Ascent FL (Thermo Labsystems, UK) fluorescent plate reader (excitation
530nm, emission at 620nm).
Efficacy of sterilisation
All samples were tested for the effectiveness of sterilisation. Samples were immersed
in Tryptone soya broth (TSB) and Fluid Thioglycollate medium (THY) for cultiva-
tion of microorganisms (Wickham Laboratories, Hampshire) for a period of 14 days at
temperatures of 20-25◦C for TSB and 30-35◦C for THY. Sterile broth was used a neg-
ative control and unsterilised samples as positive controls. The broths were examined
macroscopically every 1-3 days with clouding of the broth indicative of contamination
and inefficient sterilisation whilst a clear broth would indicate no infection and an
efficient sterilisation of the samples (n=3).
Statistical analysis
Statistical analysis was conducted using a Students two tailed t test. The difference
between the means was deemed to be statistical significant when p<0.05.
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8.2 Results
Visual inspection
Both POSS-PCU samples appeared to withstand sterilising treatments well with no
obvious distortions visible. There was however, some slight discolouring/yellowing of
the samples following gamma irradiation.
Material characterisation
Mechanical test Table 8.1 displays the mechanical properties of the materials
following exposure to EtOH, autoclaving and gamma irradiation. No significant dif-
ference was seen between the Youngs modulus, UTS or elongation at break in any of
the samples following incubation with EtOH.
Autoclaving the samples of POSS-PCU did not affect the Youngs modulus or UTS;
however, there was a slight significant (p<0.05) increase in the elongation at break,
for the casted sample, compared to the control. Autoclaving the coagulated sample
caused a minor decrease in elongation.
Whereas the coagulated samples withstood the effects of gamma irradiation well, the
casted samples suffered a decrease in their mechanical properties. The UTS for POSS-
PCU decreased from 62.3 ± 6.7 MPa to 48.9 ± 5.0 MPa (p<0.001). The reduction
in UTS translated itself to the Youngs modulus which was significantly reduced for
the casted samples of POSS-PCU.
ATR-FTIR Attenuated total reflectance fourier transform infrared (ATR-FTIR)
spectroscopy was used to analyse surface chemical changes upon sterilisation. Both
samples were unaffected by autoclaving or ethanol treatment; however, gamma irra-
diation led to a reduction in peak intensity at 1245 and 1740 cm−1(table 8.1). In
addition, there was a significant increase in the intensity of the peak at 1095 cm−1
for the casted POSS-PCU sample.
Gel permeation chromatography GPC results are summarised in figure 8.2.
Treatment with EtOH had negligible impact on the number average molecular weight
(Mn), weight average molecular weight (Mw) or polydispersity index (Pd), regardless
of incubation time, for either of the samples. Autoclaving the cast sheet of POSS-
PCU resulted in a slight increase (p<0.05) in Mw but no change in Mn, resulting
in an increase in Pd, possibly suggesting a degree of cross linking. No changes in
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(a) Cast POSS-PCU IR spectra
(b) Phase separated POSS-PCU IR spectra
Figure 8.1: ATR-FTIR analysis of cast and coagulated samples of POSS-PCU following
sterilisation with EtOH (10 mins and 24 hrs), Autoclave and gamma irradiation. Inset with
each spectra is a summary of any changes in key peak intensities (n=6, p<0.05). The peak
assignment was as follows: 1100 cm−1 (Si-O-Si), 1240 cm−1 (urethane C-O-C), 1400 cm−1
(C-C aromatic ring), 1540 cm−1 (N-H and C=N), 1589 cm−1 (C=C aromatic), 1632 cm−1
(NH2), 1736 cm−1 (C=O).
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Sample Sterilisation
technique
Youngs
Modulus
(MPa)
Tensile
Strength
(MPa)
Elongation
(%)
Cast
Control 8.61 ± 0.81 62.35 ± 6.71 823.96 ± 28.03
EtOH 10mins 7.75 ± 0.47 56.48 ± 2.98 875.36 ± 47.01
EtOH 24hours 7.75 ± 0.64 66.67 ± 3.73 828.59 ± 29.09
Autoclave 9.16 ± 0.62 62.39 ± 5.72 904.86 ± 37.40
Gamma 6.49 ± 0.46 48.87 ± 5.04 853.24 ± 51.02
Coagulated
Control 0.35 ± 0.02 1.08 ± 0.08 440.76 ± 11.66
EtOH 10mins 0.32 ± 0.03 0.98 ± 0.06 449.33 ± 25.45
EtOH 24hours 0.32 ± 0.04 1.07 ± 0.07 437.51 ± 31.43
Autoclave 0.33 ± 0.04 0.97 ± 0.05 382.84 ± 35.46
Gamma 0.35 ± 0.03 1.22 ± 0.05 407.03 ± 9.87
Table 8.1: Mechanical properties (Youngs modulus, ultimate tensile strength and elonga-
tion at break) of POSS-PCU and POSS-PCL samples following sterillisation via a number
of different techniques (n=6, p<0.05)
molecular weight distributions were detected in coagulated samples of POSS-PCU
following autoclaving. Exposure to gamma irradiation had a significant impact on
both the samples. The Mn of cast POSS-PCU significantly increased whilst the
Mw decreased (p<0.001) manifesting itself in a sizeable reduction in Pd. Meanwhile,
gamma irradiation increased the Mn and Mw of the coagulated POSS-PCU; however,
the degree of increase in Mn was greater than Mw which resulted in a slight decrease
in Pd.
Cytotoxicity
The results of the Alamar Blue assay are displayed in figure 8.3 as a percentage
of viable cells compared to control cells cultured on tissue culture plastic following
seven days of incubation. Whilst no significant differences were detected between
cell viability on EtOH treated and autoclaved samples, sterilising via gamma irradi-
ation reduced cell viability by approximately 50%, compared to EtOH treated and
autoclaved samples, on both cast and coagulated POSS-PCU samples.
Efficacy of sterilisation
The polymeric materials were incubated in TSB and THY to test the efficiency of
sterilisation (table 8.2). THY is a viscous growth medium with reduced oxygen
levels, which tests the growth of anaerobic bacteria and other organisms capable of
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Figure 8.2: Molecular weight (Mn, Mw, polydispersity) of cast and coagulated samples of
POSS-PCU following sterilisation via a 10 min incubation in EtOH, 24 hour incubation in
EtOH, Autoclaving and gamma irradiation. Data is presented as a percentage variation of
the unsterilised controls (mean ± SD, n=3).
Figure 8.3: viability after 7 day incubation, as determined by Alamar blue assay. Results
(mean ± SD) are presented as a percentage of the control cells grown on tissue culture
plastic (n=4, * = p<0.001). Gamma irradiation appeared to reduce the number of viable
cells by approximately 50%.
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growing in reduced oxygen tension. No evidence of bacterial growth was observed on
any of the materials tested following incubation in THY. TSB however, is a general
growth media for aerobic microorganisms and is designed for the growth of aerobic
bacteria and yeasts and moulds. The materials sterilised via EtOH incubation were
not fully sterile and sustained the growth of bacteria on all three samples tested of
each material. Autoclaving and gamma irradiation appear to be far more efficient
sterilisation techniques as no evidence of bacterial growth was observed on any of the
polymeric materials.
Sample Sterilisation
technique
Growth
in TSB
Growth
in THY
Cast
EtOH 10mins 3/3 0/3
EtOH 24hours 2/3 0/3
Autoclave 0/3 0/3
Gamma 0/3 0/3
Coagulated
EtOH 10mins 2/3 0/3
EtOH 24hours 3/3 0/3
Autoclave 0/3 0/3
Gamma 0/3 0/3
Table 8.2: Bacterial growth observed on each sample following incubation in Tryptone soya
broth (TSB) and Fluid Thioglycollate medium (THY) for cultivation of microorganisms.
Samples were tested in triplicates, and no evidence of bacterial growth was found on any
of the materials tested which were cultivated in THY. Growth of bacteria was observed
on all three samples of both samples sterilised via EtOH incubation and cultivated in TSB.
Autoclaved and gamma irradiated materials appeared to be fully sterile and did not support
any bacterial growth.
8.3 Discussion
Sterilisation is defined as the complete removal or destruction of viable organisms.
More practically, however, it is better defined as a process capable of delivering a
certain probability that the device is free from viable microorganisms. The physical
or chemical agents capable of achieving sterilisation without adversely affecting the
material quality, function and use, are rather limited for healthcare products. Two of
the more common sterilisation techniques are moist heat (autoclaving) and ionising
irradiation (gamma irradiation). Additional methods capable of inactivating viable
organisms exist, but are less effective than terminal sterilisation. These include dis-
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infectants such as EtOH incubation.
Depending on the chemical nature of the material and the processing method, ster-
ilisation techniques have been reported to induce changes in material properties. In
this study we investigated the effects of sterilisation on POSS-PCU nanocomposites:
a non-degradable POSS-PCU with an aromatic hard segment and carbonate based
soft segment, and vascular grafts produced from POSS-PCU via phase separation.
The properties of the sterilised samples were compared to untreated controls.
The two samples were incubated with 70% ethanol for a period of 10 minutes and 24
hours. ATR-FTIR analysis indicated that no changes in the surface chemical com-
position took place. Further, there were no significant variations in molecular weight
or mechanical properties suggesting that neither surface nor bulk properties were
affected by ethanol irrespective of incubation time. Whilst ethanol has been shown
to be useful in disinfecting lipophilic viruses and gram-positive, gram-negative, and
acid-fast bacteria; hydrophilic viruses and bacterial spores are resistant to the mi-
crobial effects of ethanol making it unsuitable for sterilising biomedical devices for
in vivo applications [274]. Cultivation in TSB broth resulted in microbial growth in
both the samples sterilised with EtOH for 10 mins and 24 hours. However, no signs
of bacterial infection or cytotxocity were observed in EPC culture with cell growth
being in excess of control cells cultured on tissue culture plastic following 7 days of
culture for the cast sheets and 75% for the porous samples.
The process of autoclaving requires samples to be exposed to high pressure saturated
steam at temperatures of 121oC or more. The combination of high temperature, hu-
midity and pressure has been shown to be quite detrimental to PUs with decreases
in UTS, hydrolysis and oxidation being reported in polyether based PUs [275]. Both
of the POSS-PCU samples appeared relatively unaffected by exposure to autoclaving
with the cast and coagulated samples retaining their shape and structure. GPC anal-
ysis suggested there was a minor increase in Mw of the cast sample which may explain
the slight increase in elongation at break experienced by the autoclaved POSS-PCU.
The small changes in behaviour may be due to a minimal degree of cross linking
experienced by the material. The coagulated sample of POSS-PCU exhibited a small
decrease in elongation at break alongside a reduction in ATR-FTIR peak intensity
at 1245cm−1. These results are consistent with chain scission of the hard segment.
The porous, coagulated sample has a significantly increased surface area, compared
to the cast sample, offering a possible explanation for the difference in behaviour be-
tween the cast and coagulated samples. Chain scission may be induced by the moist
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environment at the surface of the material as opposed to the high temperatures be-
ing experienced by the bulk. No significant changes were recorded in the molecular
weight profile of the coagulated POSS-PCU sample further reinforcing the belief that
chain scission is a surface effect as opposed to bulk. Autoclaving appears to be an
effective sterilisation technique as no sign of microbial growth was detected in either
of the broths for both the cast or coagulated samples. Further, no cytotoxic side
effects were recorded.
Mixed findings have been reported regarding the effects of gamma irradiation on PUs.
Whilst some investigators have found no change in material properties following ex-
posure to gamma irradiation, an equally significant number of publications indicate
severe degradation of material [272, 275–277]. Gamma irradiation is advantageous
in that it is a rapid and highly effective sterilisation technique; no sign of microbial
growth was detected on any of the samples following gamma irradiation. However,
in the case of both the POSS samples that were tested it caused severe damage and
displayed cytotoxic effects upon the cultured mononuclear cells reducing cell viability
by more than half on the cast and coagulated samples. Whilst the exact mecha-
nism behind this observation is unclear, there are reports in the literature of PUs
with MDI based hard segments releasing 4,4’–methylene dianiline as a degradation
product [272, 278]. Aromatic amines are known to be highly cytotoxic and gamma
irradiation has been shown to release 4,4–methylene dianiline previously giving rise
to cytotoxic side effects [279–281].
Whilst structurally there were no changes in the POSS-PCU samples, visually they
had turned a dull yellow collour. This is likely due to the MDI in the aromatic hard
segment of POSS-PCU. Exposure to gamma irradiation may have oxidised the central
methylene group of the biphenyl leading to a highly conjugated quinone chromophore
(fig 8.4).
Analysis of the surface functional groups of the cast and coagulated samples of POSS-
PCU via ATR-FTIR provided further evidence of material degradation. Reductions
in peak intensities at 1245 cm−1, 1540 cm−1 and 1740 cm−1 are all consistent with
hydrolysis of the hard segment. The significant reductions in Mw for both samples,
as well as Mn for the coagulated sample would appear to corroborate those findings.
The Mn for casted samples of POSS-PCU increased suggesting that cross linking is
taking place. As Mn is a more sensitive parameter to the lower end of the molecular
weight distribution, these results would suggest that chain scission is taking place fol-
lowed by cross linking of the low molecular weight chains of the casted POSS-PCU.
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Figure 8.4: Reaction mechanism for the formation of quinone chromophore responsible for
yellowing the samples.
An increase in ATR-FTIR peak intensity at 1095 cm−1 would reinforce these findings
as 1100 cm−1 is the region where we would expect to find ether peak as a result of
cross linking. However, it is difficult to assign this peak with any certainty as the
Si-O-Si of POSS is also expected in this region.
The effect of polymer degradation was seen in the mechanical testing of the sam-
ples. The UTS and Youngs modulus decreased significantly for the casted samples of
POSS-PCU. The coagulated sample did not display any significant changes in their
mechanical properties. This is probably due to the highly porous nature of the co-
agulated samples meaning that the true cross sectional area upon which force was
applied was considerably lower than the measured area resulting in lower than ex-
pected values. The force range upon which the samples were examined may not be
large enough to determine any detrimental effects on the polymer chains.
8.4 Conclusions
Sterilising POSS modified polyurethanes via EtOH resulted in no observable damage
but the sterilisation process was inefficient. On the other hand, both autoclaving and
gamma irradiation resulted in effective sterilisation of samples; but gamma irradiation
led to significant degradation in both POSS-PCU samples and had a cytotoxic effect
upon EPC culture. Both POSS-PCU samples did, however, withstand the effects of
autoclaving well with no structural damage observed or polymer degradation noted.
The results indicate that autoclaving is the optimal sterilisation procedure for POSS-
PCU.
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Long Term Performance of POSS-PCU
Vascular Grafts: An In Vivo Assessment
It is currently not possible to predict blood and tissue compatibility from mere in
vitro assays. Whilst in vitro testing is a useful guide which helps to elucidate the
response of individual components (e.g. proteins, platelets, cells) to the graft; they
fail to capture the complex, multifactorial, emergent behaviour encountered in the
physiological environment. This is particularly pertinent for the coagulation, inflam-
mation and wound healing behaviour of the body in response to foreign objects, which
involves multiple interconnected networks in a non-linear manner. For these reasons,
long-term studies in animals still need to be performed to assess the safety and ef-
ficacy of any medical device. This is an essential requirement for the construct to
gain CE marking or FDA approval prior to clinical application and commercialisation.
A number of animal models exist to evaluate the performance and safety of vascular
grafts. Amongst them, primates resemble humans most closely from an anatomical
and physiological point of view. They lack any dramatic growth spurts and thus are
ideal for long term studies over several years. A number of investigators have made use
of a primate model to evaluate their constructs; however, the ethical considerations
tend to restrict their use in a number of countries [282, 283]. Furthermore, primates
are expensive to purchase and maintain, compared to other species, making them
economically unviable. Whilst porcine models are popular due to the similarities in
cardiovascular anatomy and physiology, to that of humans, they are uncooperative
without full anaesthetic and are prone to rapid growth. For example, a typical 25
kg pig will grow to approximately 100 kg after 8 weeks. The rapid growth of the
animal limits the length of time the in vivo assessment can take place due to a size
mismatch between the vasculature and the graft and difficulties in animal handling.
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A number of further ‘small animal’ models have been utilised which include rabbits,
rodents and mice. These models are inexpensive and easy to anaesthetise and work
with; however, when it comes to performing surgery their small size presents quite a
technical challenge.
In this study, an ovine model was used to establish the safety and efficacy of POSS-
PCU vascular grafts. Their large size, lack of growth and low cost made them the
ideal animal model. Further, the vascular tissue of sheep is physiologically and struc-
turally similar to human tissue. The anatomy of this species facilitates easy surgical
access to vessels of appropriate size. For these reasons, the carotid artery was chosen
as the site to implant the vascular grafts. The long neck of sheep affords easy access
for follow up doppler ultrasound and assessment of patency (fig 9.1).
The optimal graft to undergo in vivo evaluation was chosen based on the previous
in vitro assessment. It was decided that the phase separated graft produced with
0% NaHCO3 would be taken forward to the animal trial. With previous PU based
grafts failing primarily due to a lack of mechanical robustness leading to dilation
and aneurysmal formation, it was thought the mechanically robust phase separated
graft, with a compliance profile independent of pressure was best placed to survive
an extended period of time in the arterial circulation. The improved biocompatibility
compared to the grafts produced with 35 and 45% NaHCO3 was also a contributing
factor. Whilst the graft produced with 55% NaHCO3 also performed well in the bio-
compatibility evaluation, it was mechanically fragile and displaced excessive dilation
at elevated pressures during the pressure-diameter evaluation.
9.1 Materials and Methods
Graft preparation
Grafts were prepared from synthesised polymer as described in chapter 4. Briefly,
a mandrel 5 mm in diameter was used to extrude an 18% POSS-PCU solution in
DMAc, through a 7 mm die, into a water bath at room temperature. The grafts were
left in the water bath for a period of 30 mins allowing the phase separation process
to take place, after which they were removed from the mandrel and left in distilled
water for a period of 48 hrs ensuring complete removal of solvent. The grafts were
then sterilised via autoclaving and thoroughly rinsed and stored in sterile distilled
water at a temperature of 4◦C.
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Figure 9.1: Digital images of (A) exposed LCA and soon to be implanted graft (B) POSS-
PCU vascular graft anastomosed end-to-end to the LCA (C) Graft after 9 months implanta-
tion surrounded by a thin layer of reddish fibrous tissue (D) Ultrasound image demonstrating
flow through the graft.
Implantation of grafts
The study was performed in compliance with the Good Laboratory Practice Regula-
tions 1999 (S.I. No. 3106) as amended by the 2004 regulations (S.I. 994) which are
based on the principles of Good Laboratory Practice as adopted by the Organisa-
tion for Economic Co-operation and Development (OECD), ENV/MC/CHEM (98)
17. They are in conformity with, and implement the requirements of, Directives
2004/09/EC and 2004/10/EC.
Ten adult sheep (animal numbers 1-10) with a body weight ranging from 45-60 kg
were used for the study. A day prior to surgery, animal diet was withdrawn and a 75
mg tablet of Aspirin was administered orally.
Animals were administered diazepam (0.3mg/kg) and buprenorphine (0.01mg/kg) in-
travenously via a cannula positioned in a cephalic vein in the animal holding pen and
then transported to the operating theatre. The sedated animals were then more
deeply anaesthetised with a further bolus of diazepam (0.3mg/kg) and ketamine
(3mg/kg) intravenously along with inhalational nitrous oxide and oxygen over isoflu-
rane via a face-mask. The animals were then transferred to the operating table and
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intubated with a cuffed endotracheal tube which was attached to a ventilator to con-
trol respiration. General anaesthesia was maintained using nitrous oxide, oxygen and
isoflurane as above via the endotracheal tube.
Prior to surgery the animals were administered the analgesic carprofen ‘Rimadyl’ (1-
2mg/kg) subcutaneously; the antibiotic cefuroxime ‘Ceporex’ (750mg) intravenously;
the calcium solution ‘Calciject’ by subcutaneous injection (50ml) and sodium bicar-
bonate 8.4% (1 ml/hr) intravenously. A continuous intravenous drip of Hartmanns
solution was delivered via a peripheral vein throughout the procedure. At least 20 mL
blood was drawn from the right jugular vein for full haematology, clinical chemistry
and coagulation screening.
A midline skin incision was made to expose and skeletalise the left carotid artery
(LCA). Heparin (500 units/10kg) was administered intravenously via the drip and
procaine 2% was applied topically to the artery to provoke dilatation. When fully
dilated, the carotid artery was divided, and vascular clamps were applied to the prox-
imal and distal ends of the artery. Animals 1-4 suffered slight spasms which caused
a diameter mismatch between the artery and graft. Meanwhile, animal 7 exhibited
abnormal physiology with the artery large and tortuous resulting in the diameter of
the artery being larger than that of the graft. A 3 cm segment of the artery was
removed and the POSS-PCU grafts were trimmed to length. Each end of the graft
was anastomosed end-to-end to a cut end of the artery using continuous 6/0 pro-
lene sutures. The in situ length of the graft was measured by ruler and recorded. On
completion of the anastomoses, the distal vessel clamp was released to allow blood ac-
cess to the anastomoses and any leakage assessed before release of the proximal clamp.
The muscle was closed with interrupted 2/0 vicryl sutures and the skin with in-
terrupted 2/0 prolene sutures. Animals were administered 1 2 mL doxapram (20
mg/mL) intravenously to improve breathing and the antibiotic oxytetracycline ‘Oxytet
20 LA’ (1ml/10kg) by deep intramuscular injection and returned to their holding pen
for recovery.
The grafts were monitored regularly using Doppler imaging (Sonosite Titan Ultra-
sound System) on study days 1, 7, 14 and then about once a month for the duration
of the study ensuring that they remain fully patent.
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Blood flow measurements
Volume blood flow was measured using Transonic Medical flowmeter system (HT207,
Transonic Medical System, USA) with a flow probe of appropriate size. The flow
probe houses two ultrasonic transducers and a fixed acoustic reflector. The trans-
ducers are positioned on one side of the vessel and the reflector midway between the
two transducers on the opposite side of the vessel. An electrical excitation causes
one of the transducers to emit a plane wave of ultrasound which intersects the vessel
and bounces off the reflector before being received by the other transducer and being
converted into electrical signals. The signals are then used to calculate the transit
time from one transducer to the other. The results may be read from a digital readout
and recorded manually.
Compliance measurements
Compliance of the graft determined by assessing the change in vessel wall diameter
during each cardiac cycle as described in chapter 5 extensively. The measurements
were taken in the sagittal plane at 90 degrees to the long axis of the vessels at three
discrete sites along the graft and the artery. Segments of the graft were also imaged
with a specially adapted duplex colour Doppler ultrasound scanning system (Easote
Picus PRO, Esate Spa, Italy) with signal output to a high resolution, echo-locked wall
tracking system (Wall Track; Pie Medical Systems, Maastricht, The Netherlands).
Real-time M-mode images of the graft and arterial wall were obtained with a 7.5-
MHz linear array probe.
Graft explantation
Animals were anaesthetised and blood samples collected as described previously. The
graft implant site was surgically exposed with any observations recorded as a study
note. The graft was explanted intact along with at least 1cm of native vessel at each
extremity and pinned, fully extended, to an appropriate backing with the proximal
end identified with a marker suture. The patency of each harvested graft was as-
sessed by perfusion of physiologic saline and the specimen was placed in 0.9% saline
to remove blood but care was taken to avoid dislodging thrombi. A specimen of the
un-operated right carotid artery was also collected and treated similarly.
The animal was exsanguinated by implanting a cannula into the right carotid artery
and allowing blood to flow to waste. Specimens of the lungs, heart, liver, kidneys,
spleen and mesenteric lymph nodes, along with any other tissues considered relevant
by the pathologist, were then transferred to 10% neutral buffered formal saline and
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stored for later examination.
Histology
Specimens of the graft and other organs, as detailed in the graft explantation section,
were fixed in 10% neutral buffered formal saline for a minimum of 48 hrs. The
whole graft specimen, including native vessel at each end, was divided transversely
at 2.5 mm intervals along its length. Samples of the graft were placed in pairs
in processing cassettes in such a way that the proximal surface was presented for
microtomy. These and other samples that were then processed by routine automated
procedures to wax embedding. From each wax block, two 5 micron sections were
cut; one section stained with haematoxylin and eosin and the other with picrosirus
red. Sections of the graft were examined for cellular integration of the graft, chronic
inflammatory response, healthy cells, apoptotic cells, proliferating cells, macrophages,
T cells, intimal hyperplasia and the presence of collagen.
9.2 Results
Gross observation at implantation and explantation
The graft was found to be easy to handle, cut and suture. Upon perfusion, by re-
leasing the proximal and distal clamps, the grafts began to pulsate gently which was
visible both to the naked eye and through palpation. The grafts slowly became a
reddish colour as blood was continuously flowing through with no leakage or oozing
of blood that was apparent. Neither was there any release of blood at the anastomosis
as the sponge like structure of the graft was able to self-seal following perforation by
the suture needle.
Grafts 1 and 4 were found to be immediately non-patent (within 24 hrs post-implant)
and graft 7 was found to be non-patent at day 14. The remaining 7 grafts were fully
patent and functioning 9 months post-op at termination. The 7 grafts displayed no
signs of infection, scar tissue or adhesions and were found to be pulsating strongly
indicative of fully functioning and patent grafts. A layer of reddish fibrinous material
appeared to surround the grafts. Upon explantation, the 7 grafts were perfused ex
vivo with saline solutions, at which point none of the 7 grafts provided any resistance
to the flow of liquid through the lumen. Further, there was no change in the dimen-
sions of the graft upon explantation suggesting that the grafts are relatively elastic
and can maintain arterial blood flow without dilation and aneurysmal formation.
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The patency of the POSS-PCU grafts were compared to the 3 PTFE grafts implanted
in the same position. PTFE grafts were found to have occluded within 3 weeks of
implantation.
Toxicology screening
Blood samples were collected both on the day of, and prior to, surgery and the day of,
and prior to, termination into appropriate tubes. No abnormalities were reported with
any of the parameters analysed, which included immune cell count, plasma protein
activations markers (prothrombin time and activated partial thromboplastin time)
and serum protein counts. The lack of any significant difference in blood clotting
time pre- and post implantation was positive as it is indicative of the graft having no
significant impact on the thrombogenic response.
Blood flow rates
Blood flow rates were measured both pre- and post grafting at implantation and ex-
plantation and are presented in table 9.1 for all the animals with a summary in figure
9.2. The mean blood flow through the LCA, prior to implantation, was found to be
364.55 ± 87.83 mLmin−1. There was some variation between the different animals
with the range of measured blood flow rates being 264 mLmin−1.
Following implantation of the grafts, the mean flow rate reduced slightly to 330.92
± 80.63 mLmin−1 with the range narrowing a little to 209 mLmin−1. There was no
significant difference in the perfusion rates between the native LCA and the replace-
ment POSS-PCU vascular grafts.
Flow rates were re-measured prior to explantation. Having been implanted for a
period of 9 months, the mean flow rate through the grafts was found to be 311.8
± 62.22 mLmin−1 with a range of 270 mLmin−1. Animal 3 was excluded from the
measurements as the reading of 32 mLmin−1 appeared to be an anomaly, possibly
due to inappropriate equipment and/or user error. The flow rates through the RCA
were also determined, allowing a comparison between the grafted LCA and RCA.
The mean flow rate was 387.5 ± 177.87 mLmin−1 through the RCA which was found
to be not significantly different (p=0.2045) to the grafted LCA.
On comparing the blood flow rate through the grafts post-grafting at day 0 (mean
330.92 ± 80.63 mLmin−1) and just prior to explantation after 9 months (mean 311.8
± 62.22 mLmin−1), no significant differences was detected (p=0.3408). From the
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blood flow rates, it can be concluded that the perfusion efficiency is not restricted by
grafting and nor does it diminish over time.
Animal
No
LCA Pre-
grafting
(mLmin−1)
LCA Post-
grafting
(mLmin−1)
Graft at
termination
(mLmin−1)
RCA at
termination
(mLmin−1)
1 380 350 Non-patent at termination
2 480 473 Appropriate probe not available
3 400 280 32 330
4 340 480 Non-patent at termination
5 350 230 230 400
6 410 404 320 410
7 Not recorded 310 Non-patent at termination
8 292 282 400 400
9 494 300 325 670
10 231 298 284 115
Table 9.1: Blood flow rates, as measured using a Transonic flowmeter, of the left carotid
artery (LCA) both pre- and post grafting, the graft just prior to explantation after 9 months
and the right carotid artery (RCA). Measurements were taken from all 10 animals in the
study.
Compliance
Graft compliance was assessed in vitro in chapter 5 and was found to be 5.9 ± 0.4
%mmHg−1 × 10−2 through the physiological pressure range. The compliance of the
graft in vivo was found to be similar at 5.4 ± 1.6 %mmHg−1 × 10−2. The average
compliance of the LCA prior to graft implantation was not significantly different at 5.3
± 2.64 %mmHg−1×10−2. Following 9 months implantation, the graft compliance did
not significantly alter and remained at 5.62 ± 3.04 %mmHg−1×10−2 which compared
favourably with the compliance of the RCA which was 5.48 ± 2.45 %mmHg−1×10−2.
These results would indicate that the compliance properties are not compromised
upon implantation either through graft degradation or by the growth of connective
tissue which surrounded the graft (fig 9.3).
Histology
Figure 9.4 displays representative histology images of the patent grafts upon explan-
tation after 9 months. There appears to be some significant cellular infiltration from
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Figure 9.2: Mean blood flow rates through the native carotid arteries and the graft. LCA:
left carotid artery, RCA: right carotid artery
Figure 9.3: Compliance values of the native ovine LCA, RCA and POSS-PCU vascuar
grafts on day 0 and after 9 months implantation. No significant differences were detected
between the different subjects. Measurements were taken on all 12 animals at the physio-
logical pressure.
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the adventitia into the structure of the graft (fig 9.4A, B). However, those cells do
not migrate into the lumen of the graft which, with is largely devoid of any great
cellularisation (fig 9.4C). There is evidence for minor cell deposition in the lunem but
there is no invasion and build up of tissue in the luminal space suggesting that there
are no signs of IH formation (fig 9.4D). Picrosirius red stain confirmed these findings
as there were no indications of collagen deposition in the luminal space of the graft
(fig 9.4E). The adventitial tissue surrounding the graft is collagenous in nature and
there is minor deposition of collagen in the structure of the graft.
Histology analysis was also conducted on the animals which were terminated prior
to the end of the study (fig 9.4F). All of the non-patent grafts demonstrated similar
features, namely, the length of the graft was filled to occlusion with clotted blood.
This exists from just proximal of the proximal anastomosis to just distal of the distal
anastomosis. Rather curiously, the thrombus and clot appear to be disassociated from
the lumen with no cells deposited on the luminal border of the implanted grafts. No
integrated adventitial growth is seen on any of these grafts.
9.3 Discussion
There is an acute clinical need for alternative conduits for small calibre vascular by-
pass grafts. Intense research effort has taken place aimed at developing more suitable
grafts, which are not prone to thrombosis and/or IH. Other requirements, such as ‘off
the shelf’ availability and available in a number of sizes further complicate matters.
Several tissue engineering paradigms have been proposed, which have been discussed
at length in chapter 2; however none of them have been wholly successful. A lack of
radial strength in tissue engineered constructs severely limits their use in the arterial
circulation [129]. Further, the high costs associated with their production is rather
prohibitive to widespread clinical use; as is the complex manufacturing methods which
limits them to a few highly specialised clinics [126, 127]. The time period required
for their production means tissue engineered constructs cant be used in emergency
revascularisation procedures, which invariably, the majority of situations requiring
vascular grafting are [126, 127]. Many of the drawbacks are due to a fundamental
lack of knowledge in cell biology and cannot be rectified easily. Consequently, no al-
ternative concepts have emerged which could replace or improve the current industry
standard Dacron or PTFE grafts.
The approach taken in this thesis has been to develop a prosthetic graft which
meets all the functional requirements of a small calibre graft, whilst possessing a
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Figure 9.4: Representative histology images of POSS-PCU vascular graft cross-sections.
Sections are taken from the proximal anastomosis, the main body of the graft and the distal
graft. Images A-D display significant infiltration of cellular material from the adventitia.
Image E indicates that whilst the adventitial tissue growth was collagenous in nature, there
was no evidence of collagen in the body of the graft. Image F is of a thrombosed graft
displaying a solid thrombus in the lumen of the graft. Interestingly, the thrombus is not
attached to the graft lumen but has formed in the centre of the conduit.
more thromboresistant surface which is not prone to occlusion on prolonged exposure
to blood; thus offering an improved and readily available, viable treatment option.
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Whereas the previous chapters have discussed at length the fabrication process, func-
tional mechanical properties and biocompatibility in vitro; the purpose of this chapter
was to determine the performance and healing of a POSS-PCU vascular graft follow-
ing long-term implantation in a suitable animal model. A senescent ovine model was
selected for implanting POSS-PCU vascular grafts. The long neck region and readily
accessible carotid arteries were highly appealing attributes of this model. The coag-
ulation system of sheep has been previously been described as being similar to that
of humans and has been used in a number of material evaluation tests [284]. Its use
is recommended by the International Regulatory Affairs Offices of the FDA [285].
Further, the adult sheep are easy to handle and do not show further growth, thus
there will be minimal disruption due to size mismatch throughout the study time
period.
The decision to implant the graft produced with 0% NaHCO3 was taken with the
knowledge that mechanical vulnerability upon prolonged implantation is a significant
drawback to using PU vascular grafts. PU grafts can be susceptible to dilation, and
subsequent aneurysmal formation, in the arterial circulation. Therefore, the more
porous grafts produced with NaHCO3 were not implanted. The graft chosen to be
implanted displayed a compliance profile of circa 5 %/mmHg ×10−2 throughout the
mean arterial pressure range in vitro, which was a reasonable match to the compli-
ance of the sheep carotid artery.
Vascular grafts were implanted in the left carotid artery (LCA) of 10 adult sheep,
using a double end-to-end anastomosis, and left for a period of 9 months. Doppler
sonography was used to periodically examine the grafts to ensure they remained
patent. Once implanted, the compliance profile of the grafts was measured in vivo
to ensure there was no significant mismatch. There was no significant difference be-
tween the compliance of the graft in vitro or in vivo, or indeed between the graft and
the LCA pre-operatively indicating excellent initial functionality. To further deter-
mine the functional behaviour of the newly implanted grafts, blood flow rates were
determined both pre- and post-operatively. Again, there were no significant differ-
ences between the flow of blood through the native LCA or the grafted LCA. With
no significant difference in compliance or flow of the LCA pre- and post-operatively
being observed, the synthetic graft does not cause any impedance or increase vascular
resistance upon implantation.
Following implantation, 2 grafts were found to be occluded at day 1 (nos. 1 and 4)
whilst a further graft (no. 7) was found to be occluded after day 14. The early or
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acute failure (<30 days) of 3 of the grafts is a cause for concern. Rather intriguingly,
the histology of the failed grafts (fig 9.4F) displays the thrombus formation being
detached from the internal body of the graft. This would suggest that it was not the
surface of the graft per se that caused the thrombotic occlusion. If the biomaterial
itself was responsible for initiating coagulation, one would expect the thrombus to be
attached to surface of the graft with adhesion mediated by fibrin. The exact cause
of graft failure is difficult to ascertain; however, early graft failure is often associ-
ated with technical issues which include surgical technique [286]. A diverse range of
factors, including the type of anaesthesia, have been implicated in early graft occlu-
sion [287,288]. Further graft related issues could also have contributed to the sudden
thrombus formation. Had any residual solvent (DMAc) not been leeched and was
still present in the grafts, then that would cause a rather dramatic and immediate
thrombotic response.
The patency rate of POSS-PCU vascular grafts was 70% (7/10). On examining graft
compliance after 9 months in vivo, no significant changes were detected. The compli-
ance of the RCA was also determined, that too remained circa 5 %/mmHg ×10−2.
Previous studies have reported a significant reduction in graft compliance following
implantation and wound healing [289]. This is usually a consequence of excessive fi-
brovascular infiltration in and around the graft. From the histology images (fig 9.4)it
is clear that there is no significant infiltration of adventitial tissue which is likely to
cause any restrictions in graft compliance.
Blood flow rates after 9 months implantation were also measured through the grafted
LCA and compared with flow rates through the pre-grafted LCA and the RCA.
Again, no significant changes were seen, suggesting perfusion efficiency is unhindered
by grafting with POSS-PCU vascular grafts. As there is no restrictive barrier due
to narrowing of the lumen, and the graft-artery mismatch is minimal; one would not
expect to see any great reduction in the blood flow rates. With IH being the most
common cause of synthetic small calibre graft failure, the lack of narrowing of the
lumen is a promising finding.
A closer examination of the histology sections demonstrates that there was little in
the way of cellular deposits or mineralisation on the luminal surface of the graft.
Previous PU implants have been prone to calcification and mineralisation upon pro-
longed implantation [290]. A link has been made between graft hydrophilicity and
mineralisation rate [291]. It is possible that the hydrophobic nature of POSS-PCU
provided a surface resistant to the accumulation of mineral ions.
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The lack of EC adhesion is of concern. The conventional paradigm in developing pros-
thetic grafts is that spontaneous endothelialisation is an absolute necessity. Whilst
the POSS-PCU graft has not endothelialised, it was patent and functioning 9 months
after implantation. Possible reasons for the lack of endothelialisation may be that
the exposed surface lacked an open-pored structure. The lack of pores would mean
there would not be any readily available tethering points for cells to adhere and stick
to. Considering the luminal surface is exposed to high shearing forces in the arterial
circulation, there is a risk that any adhered cellular material will be washed away by
the continuous pulsatile flow of blood if adhesion is not strong enough.
Whilst endothelialisation is considered a necessary requirement, interpreting endothe-
lialisation studies in animal models is a challenge task. Despite countless years of
research and the development of a great number of grafts which have, to a certain ex-
tent, endothelialised in a range of animal models, including sheep; none of them have
successfully endothelialised in humans [292]. Even when grafts do form an endothe-
lium, there is no guarantee that the EC are of the correct phenotype. EC have a wide
range of functions and can range from the pro-thrombogenic to anti-thrombogenic.
Previously, it has been shown that a fully endothelialised PTFE graft resulted in a
greater degree of IH compared to the control PTFE graft [153]. This is likely to be
a direct consequence of having EC in the wrong phenotype. The successful healing
of a vascular graft is a great deal more complex, inflammation-mediated process as
opposed to the rather simplistic view of mere endothelialisation [293–295].
9.4 From Lab to Patient
A 26 year old male had developed a right femoral artery pseudoaneurysm (FAP) fol-
lowing continued and repeated intravenous drug use. The repeated puncture wounds
had resulted in a haematoma forming outside the artery wall as a result of a leaking
hole in the artery. Whereas ligation and excision of the pseudoaneurysm, without
revascularisation, is an accepted means of treatment in the majority of patients; in
this case, the patient had presented late when complications such as bleeding, sep-
sis and limb ischaemia had occurred making management of the FAP more difficult.
This resulted in the pseudoaneurysm rupturing (fig 9.5A) and acute interruption of
femoral artery flow. In these circumstances a high probability of amputation is gen-
erally expected.
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Once the clinical decision to restore femoral blood flow was made, a suitable conduit
for reconstructing the infrainguinal vasculature was required. Although the GSV is
the generally favoured conduit for lower extremity arterial reconstructions, its avail-
ability is restricted in patients with a history of drug abuse, as the superficial veins
are commonly damaged by prolonged direct injections. Autologous arterial grafts
were not considered due to the length of the conduit required. Autologous grafts are
often severely limited in their use due to insufficient lengths. Consequently, prosthetic
grafts are often the only viable option for arterial reconstructions in this subset of
patients.
Ethical approval was granted to treat the patient with a POSS-PCU vascular graft,
as opposed to the more conventionally used PTFE graft. PTFE grafts are prone to
infection and thrombosis. A POSS-PCU graft was fabricated with an internal diam-
eter of 5.1 mm and length of 300 mm. The graft was trimmed to the required length
of 180 mm at the on-site and was used for an iliac to femoral reconstruction (fig 9.5).
Following implantation and on future examinations, no evidence of infection or throm-
bosis was witnessed. Further, the graft was monitored via Duplex Sonography. The
Doppler waveform obtained from the reconstructed iliac-femoral artery demonstrated
a low resistance profile with a characteristic triphasic Doppler signal throughout the
cardiac cycle. An initial fast upstroke to peak systole was followed by reversal of
blood flow during early diastole and a forward flow component during late diastole.
Flow rates were found to be equivalent, both proximal and distal to the graft, with
the peak systolic velocity approximately 60-80 cms−1. The graft was implanted June
2011 and, as yet, appears to be fully patent and fully functioning. The patient is
being monitored regularly, every 3 months, via Doppler ultrasound.
9.5 Conclusions
In this chapter, the functional behaviour and tissue compatibility of POSS-PCU vas-
cular grafts was assessed in vivo. Grafts were implanted into the left carotid artery
of 10 adult sheep for a period of 9 months. Grafts were monitored via Doppler
sonography for patency. The compliance and flow rates were measured pre- and
post-operatively as well as pre-explanting. Furthermore, the explanted grafts were
exposed to histological examination. POSS-PCU vascular grafts exhibited a 70% pa-
tency rate whereas the PTFE grafts failed within the first 3 weeks of implantation.
Grafts did not compromise the functional properties of the artery with flow rates
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Figure 9.5: Digital images of (A) femoral artery pseudoaneurysm (B) exposed iliac artery
proximal to pseudoaneurysm (C) POSS-PCU vascular graft (180 mm length) used for re-
construction (D) graft-iliac anastomosis (E) graft-femoral anastomosis and (F) complete
reconstruction from the above groin iliac artery to the below groin femoral artery.
and compliance unchanged after grafting and comparable to the native right carotid
artery. Despite the lack of a fully functioning endothelium, there was no sign of inti-
mal thickening or hyperplasia even after 9 months implantation.
Following the animal trial, a POSS-PCU graft was used for clinical evaluation in a
168
9.5. CONCLUSIONS
human patient. The graft was used to treat an iliac-femoral pseudoaneurysm in a 26
year old male. To date, the graft is fully patent and functioning with no detrimental
effects on perfusion efficiency.
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Summary and Future Outlook
Prosthetic vascular grafts have been an integral tool of vascular surgery for over half
a century. In this time, whilst large calibre grafts (>5 mm) have performed im-
pressively, with patency rates in excess of 90% in the aorto-iliac position, the use of
synthetic small calibre grafts has been met with failure [25, 26]. Despite continuous
research, no clinically viable conduit has been developed which could help to meet
the critical need for small calibre arterial replacements. Failure is often attributed to
material surface thrombogenicity and the development of anastomotic IH.
A variety of paradigms have been explored, with sophisticated tissue engineering ap-
proaches dominating in recent years. However, despite the intensive research effort,
little progress has been made in tackling the key drawbacks to using tissue engineer-
ing concepts, namely: cost, time, availability and lack of radial strength for exposure
to the arterial circulation.
The research in this thesis aimed to develop a synthetic small calibre graft which has
the functional properties to be used as an arterial replacement. By using a bioma-
terial, POSS-PCU, with improved biostability, blood compatibility and viscoelastic
properties; it was hoped the two primary modes of graft failure could be alleviated.
The first challenge faced in this thesis was to develop a facile manufacturing method
to produce vascular grafts less than 5 mm in diameter. The protocol had to be flexible
to allow the production of grafts in a range of dimensions, depending on the clinical
need or physiological requirement, with a degree of porosity and with mechanical
properties resembling those of soft tissue. Phase separation was exploited as a means
to produce porous membranes, and a bespoke extrusion machine was commissioned
to produce cylindrical conduits. Key parameters in the extrusion-phase separation
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method which affect the final graft dimensions and morphology were optimised. GPC
and DSC analysis confirmed that in undergoing phase separation from solution, the
POSS-PCU polymer was not damaged or degraded in any way. Furthermore, GCMS
and ICP-OES were utilised to confirm that after extrusion, no impurities or additives
(DMAc and NaHCO3) remain in the grafts. Chapter 4 also explored changes in graft
morphology (wall thickness, pore size and porosity); particularly in response to the
addition of an inorganic filler, NaHCO3 and the temperature at which phase sepa-
ration takes place. The introduction of NaHCO3 into the polymer matrix appeared
to have a significant effect on graft morphology following phase separation. More
homogenous, porous walls were produced with pore size increasing with the concen-
tration of NaHCO3. Wall thickness was also significantly reduced with the continued
addition of NaHCO3. At the completion of chapter 4, cylindrical conduits in a range
of dimensions, pore sizes and porosities could be manufactured, in a reproducible and
scalable manner, depending on the clinical need.
Following on from chapter 4, the functional properties of the manufactured grafts
were assessed. The effect of 3 different wall thicknesses and 3 different porosities
(corresponding to 3 different NaHCO3 concentrations) on the dynamic mechanical
properties of the grafts was investigated. Blood vessels have numerous complex func-
tions; however, the primary role of any vessel is to transport blood efficiently. The
ability of the different vascular grafts to propagate the blood flow was assessed in
a physiological flow circuit. The strength of the graft was characterised in terms
of suture retention force, an important parameter in the development of any arte-
rial replacement. Finally, the feasibility of incorporating an external reinforcement
to minimise graft kinking was evaluated. Phase separated, POSS-PCU grafts had
tensile strength in excess of the native artery and suture retentions strengths in ex-
cess of the generally accepted value of 2N. The grafts were viscoelastic in nature,
and displayed compliance profiles similar to the native iliac artery and were far more
compliant than the current industry standard Dacron or PTFE grafts. Whilst the
introduction of an external reinforcement did significantly improve the kink resistance
of the grafts, the reinforcement eventually delaminated and separated from the graft.
However, whilst the kink resistance improved with the introduction of an external
reinforcement, the graft compliance suffered a dramatic decrease. The compliance
values of externally reinforced grafts were below acceptable levels and closer to val-
ues associated with Dacron and PTFE grafts.
The aim of chapter 6 was to provide an extensive characterisation of the surface
properties of vascular grafts as a precursor for assessing the biocompatibility of the
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grafts. From previous studies, the cast sheet of POSS-PCU, that has not been sub-
jected to phase separation, is known to be biocompatible, illicit a minimal immune
response and is conducive to EC growth [183, 185]. The surfaces of phase separated
POSS-PCU with 0, 35, 45 55% NaHCO3 were compared and contrasted to the cast
sheet. An initial characterisation of the surface chemistry was provided via SIMS and
ATR-FTIR analysis. The key finding was that there is significantly less of the POSS
moiety on the surface of the phase separated samples. The surface wettability was
assessed using a goniometer. POSS-PCU is highly hydrophobic; however, following
phase separation, the degree of hydrophobicity is reduced possibly as a consequence
of fewer POSS moieties at the surface. The addition of NaHCO3 caused a minor
increase in the contact angle which can be attributed to an increase in surface rough-
ness and exposure to an increased surface area which was a consequence on adding
NaHCO3. The major difference observed between the surfaces was that phase sepa-
rating produces a significantly rougher surface and the addition of NaHCO3 resulted
in an open-pored surface. A histogram of pore size distribution was constructed
which demonstrated that surface pore size was in the region of 5-10 µm. Finally, the
substrate stiffness has recently been suggested to be an important mediator of cell
function, and as such, it was characterised between the different samples. No signifi-
cant difference was detected between the samples with all of them having a reduced
modulus of circa 0.6 GPa.
Having characterised the surface properties of the grafts, biocompatibility of each sur-
face was investigated using a wide range of assays. Grafts produced with NaHCO3 ap-
peared to activate the coagulation cascade the most as the concentration of kallikrein
was most abundant on those surfaces. This is likely to be a result of the increase
in surface area of the rougher substrates. Platelets were attached to the phase sep-
arated substrates far more so than the cast sample which also translated into the
degree of activation. PBMC were culture on the different surfaces to assess the in-
flammatory potential of the grafts. After 7 days, PBMC were all highly activated and
pro-inflammatory. A look at the cytokine release profiles confirmed these findings.
However, the graft produced with 0 and 55% NaHCO3 elicited the highest concentra-
tion of IL-10, an anti-inflammatory cytokine which can down-regulate the production
of other pro-inflammatory cytokines. In looking at the endothelialisation potential of
the different grafts, all of the surfaces adhered HUVEC and EPC. There were subtle
differences in the rates of growth on the different grafts but cell growth was compa-
rable to TCP control in the case of HUVEC. For EPC, growth was significantly less
on the POSS-PCU compared to TCP; however no cytotoxic side effects were detected.
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Having completed a thorough in vitro assessment of the grafts developed in chapter
4, a pre-clinical study was designed to examine the long term tissue compatibility
and performance in vivo. Before grafts could be implanted a suitable sterilisation
technique was sought which does not damage or degrade the graft material. In chap-
ter 8, grafts were exposed to a very mild disinfectant, 70% EtOH, autoclaving and
gamma irradiation. Ethanol did not harm the material properties but neither did it
sterilise the grafts to an acceptable level. Gamma irradiation was a very successful
steriliser but it caused severe damage to the biomaterial and resulted in cytotoxic side
effects. Autoclaving was chosen as the optimal technique to sterilise the grafts as it
was efficient in sterilising, maintained cell growth, and did not cause any significant
damage to the material.
For the commencement of the animal study, a decision was required on which graft was
best placed to withstand a long-term pre-clinical study. The decision was based pri-
marily on the results from chapters 5 and 7. Taking into consideration that previous
PU grafts are prone to radial dilation and mechanical fragility upon prolonged implan-
tation in vivo, the graft produced with 0% NaHCO3 was chosen for pre-clinical eval-
uation. It displayed compliant behaviour independent of pressure, so it was thought
that it was least likely to enlarge circumferentially compared to the other graft sam-
ples. It also had an acceptable immune response and sustained EC growth. The graft
was implanted into the left carotid artery of 10 sheep, and on immediate implanta-
tion, no significant difference was seen between compliance and blood flow rates in
the native artery of the grafted artery. After implantation for 9 months, the compli-
ance and flow rates were assessed again and there still were no significant differences
between the grafted and native artery. The patency rate of the grafts were 70% with
3 grafts failing very early in the trial due to thrombus formation. The PTFE grafts
used as controls in this study all failed due to thrombosis within 3 weeks. Histology
results confirmed tissue ingrowth from the adventitial side of the POSS-PCU grafts,
but no cellularisation was seen on the luminal side.
Following on from the results of the pre-clinical trial; an initial clinical evaluation was
undertaken by implanting the graft into a 26 year old male, human patient, with a
FAP. At the time of writing, the graft is patent and fully functioning.
In the absence of autologous conduits, POSS-PCU grafts offer a viable alternative
for vascular surgeons to use in small calibre applications such as the peripheral and
coronary circulation. Whilst there is room for improvement we believe the grafts de-
veloped in this thesis can be successfully translated to clinical practice. In comparing
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POSS-PCU grafts with PTFE, the POSS-PCU grafts performed considerably better.
10.1 Further Work
Having conducted a pre-clinical trial in an ovine model, the next step would be for
a clinical trial to test the efficacy of POSS-PCU grafts in humans. Regulatory ap-
proval is being sought to commence a clinical trial with POSS-PCU grafts acting as
arteriovenous grafts for kidney dialysis. The model is relatively low risk with failure
being non-fatal.
Further studies to improve the thrombogenicity of the grafts are also merited. The
graft can be functionalised with a range of chemistries to include, amongst other
things, NO donors, popular anticoagulants, such as heparin and hirudin, and pro-
teins such as Protein C – an anti-coagulant found on the surface of EC. Further, a
robust model should be developed which can assess blood compatibility of the sub-
strates under flow. Flow is an important mediator in blood-material interactions, and
to get a better understanding of the performance materials, they should be examined
in ex vivo conditions.
Similarly, strategies to improve endothelialisation of the graft by functionalising the
biomaterial can be developed. A great number of peptides and proteins have been
reported to improve endothelialisation ranging from CD34 to RGD. Care should be
taken to ensure that the EC grown on the material are of the correct phenotype.
Looking to the future, the work presented in this thesis can be relatively easily trans-
lated into tissue engineering paradigms. Tissue engineering a blood vessel initially
requires a scaffold which at the time of implantation displays the physical character-
istics of an ideal vascular graft. Once implanted, the graft should slowly biodegrade
being replaced by regenerated tissue, without compromising the functional properties
of the graft. The graft manufacturing and assessment techniques presented in this
thesis are all valid for assessing a tissue engineering scaffold. The biomaterial would
require re-formulation to include a biodegradable component, ideally without com-
promising the initial mechanical properties. The degradation rates would have to be
carefully characterised and matched with the regeneration rates of vascular tissue.
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